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Abstract 
Persister cells are able to survive in the presence of high concentrations of 
antibiotic, and re-grow once the antibiotic has been removed. Unlike 
conventional antibiotic resistance, the antibiotic tolerance of persister cells is 
due to phenotypic switching, and is non-inherited. There is growing evidence for 
a role of persisters in various persistent bacterial diseases. Burkholderia 
pseudomallei is a pathogen which causes melioidosis, which often persists in 
the host despite antibiotic treatment. As persister cells may contribute to 
persistent melioidosis, this study investigated persisters in B. thailandensis, as a 
model for B. pseudomallei. 
 
Treatment of B. thailandensis with ceftazidime, ciprofloxacin, imipenem or 
trimethoprim demonstrated persister cells which survived antibiotic treatment. 
Persister frequencies were increased in the absence of oxygen, and higher in 
stationary phase cultures compared with growing cultures. Drug concentration 
did not affect persister frequencies, and inherited antibiotic resistance was not 
detected. Different persister fractions were detected using treatment with 
multiple antibiotics, indicating heterogeneous susceptibility to antibiotics. 
 
In order to increase understanding of the molecular basis of B. thailandensis 
persister cells, a transposon mutagenesis-based sequencing approach was 
used on persister cultures. This indicated some issues with genome coverage 
and mutant diversity. Genes were identified from mutants present before and/or 
after ciprofloxacin treatment. 
 
In order to try to eradicate persister cells from a culture, two anti-persister 
strategies were tested. Itaconate appeared to stimulate growth of 
B. thailandensis, increasing susceptibility to the antibiotic ceftazidime. However, 
the overall effect of the combination was no greater than ceftazidime alone in 
the conditions tested. Metronidazole was effective against a persister culture 
under anaerobic conditions, suggesting it may be useful in treating anaerobic 
persisters. Treatment of B. pseudomallei infected mice with metronidazole and 
ceftazidime did not improve survival over ceftazidime treatment alone. 
8 
 
Declaration  
All of the results and data presented in this thesis were generated by Michael 
Steele, unless otherwise stated. 
MiSeq and HiSeq sequencing was carried out by Dr Karen Moore and Audrey 
Farbos (University of Exeter). Initial read analysis was performed by Paul 
O’Neill (University of Exeter). Reads were then mapped to the genome by Dr 
Ron Yang (University of Exeter). 
Mouse infection studies were carried out by Felipe Cia and Dr Greg Bancroft 
(London School of Hygiene and Tropical Medicine). 
 
  
9 
 
List of figures 
         Page number 
Chapter 1 
Figure 1.1 – Persisters in bacterial cultures      22 
Figure 1.2 – Model for persisters in a biofilm     23 
Figure 1.3 – Type II toxin-antitoxin systems      32 
Figure 1.4 – Strength of evidence for endemicity of melioidosis   45 
Figure 1.5 – Clinical events after infection with B. pseudomallei   47 
Figure 1.6 – Model for intracellular lifestyle of B. pseudomallei   51 
 
Chapter 3 
Figure 3.1 – Growth of B. thailandensis E264 in LB    94 
Figure 3.2 – CFU/ml measurements of stationary phase B. thailandensis  
E264 after treatment with antibiotic for the time indicated    98 
Figure 3.3 – CFU/ml measurements over time of B. thailandensis in 24  
well plate with LB, LB and DMSO, or LB and water     100 
Figure 3.4 – Effect of different concentrations of antibiotic on persister 
frequency           102 
Figure 3.5 – Growth of culturable survivors on non-selective agar plates  
and agar containing antibiotic         104 
Figure 3.6 – Effect of growth phase on MIC      108 
Figure 3.7 – CFU/ml measurements of mid-exponential phase  
B. thailandensis E264 after treatment with antibiotic     109 
Figure 3.8 – effect of oxygen levels on MIC      112 
Figure 3.9 – effect of 20mM sodium nitrate on MIC under aerobic  
conditions          113 
Figure 3.10 – Effect of oxygen on CFU/ml counts of B. thailandensis  115 
Figure 3.11 – Effect of oxygen levels on persister frequency during  
incubation of stationary phase B. thailandensis with antibiotics   117 
Figure 3.12 – Effect of secondary antibiotic treatment on  
ceftazidime-treated cultures        119 
Figure 3.13 – Effect of secondary antibiotic treatment on  
ciprofloxacin-treated cultures        121 
 
Chapter 4 
Figure 4.1 – Schematic of transposon mutagenesis     135 
Figure 4.2 – overview of transposon library screening and sequencing  136 
Figure 4.3 – Agarose gel of PCR to amplify a 195bp fragment within 
B. thailandensis 16S rRNA        138 
Figure 4.4 – Representative gel of PCR to amplify a 544bp fragment  
within the miniTn5 kanamycin resistance gene      140 
Figure 4.5 – ampicillin resistance of colonies obtained after conjugation 142 
Figure 4.6 – Gradient PCR, using primers Bla3_Fw and Bla3_Rv   144 
10 
 
Figure 4.7 – PCR to amplify the ampicillin resistance gene of the pUT-
miniTn5Km2 plasmid         145 
Figure 4.8 – Increased ciprofloxacin resistance for seven transposon  
mutants, compared with wild-type B. thailandensis     147 
Figure 4.9 – Increased ciprofloxacin resistance in miniTn5 mutant A3  148 
Figure 4.10 – arbitrary PCR to amplify transposon flanking region in  
miniTn5 mutant A3          151 
Figure 4.11 – Representation of miniTn5-pglY junction in mutant A3  152 
Figure 4.12 – PCR to confirm the transposon insertion site in pglY   153 
Figure 4.13 – growth of B. thailandensis wild type and miniTn5-pglY  
mutant in LB           155 
Figure 4.14 – Agarose gel showing representative results of  
B. thailandensis-specific PCR of miniTn5 library 1B     159 
Figure 4.15 – Agarose gel showing representative results of transposon-
specific PCR of miniTn5 library 1B       160 
Figure 4.16 – CFU/ml measurements of a B. thailandensis miniTn5  
library before and after treatment with ceftazidime or ciprofloxacin   162 
Figure 4.17 – Method used for library preparation for sequencing   164 
Figure 4.18 – optimisation of yield from transposon-specific PCR   167 
Figure 4.19 – Efficacy of bead based size selection method, using test  
library           169 
Figure 4.20 – Bioanalyser traces of fragmented DNA libraries   171 
Figure 4.21 – Schematic of qPCR primers      176 
Figure 4.22 – Schematic figure to show sequencing of DNA fragments  180 
Figure 4.23 – MiSeq result: number of de-multiplexed reads identified to  
each pool of 1 or 2 libraries        181 
Figure 4.24 – HiSeq result: number of de-multiplexed reads identified to  
each library in pool 1         185 
Figure 4.25 – Transposon insertion distribution in input pool    189 
Figure 4.26 – comparison of replicate libraries      191 
Figure 4.27 – comparison of input and output lists     192 
 
Chapter 5 
Figure 5.1 – Schematic of the glyoxylate bypass and the TCA cycle  208 
Figure 5.2 – Initial screening of itaconate for growth-inhibitory effects in  
LB            210 
Figure 5.3 – Growth of B. thailandensis in the presence of itaconate in 
microtitre trays          212 
Figure 5.4 – Net effect of itaconate on ceftazidime treatment of  
B. thailandensis         214 
Figure 5.5 – Effect of itaconate and ceftazidime in combination on  
CFU/ml and OD600nm of B. thailandensis cultures, normalised against  
itaconate treated cultures         216 
Figure 5.6 – Effect of itaconate on the CFU/ml and OD600nm of different  
culture densities of B. thailandensis       218 
11 
 
Figure 5.7 – Persister frequencies for cultures treated with co-trimoxazole 
under different oxygen conditions       220 
Figure 5.8 – Effect of metronidazole and co-trimoxazole combination  
treatment in anaerobic conditions       221 
Figure 5.9 – Survival of B. pseudomallei 576 treated BALB/c mice treated  
with ceftazidime and metronidazole       223 
 
List of tables 
         Page number 
Chapter 2 
Table 2.1 – Antibiotics used and storage conditions     61 
Table 2.2 – Primers used in this work       68 
Table 2.3 – 16S PCR program        71 
Table 2.4 – Kan PCR program        72 
Table 2.5 – Amp PCR program        74 
Table 2.6 – Arb-PCR program, round one      75 
Table 2.7 – Arb-PCR program, round two      76 
Table 2.8 – PglY PCR program        78 
Table 2.9 – Transposon library amplification program     79 
Table 2.10 – qPCR program        82 
 
Chapter 3 
Table 3.1 – Minimal inhibitory concentrations towards stationary phase 
B. thailandensis E264         95 
Table 3.2 – concentrations of antibiotics used in persister frequency  
assays, in relation to MICs        97 
Table 3.3 – Frequency of colonies displaying antibiotic resistance after  
24 hours of antibiotic treatment         105 
Table 3.4 – Minimum inhibitory concentrations for mid-exponential phase 
B. thailandensis E264         107 
Table 3.5 – summary of MIC values for aerobic, microaerophilic and  
anaerobic B. thailandensis        111 
 
Chapter 4 
Table 4.1 – alignment of pglY gene sequence      156 
Table 4.2 – alignment of PglY protein sequence     157 
Table 4.3 – Transposon-containing DNA yields for NEBNext and  
NEXTflex kits          165 
Table 4.4 – Summary of bioanalyser traces of fragmented DNA libraries  172 
Table 4.5 – Summary of Bioanalyser data for PCR amplification and size 
selection steps of library preparation       174 
12 
 
Table 4.6 – Summary of size selected libraries      177 
Table 4.7 – MiSeq result: number of de-multiplexed reads containing 
transposon end sequence         182 
Table 4.8 – HiSeq result: number of de-multiplexed reads containing 
transposon in pool 1         186 
Table 4.9 – top 15 genes of “lost in treatment” list: genes present in input  
list but not in output list         193 
Table 4.10 – top 15 genes of “survived treatment” list: genes present in  
input list and output list         194 
 
Appendix 
Appendix 1 – Full “lost in treatment” TraDIS gene list    259 
Appendix 2 – Full “survived treatment” TraDIS gene list   263 
  
13 
 
List of abbreviations 
%  Percent 
°C  Degrees centigrade  
ACN  Aconitase 
ADEP  Acyldepsipeptide 
AMP  Antimicrobial peptide 
ANOVA Analysis of variance 
AP  Aminoglycoside potentiation 
AQ  2-alkyl-4(1H)-quinolones 
ATP  Adenosine triphosphate 
β  Beta 
BGD  Burkholderia genome database 
BLAST Basic local alignment search tool 
bp  Base pair 
BSL  Biosafety level 
C10 3-[4-(4-methoxyphenyl)piperazin-1-yl]piperidin-4-yl biphenyl-4-
carboxylate 
CaCl2  Calcium chloride 
CEF  Ceftazidime treatment (murine infection) 
CF  Cystic fibrosis 
CFU  Colony forming unit 
CO2  Carbon dioxide 
ClpP  Casein lytic protease 
CPS  Capsule polysaccharide 
CRP  C-reactive protein 
CT  Computed tomography 
DHFR  Dihydrofolate reductase 
DHPS  Dihydropteroate synthase 
DMSO Dimethyl sulfoxide  
DNA  Deoxyribonucleic acid 
dNTP  Nucleoside triphosphate 
DSB  Double-stranded breaks 
EDTA  Ethylenediaminetetraacetic acid 
FCBR  Flow-cell binding region 
14 
 
FU  Fluorescent units 
γ  Gamma 
g  Gram 
GC  Guanine-cytosine (ratio) 
GI   Genomic island or Gastrointestinal  
Gm Gentamicin (if followed by a number, this indicates the 
concentration, in µg/ml) 
GTP  Guanosine triphosphate 
h  Hour 
H2  Hydrogen 
H202  Hydrogen peroxide 
Hip  High persistence 
HITS  High-throughput insertion tracking by deep sequencing 
HTS  High-throughput sequencing 
ICL  Isocitrate lyase 
IDH  Isocitrate dehydrogenase 
IFN  Interferon  
iNOS  Inducible nitric oxide synthase 
INSeq  Insertion sequencing 
JAK-STAT Janus kinases – signal transducers and activators of transcription 
Km Kanamycin (if followed by a number, this indicates the 
concentration, in µg/ml) 
KEGG  Kyoto encyclopaedia of genes and genomes 
KynB  Kynurenine formamidase 
L  Litre 
LA  Lysogeny agar 
LB  Lysogeny broth 
LFI  Lateral flow immunoassay 
Log10  Logarithm to base 10 
LPS  Lipopolysaccharide 
LT  “Lost in treatment” list 
m  Milli or metre 
γ  Micro  
M  Molar 
Mbp  Megabase pairs 
15 
 
MCL  Methylcitrate lyase 
MDT  Multi-drug tolerance/tolerant 
MgSO4  Magnesium sulphate 
MIC  Minimal inhibitory concentration 
min  minute(s) 
MNGC Multi-nucleated giant cell 
mol  Mole 
MPX  Multiplex (primer) 
mRNA messenger ribonucleic acid 
MTZ  Metronidazole (murine infection) 
n  Nano  
NADH  Reduced nicotinamide adenine dinucleotide 
NaCl  Sodium chloride 
NaOAc Sodium acetate 
NaOH  Sodium hydroxide 
NCBI  National centre for biotechnology information 
N2  Nitrogen 
NO  Nitric oxide 
O2  Oxygen 
OD Optical density (if followed by a number, this indicates the 
wavelength, in nm) 
p  Pico or probability 
PBP  Penicillin-binding protein 
PCR  Polymerase chain reaction  
PGL  Phage growth limitation 
pH  Potential of hydrogen 
p.i.   Post inoculation 
PIP  Peak incident power 
PMF  Proton motive force 
PolyP  Inorganic polyphosphate 
(p)ppGpp Guanosine (penta) or tetraphosphate 
qPCR  quantitative real time polymerase chain reaction  
QS  Quorum sensing 
R2  R-squared (coefficient of determination) 
RNA  Ribonucleic acid 
16 
 
ROS  Reactive oxygen species 
RPM  Revolutions per minute 
rRNA  Ribosomal ribonucleic acid 
SR  Stringent response 
ST  “Survived treatment” list 
t  Time/time-point  
T3SS  Type 3 secretion system 
T6SS  Type 6 secretion system 
TA  Toxin-antitoxin 
TAE  Tris-acetate-EDTA 
TCA  Tricarboxylic acid 
TE  Transposable element 
TES  Transposon end sequence 
Tm  Melting temperature 
Tn-Seq Transposon sequencing 
TNF  Tumour necrosis factor 
TraDIS Transposon directed insertion site sequencing 
tRNA  Transfer ribonucleic acid 
UTI  Urinary tract infection 
VBNC  Viable but non-culturable 
WT  Wildtype 
w/v  Weight to volume 
V  Volts 
v/v  Volume to volume 
 
  
17 
 
Conference presentations 
Society for General Microbiology Spring Conference – Manchester, England. 
March 2013.  
“Persister bacteria prevent eradication of Burkholderia thailandensis by 
melioidosis antibiotics.” 
Michael Steele, Claudia Hemsley, Helen Atkins, Richard Titball. 
Poster. 
 
World Melioidosis Congress – Bangkok, Thailand. September 2013.  
“A reporter system for studying persisters in Burkholderia populations.” 
Michael Steele, Claudia Hemsley, Helen Atkins, Richard Titball. 
Poster. 
 
Infection and Immunity Meeting – Hua Hin, Thailand. September 2013.  
“A reporter system for studying persisters in Burkholderia populations.” 
Michael Steele, Claudia Hemsley, Helen Atkins, Richard Titball. 
Poster and oral presentation. 
 
European Melioidosis Congress – Cambridge, England. March 2015.  
“Persister cells in Burkholderia thailandensis” 
Michael Steele, Claudia Hemsley, Helen Atkins, Richard Titball 
Mini-poster. 
 
 
 
 
 
 
18 
 
Acknowledgements 
I dedicate this thesis to my mum and dad, Celesta and Mark Steele. You 
supported me for so many years, and I still keep you in my heart and head.  
 
Thank you to my sister Emily, and to the rest of my family. Thank you to my 
girlfriend Gemma for always supporting me. Thanks to Jane and Yvonne for 
their kindness. I would also like to thank my friends in Leicester, and the friends 
I have made throughout the project, especially Harriet, Andrea, Vanessa, Babs 
and Aaron. 
 
I would like to thank my University supervisors Prof Rick Titball and Dr Claudia 
Hemsley, for their continued advice and support with the project, and for their 
helpful feedback on drafts of this thesis. Thanks also to Dr Helen Atkins at the 
DSTL for helpful discussion and advice. Thanks to my friends and colleagues at 
the University, past and present. Thanks to Dr Monika Bokori-Brown for her 
help, in particular with transposon mutagenesis, and a willingness to dig out 
dusty protocols from 2009 to help me. Thanks to Dr Nicola Senior for her help 
with the TraDIS library preparation, and to Dr Karen Moore for her patience and 
support throughout the challenges of library preparation and sequencing. Thank 
you to Dr Paul O’Neill and Dr Ron Yang for helping me make sense of the 
sequencing data. Thanks also to scientists outside of the university who have 
provided helpful discussion at conferences and by email.  
 
Thank you to the DSTL and University of Exeter for funding the research 
component, under the PhD studentship DSTLX-1000060221 “Pathways that 
enhance antibiotic efficacy” 1/10/12-30/9/15. 
Thank you to Dr Steve Bates and Dr Ed Galyov for examining my thesis and 
providing helpful feedback. 
 
 
  
19 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction 
 
 
 
 
 
 
 
 
 
20 
 
1.1 Persister cells 
1.1.1 Overview  
In 1944, it was found that penicillin invariably failed to sterilise a culture of 
Streptococcus pyogenes, resulting in a small population of bacterial cells which 
produced growth upon re-culture in fresh media (Bigger 1944). These bacteria 
were not resistant mutants, but rather were in a transient state which protected 
them from killing by antibiotics, and were termed persisters. These observations 
form the basis for the definition of a persister cell to be used in this thesis: a 
persister cell is a cell which can be cultured after treatment with one or more 
antibiotics at a high (greater than minimal inhibitory concentration (MIC)) 
concentration. Antibiotic tolerance is used here to refer to the ability of 
persisters to avoid killing when exposed to an antibiotic, and re-grow in culture 
once the antibiotic have been removed (figure 1.1A).  
 
Research into persisters is driven by the fact that they are believed to contribute 
to the failure of antibiotics to treat infections in the absence of conventional 
inherited antibiotic resistance (Levin and Rozen 2006, Fauvart, De Groote et al. 
2011). Persisters are strongly believed to play a role in numerous chronic and 
persistent infectious diseases, such as Pseudomonas aeruginosa in Cystic 
Fibrosis (CF) pneumonia, Staphylococcus aureus in wounds and on implanted 
devices, and tuberculosis (reviewed by (Fauvart, De Groote et al. 2011, Conlon 
2014)). Persisters may contribute to the drug tolerance of biofilms (figure 1.2) 
and to relapse of disease after antibiotic treatment has stopped (Levin and 
Rozen 2006, Fauvart, De Groote et al. 2011, Cohen, Lobritz et al. 2013, Stewart 
2015). Also, they are predicted to be a reservoir for the emergence of 
conventional antibiotic resistance (Levin and Rozen 2006, Cohen, Lobritz et al. 
2013).  
 
Supporting these predictions, there is evidence for selection of persisters in 
vivo. Sequencing of longitudinal P. aeruginosa isolates of CF patients has 
suggested that mutations which increase persister frequencies are selected for 
in vivo (Mulcahy, Burns et al. 2010), and persister frequencies are higher in 
strains which cause repeated, relapsing infection than those that cause acute 
infections (Mulcahy, Burns et al. 2010, Goneau, Yeoh et al. 2014). In addition, 
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non-replicating Salmonella persisters have been directly observed inside host 
cells (Helaine, Cheverton et al. 2014, Fisher, Cheverton et al. 2016), and 
S. aureus persisters tolerant to multiple antibiotics are present in deep-seated 
infections in mice (Conlon, Nakayasu et al. 2013). These studies indicate that 
persisters may be involved in persistent disease. Therefore, it is hoped that an 
increased understanding of persisters will lead to improved treatment of 
persistent infectious diseases (Fauvart, De Groote et al. 2011, Kint, Verstraeten 
et al. 2012, Cohen, Lobritz et al. 2013). 
 
The presence of antibiotic tolerant persister cells can be demonstrated 
experimentally in vitro (figure 1.1B). In this assay, a culture of bacteria is treated 
with antibiotic, usually at least at 10x MIC. The number of cells that can re-grow 
(form a colony) when the antibiotic is removed is quantified. The number of 
culturable cells initially drops as the susceptible population is killed or becomes 
non-culturable. The presence of persisters then becomes apparent, as a 
population which survive (Keren, Kaldalu et al. 2004, Levin and Rozen 2006, 
Lewis 2007, Brauner, Fridman et al. 2016). Importantly, these bacteria do not 
display inherited antibiotic resistance; upon re-culture, persisters generate a 
population which behaves as the original culture (Bigger 1944, Keren, Kaldalu 
et al. 2004). 
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Figure 1.1 – Persisters in bacterial cultures 
Bacterial culture treated with antibiotics. 
A) top panel: a population of non persisters (red cells) can give rise to a 
population containing persisters (black cells), as seen in the middle panel. 
Bottom panel: antibiotic treatment results in non-persisters being killed or 
rendered non-culturable, leaving surviving persisters as the only culturable 
fraction. 
Removal of antibiotic enables the surviving persisters to generate a new 
population (arrow back to top panel). 
 
B) measurement of culturable cells over time (or at different doses of antibiotics 
[AB]) demonstrates biphasic kinetics (solid line). In the first phase (steep dotted 
line), the majority of cells (non-persisters) die or become non-culturable. In the 
second phase (shallow dotted line), the persisters are detected as a more stable 
population which declines at a lower rate. 
 
Reprinted from Tends in Microbiology, volume 20, C. Kint, N. Verstraeten, M. 
Fauvart and J. Michiels, New-found fundamentals of bacterial persistence, 
Pages 577-585, Copyright (2012), with permission from Elsevier. 
(Kint, Verstraeten et al. 2012). 
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Figure 1.2 – Model for persisters in a biofilm 
Left: A biofilm attached to a surface contains persister cells (blue) and non-
persister cells (“regular cells”, red). Both cell types may also be outside of the 
biofilm. 
The combination of antibiotic treatment and immune system kills all the non-
persister cells, and the persister cells that are outside the biofilm.  
Right: persisters in the biofilm survive antibiotic treatment and activity of the 
immune system. The biofilm protects persisters from the immune system. 
Antibiotic concentration then drops. Persisters then re-generate a new 
population of non-persister cells and persisters in the biofilm, which again 
sheds both cell types (left panel again). 
 
From (Lewis 2010). 
Elsevier: Permission not required for use in thesis. 
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1.1.2 Persister cell biology  
Persisters have long been believed to be non-growing, as this could account for 
their tolerance to antibiotics, which generally target growing cells (Bigger 1944, 
Keren, Kaldalu et al. 2004, Keren, Shah et al. 2004, Lewis 2007). Retrospective 
analysis of Escherichia coli grown in microfluidic chambers indicates that 
persisters are non-growing or slowly growing cells (Balaban, Merrin et al. 2004). 
Persisters are thought to have a reduced metabolism or even dormancy, a 
possible state of complete metabolic shutdown (Lewis 2007, Wood, Knabel et 
al. 2013). Experimental evidence for low metabolic activity has primarily come 
from transcriptomic studies (see below), and studies on populations with low 
translation activity, which are enriched for persisters (Shah, Zhang et al. 2006, 
Maisonneuve, Shakespeare et al. 2011, Kwan, Valenta et al. 2013).  
 
Recent studies have contested the idea that all persisters are non-growing 
and/or dormant. Persister assays conducted on differentially growing sub-
populations of an E. coli culture indicated that persisters can display a range of 
growth rates, although most persisters were non-growing. Many persisters 
displayed metabolic activity (measured using redox stain). Together, these 
findings challenge the traditional view of all persisters being non-growing and/or 
dormant (Orman and Brynildsen 2013). Additionally, drug tolerance 
mechanisms which function independently of growth rate have led to 
observations of replicating persisters in Mycobacterium smegmatis (Wakamoto, 
Dhar et al. 2013). The questions of non-growth and dormancy in persisters are 
further discussed elsewhere (Allison, Brynildsen et al. 2011, Orman and 
Brynildsen 2013, Wood, Knabel et al. 2013), as is the current knowledge of 
persister metabolism (Amato, Fazen et al. 2014, Maisonneuve and Gerdes 
2014, Prax and Bertram 2014). 
 
Direct measurements of the molecular profile of persisters, such as 
transcriptome analysis, often require persister isolation. There are a number of 
hurdles which complicate this, including the transient nature of persisters, their 
low frequency in a bacterial culture, and the difficulty in separating them from 
other cell populations (e.g. dead cells, viable but non-culturable cells (VBNCs)) 
in antibiotic treated cultures. Nonetheless, cultures have been enriched for 
persisters based on low translation (Shah, Zhang et al. 2006) and selection 
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using a lytic antibiotic (antibiotic tolerance) (Keren, Shah et al. 2004, Keren, 
Minami et al. 2011). Transcriptome analysis of these populations have indicated 
up-regulated expression of toxin-antitoxin (TA) toxins (section 1.1.4.1), 
compared with untreated cultures, and down-regulated expression of a range of 
essential cellular processes such as translation and DNA replication (Keren, 
Shah et al. 2004, Shah, Zhang et al. 2006, Keren, Minami et al. 2011). 
However, at least for E. coli, VBNCs may contribute noise to these datasets. It 
has been shown for E. coli that, like persisters, VBNCs can survive antibiotic 
treatment and provide contaminating RNA in transcriptomic studies of persisters 
(Orman and Brynildsen 2013). Transcriptome analyses of persisters in other 
bacteria have indicated that persisters have a distinct expression profile from 
other cells. The transcriptome of B. thailandensis persisters suggested activity 
of alternative metabolic pathways, such as the arginine deimination pathway 
and denitrification (Hemsley, Luo et al. 2014). Transcriptomic data from 
B. cenocepacia persisters indicated general down-regulation of metabolism but 
activity of certain metabolic pathways, such as the glyoxylate bypass (Van 
Acker, Sass et al. 2013). 
 
Alternative studies which do not require persister cell isolation have shed light 
on the phenotype and activity of persisters. Persisters are able to metabolise 
certain carbon sources, which generates metabolism and proton motive force, 
resulting in killing by aminoglycosides (Allison, Brynildsen et al. 2011). This 
process is called aminoglycoside potentiation (AP) (Allison, Brynildsen et al. 
2011, Orman, Mok et al. 2015). Using this approach, Orman and Brynildsen 
screened a range of carbon sources in E. coli persisters tolerant to ofloxacin. 
Glucose and glycerol produced a strong AP effect, suggesting that metabolism 
of these carbon sources occurs in persisters. In contrast, succinate and 
arabinose produced no AP effect, and therefore were not used in persisters 
(Orman and Brynildsen 2013).  Later analysis of this process indicated that 
carbon source metabolism in persisters depends on the global transcriptional 
regulator C-reactive protein (CRP) (Mok, Orman et al. 2015).  These results 
indicate that carbon metabolism, including glycolysis, TCA cycle and electron 
transfer occur in persisters to varying extents, depending on the carbon sources 
available, and that this process is regulated on a global transcriptional level. 
26 
 
Also using the AP method above, P. aeruginosa persister cells were shown to 
metabolise mannitol and glucose (Barraud, Buson et al. 2013). 
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1.1.3 Antibiotic tolerance mechanisms 
It is widely known that antibiotics are generally less effective against slowly/non-
growing cells than against rapidly growing cells (Cozens, Tuomanen et al. 1986, 
Eng, Padberg et al. 1991, Spoering and Lewis 2001, Keren, Kaldalu et al. 
2004). As persisters are believed to be slow- or non-growing and have low 
metabolic activity, tolerance is thought to come from inactivation of these drug 
targets, so that their function cannot be subverted by antibiotics (Keren, Shah et 
al. 2004, Lewis 2007, Wood, Knabel et al. 2013). Many antibiotics depend on an 
active target to exert their toxicity. For example, type II topoisomerases (such as 
DNA gyrase), the target of the fluoroquinolone class of antibiotics, cause 
transient double-stranded breaks (DSBs) as part of their normal activity altering 
DNA topology. Fluoroquinolones stabilise these DSBs, preventing re-joining of 
DNA strands, leading to inhibition of DNA replication and transcription, and cell 
death (reviewed by (Drlica, Malik et al. 2008, Kohanski, Dwyer et al. 2010)). As 
another example, β-lactam antibiotics cause lysis by inhibiting the 
transpeptidation activity of penicillin binding proteins (PBPs), which normally 
catalyse formation of the peptidoglycan layer in the cell wall. This prevents 
cross-linking of peptidoglycan chains, weakening the cell wall and resulting in 
lysis (Hayes and Orr 1983, Rodloff, Goldstein et al. 2006, Papp-Wallace, 
Endimiani et al. 2011). As process involving these drug targets, such as DNA 
replication and cell wall synthesis, are thought to be inactive in non-growing 
persisters, this is believed to confer tolerance to antibiotics which target these 
processes (Keren, Shah et al. 2004, Lewis 2007, Wood, Knabel et al. 2013).  
 
Supporting the role for drug target inactivation in antibiotic tolerance, inhibiting 
drug targets with sub-inhibitory treatment with an antibiotic increases tolerance 
to high concentrations of the same antibiotic in E. coli (Goneau, Yeoh et al. 
2014). In another report, inhibiting transcription or translation, which would 
reduce levels of drug targets, increased the number of persisters (Kwan, 
Valenta et al. 2013). Therefore drug target inactivation due to slow/non-growth 
and/or low metabolic activity is thought to contribute to antibiotic tolerance of 
persisters. 
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Killing as a direct result of drug-target interaction is the traditional view of 
antibiotic-based killing. More recently, an additional basis for antibiotic killing 
has emerged. Kohanski et al. suggested that antibiotics, regardless of initial 
target, generate reactive oxygen species (ROS) which contribute to cell killing 
(Kohanski, Dwyer et al. 2007). Since then, there has been increasing support 
for the notion that ROS generation by antibiotics contributes to killing, in 
addition to the conventional toxicity caused by drug-target interaction (Wang 
and Zhao 2009, Kohanski, Dwyer et al. 2010, Dwyer, Belenky et al. 2014, Zhao, 
Hong et al. 2015). However, the idea is highly contested, partly due to concerns 
over the techniques used to detect ROS (Keren, Wu et al. 2013, Liu and Imlay 
2013, Imlay 2015). The level of involvement of ROS in antibiotic killing is still 
under investigation; the current literature on the subject is reviewed elsewhere 
(Dwyer, Collins et al. 2015, Imlay 2015, Zhao, Hong et al. 2015). Here, the 
focus is on resistance to killing by ROS as a potential mechanism of antibiotic 
tolerance in persisters. 
 
Several studies have suggested that protection against ROS contributes to the 
antibiotic tolerance of persisters. For example, catalases, which convert toxic 
hydrogen peroxide into oxygen and water, have been shown to be up-regulated 
in persisters and regulated by the stringent response (SR) (Nguyen, Joshi-Datar 
et al. 2011, Khakimova, Ahlgren et al. 2013). The functional role for these 
enzymes in antibiotic tolerance has been demonstrated by the fact that mutating 
the genes encoding these enzymes, or inhibiting catalases chemically, results in 
fewer persisters in antibiotic treated E. coli, P. aeruginosa and B. cenocepacia 
(Wang and Zhao 2009, Khakimova, Ahlgren et al. 2013, Van Acker, Sass et al. 
2013). In addition to active ROS detoxification, persisters generate lower levels 
of ROS due to altered metabolism. B. cenocepacia persister cells tolerant to 
tobramycin use alternative pathways to preclude the generation of ROS. The 
glyoxylate bypass is a variation of part of the TCA cycle, which results in less 
NADH generation (and hence oxidative phosphorylation) compared with the full 
TCA cycle. Increased activity of this pathway in persisters results in less 
electron transport chain activity compared with use of the full TCA cycle (Van 
Acker, Sass et al. 2013).  Therefore persisters generate less ROS than non-
persisters, resulting in less killing by antibiotics (Van Acker, Sass et al. 2013). 
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Together, these reports suggest that protection against ROS is an additional 
form of protection for persister cells when exposed to antibiotics. 
 
The SOS response is induced by single stranded DNA, primarily resulting from 
DNA damage, and results in activation of a number of responses which result in 
DNA repair and adaptation, reviewed by (Baharoglu and Mazel 2014). SOS-
deficient mutant E. coli strains have fewer ciprofloxacin persisters, as they are 
less able to repair damage caused by antibiotics (Goneau, Yeoh et al. 2014, 
Volzing and Brynildsen 2015). This suggests that the SOS response is involved 
in tolerance to DNA-damaging antibiotics. Expanding on this, SOS response 
mediated DNA repair appears to be activated not during antibiotic treatment, but 
during re-growth of persisters after treatment, suggesting it enables the 
persisters that survive fluoroquinolones to re-grow (Volzing and Brynildsen 
2015).  
 
In specific cases, other phenotypic mechanisms have been observed to enable 
a sub-population to survive antibiotic treatment. For example, treatment of an 
isogenic culture of M. smegmatis with isoniazid results in the death of the 
majority of bacteria, but a sub-population survives and re-grows after treatment 
(persisters) (Wakamoto, Dhar et al. 2013). The tolerant sub-population has 
lower levels of the catalase-peroxidase KatG, an enzyme required to activate 
the drug, compared with susceptible cells. Therefore less activated isoniazid is 
generated in persisters. Levels of KatG and hence susceptibility to isoniazid 
were independent of growth rate, enabling phenotypic antibiotic tolerance of a 
growing population (Wakamoto, Dhar et al. 2013). 
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1.1.4 Formation of persister cells 
Persisters are thought to arise primarily from exposure to stressful conditions 
(Lewis 2010, Helaine and Kugelberg 2014, Maisonneuve and Gerdes 2014). 
For example, persister frequencies are higher in stationary phase cultures, 
which undergo nutrient stress and growth limitation, than in exponentially 
growing cultures (Spoering and Lewis 2001, Keren, Kaldalu et al. 2004, Keren, 
Minami et al. 2011, Lechner, Lewis et al. 2012, Butt, Higman et al. 2014). Other 
stresses that can increase persister cell formation include carbon source 
transitions, low oxygen levels, exposure to oxidants and even antibiotic 
treatment (Dorr, Vulic et al. 2010, Hamad, Austin et al. 2011, Wu, Vulic et al. 
2012, Amato, Orman et al. 2013). These findings suggest that 
extracellular/deterministic factors can influence persister cell formation.  
 
However, cells can also form persisters in unstressed conditions (Balaban, 
Merrin et al. 2004). This suggests that intracellular factors can influence 
persister cell formation in the absence of external signals. Combining these 
findings, it is believed that persisters form through internal mechanisms which 
can be regulated by extracellular factors (reviews by (Cohen, Lobritz et al. 2013, 
Helaine and Kugelberg 2014, Maisonneuve and Gerdes 2014)). Two key 
mechanisms linked to persister cell formation are discussed below: TA systems 
and the SR. 
 
1.1.4.1 Toxin-antitoxin systems 
The first mechanism of persister cell formation was suggested after chemical 
mutagenesis of E. coli, which demonstrated  mutants with “high persistence” 
(Hip) phenotypes (Moyed and Bertrand 1983). Mutations in these hip strains 
were mapped to the hipA gene of the hipBA operon, which encodes a toxin-
antitoxin system (Moyed and Bertrand 1983, Moyed and Broderick 1986, Black, 
Kelly et al. 1991). In TA systems, a toxin inhibits a cellular target, while an 
antitoxin binds to the toxin and blocks its inhibitory activity. HipBA is a type II TA 
system, where both toxin and antitoxin are proteins (figure 1.3). HipA is an 
inhibitor of glutamyl-tRNA synthetase (Germain, Castro-Roa et al. 2013, Kaspy, 
Rotem et al. 2013). Therefore, if HipA is not neutralised by HipB, uncharged 
tRNA accumulates in the cell. This activates the SR, causing growth arrest and 
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formation of persister cells (Germain, Castro-Roa et al. 2013, Kaspy, Rotem et 
al. 2013). Collectively, TA toxins  target a range of cellular processes, including 
translation (e.g. the ribosome), replication (e.g. DNA gyrase) and membrane 
integrity (e.g. inner cell membrane), therefore, there are many ways in which TA 
systems as a whole can influence persister cell formation (reviews by (Gerdes 
and Maisonneuve 2012, Wagner and Unoson 2012, Wen, Behiels et al. 2014)).  
 
TA toxins, particularly type II TA toxins, have been implicated as effectors of the 
switch from non-persister to persister cell, due to their ability to inactivate 
cellular targets of antibiotics (Keren, Shah et al. 2004, Gerdes and 
Maisonneuve 2012). Transcriptomic data from persister cultures showed up-
regulation of toxin encoding genes, despite a general down-regulation of 
metabolism, supporting a role for TA systems in metabolically inactive persister 
cells (Keren, Shah et al. 2004, Shah, Zhang et al. 2006, Keren, Minami et al. 
2011). Additionally, over-expression of genes encoding TA toxins causes a rise 
in the number of persister cells in a culture (Korch and Hill 2006, Maisonneuve, 
Shakespeare et al. 2011, Slattery, Victorsen et al. 2013, Butt, Higman et al. 
2014).  
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Figure 1.3 – Type II toxin-antitoxin systems 
The genes encoding the antitoxin and toxin proteins are on a co-regulated 
operon. Transcription from the promoter generates mRNA for toxin and 
antitoxin, which are used to produce proteins. Toxins inhibit cellular functions, 
leading to growth arrest. Antitoxins sequester toxins into a complex, enabling 
growth. Both the toxin-antitoxin complex and free antitoxin can repress 
transcription of the operon, lowering levels of toxin. Degradation of antitoxin by 
ATP-dependent proteases, such as Lon, increases the ratio of toxin: antitoxin, 
leading to free toxin and growth arrest. 
 
From (Yamaguchi, Park et al. 2011).  
Elsevier: Permission not required for use in thesis. 
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Significant overlap in function of TA toxins has been reported. In E. coli, various 
type II TA systems have been shown to increase persister frequencies when 
over-expressed (Maisonneuve, Shakespeare et al. 2011). Deletion of any one 
these individual systems has no effect on persister frequency, indicating that 
these systems can compensate for the loss of one another (Maisonneuve, 
Shakespeare et al. 2011). However, deletion of all 10 mRNA-targeting type II 
TA systems in a single strain resulted in a >100-fold reduction in persister 
frequency. Therefore, in E. coli, TA systems function cumulatively in persister 
cell formation, but the functions of individual systems may be redundant. 
Removal of some individual systems does result in a reduction in persister 
frequencies for other bacteria, such as M. tuberculosis, B. pseudomallei and 
Salmonella typhimurium (Singh, Barry et al. 2010, Butt, Higman et al. 2014, 
Helaine, Cheverton et al. 2014), and in some conditions for E. coli (Dorr, Vulic 
et al. 2010). These results suggest that the importance of individual systems in 
persister cell formation is variable, and may be dependent on organism and 
assay/culture conditions.  
 
Persister cell formation by TA toxins is a complex, highly regulated process. 
The ratio of toxin to antitoxin in individual systems determines whether there will 
be excess free toxin or neutralised toxin-antitoxin complexes i.e., whether or not 
that system will contribute to growth inhibition by inhibiting cellular function. This 
ratio can vary within individual cells due to stochastic (random) fluctuations in 
the number of toxin and antitoxin molecules, and autoregulation of TA system 
expression (Fasani and Savageau 2013). Also, antitoxins may be degraded by 
proteases such as Lon or casein lytic protease (ClpP), increasing the ratio of 
toxin to antitoxin (Kim, Wang et al. 2010, Maisonneuve, Shakespeare et al. 
2011). These processes result in variation in the amount of excess toxin 
between individual cells within a population, resulting in heterogeneity in cellular 
target activity and growth rate across the population. Cells with excess free 
toxin above a threshold number of molecules are more likely to be non-growing 
persisters (Rotem, Loinger et al. 2010).  
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1.1.4.2 Stringent response and (p)ppGpp 
The SR is a chemical pathway which is activated by a range of stresses 
including oxidative stress and nutrient starvation, and results in adaptation and 
protective responses. The main effector of the SR is (p)ppGpp (which refers to 
the two guanosine derivatives ppGpp and pppGpp). In stressful conditions, 
(p)ppGpp is generated by RelA, and interacts with a range of cellular targets 
(Gaca, Colomer-Winter et al. 2015). This results in inhibition of translation, 
replication and GTP biosynthesis. (p)ppGpp also transcriptionally regulates 
expression of various genes, resulting in non-growth and adaptation to stress 
(reviewed by (Gaca, Colomer-Winter et al. 2015)). 
 
The SR and (p)ppGpp have been linked to persister cell formation, but the ways 
in which they regulate this process are still being investigated. Korch et al. first 
suggested that (p)ppGpp was essential for the high persistence phenotype of 
the E. coli HipA7 strain (Korch, Henderson et al. 2003), a mutant strain which 
produces >100x more persisters than wild type (Moyed and Bertrand 1983). 
Deletion of the genes producing the SR effector (p)ppGpp restored persister 
frequencies of HipA7 to wild type levels (Korch, Henderson et al. 2003). The SR 
has since been linked to persister formation in wild type strains, suggesting it 
plays a role in normal persister formation, in addition to high persistence. It has 
been shown that mutants unable to produce (p)ppGpp, which are deficient in 
the SR, produce persisters at a lower level (Nguyen, Joshi-Datar et al. 2011, 
Maisonneuve, Castro-Camargo et al. 2013).  In E. coli, (p)ppGpp has been 
suggested to regulate TA system activity by increasing levels of inorganic 
polyphosphate (PolyP), which then positively regulates Lon protease, leading to 
anti-toxin degradation and release of toxin (Maisonneuve, Castro-Camargo et 
al. 2013, Germain, Roghanian et al. 2015). Furthermore, the SR regulates many 
processes associated with persister cells, such as growth inhibition and 
antioxidant defences, which may indirectly influence tolerance to antibiotics 
(reviewed by (Gaca, Colomer-Winter et al. 2015)). 
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1.1.5 Eradication of persister cells  
1.1.5.1 Increasing sensitivity to antibiotics  
Stimulating growth in persisters would theoretically activate their antibiotic 
targets, restoring antibiotic susceptibility to that of the rest of the bacterial 
population. Of a chemical library tested against E. coli, 3-[4-(4-
methoxyphenyl)piperazin-1-yl]piperidin-4-yl biphenyl-4-carboxylate (C10) was 
found to eradicate persisters in E. coli when treated with antibiotics (norfloxacin 
or ampicillin), but had no effect on bacterial viability in the absence of antibiotic. 
This suggests that C10 specifically targets persisters. Culture of C10 with 
persisters demonstrated that C10 stimulated the persisters to revert to growing 
cells, making them susceptible to antibiotic, although the mechanism of 
reversion is not known (Kim, Heo et al. 2011).  
 
As described in section 1.1.4.2, (p)ppGpp is increasingly being recognised as a 
key regulator of persister cell formation and maintenance. Inhibition of (p)ppGpp 
may sensitise persisters to antibiotics, by disabling some of the SR-mediated 
antibiotic tolerance mechanisms (Gaca, Colomer-Winter et al. 2015). Inhibition 
of (p)ppGpp synthesis or degradation of (p)ppGpp are two strategies being 
developed against biofilms (Wexselblatt, Oppenheimer-Shaanan et al. 2012, de 
la Fuente-Nunez, Reffuveille et al. 2014, Reffuveille, de la Fuente-Nunez et al. 
2014). Given the success of these approaches, there is interest in developing 
(p)ppGpp inhibitors to sensitise persisters to antibiotics in combination therapy 
(Gaca, Colomer-Winter et al. 2015).  
 
Given the possible contributing role for ROS in antibiotic killing (section 1.1.3), 
inhibiting the ROS defences of persisters may have potential as an adjuvant to 
antibiotics. As described in section 1.1.3, inhibiting catalases or superoxide 
dismutases reduces the number of persisters when used in combination with 
antibiotics. For example, superoxide dismutase inhibition by 
diethyldithiocarbamate results in fewer persisters in a B. cenocepacia biofilm, 
when combined with tobramycin (Van Acker, Sass et al. 2013). In a related 
approach, the authors also reported that inhibiting pathways which preclude 
ROS generation can increase the efficacy of antibiotics. Inhibiting the glyoxylate 
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bypass increased the amount of ROS in tobramycin treated B. cenocepacia 
persisters (Van Acker, Sass et al. 2013).  
 
The SOS response is also a target for inhibition in persisters. This increases 
their sensitivity to DNA-damaging antibiotics. For example, Lu and Collins used 
a bacteriophage gene delivery system to repress the SOS response in E. coli. 
This reduced the number of persisters when used in combination with ofloxacin, 
due to repression of DNA damage repair (Lu and Collins 2009). The 
phage/antibiotic combination led to improved treatment of chronically infected 
mice.  
 
A strategy which exploits the limited metabolic activity of persisters was 
demonstrated by Allison et al., which formed the basis of the aminoglycoside 
potentiation (AP) assay described in section 1.1.2. It was found that persisters 
tolerant to several aminoglycosides had a lower proton motive force (PMF) than 
non-persisters. As aminoglycosides require PMF to enter a bacterial cell (Taber, 
Mueller et al. 1987), persisters are believed to have reduced uptake of the drug 
(Allison, Brynildsen et al. 2011). Stimulating respiration with carbon sources 
such as glucose and mannitol sensitised persisters to gentamicin by activating 
PMF; the drug was then able to enter and kill persisters. This resulted in 
eradication of persisters in E. coli planktonic cultures as well as E. coli and 
S. aureus biofilms, and improved treatment of a murine infection model (Allison, 
Brynildsen et al. 2011). Using this method, mannitol was also found to increase 
uptake and killing of the aminoglycoside tobramycin by P. aeruginosa persisters 
(Barraud, Buson et al. 2013). Aminoglycosides can also be potentiated against 
persisters in a range of bacteria by inducing an alkaline environment (such as 
by adding basic amino acids). This causes a pH gradient, increasing the PMF 
and enabling drug uptake into the cell (Lebeaux, Chauhan et al. 2014). 
However, it is not clear what effect this has on the persister cell metabolism, if 
any.  
 
1.1.5.2 Directly inhibiting persisters 
Acyldepsipeptides (ADEPs) are antibiotics currently being developed, which 
target the cellular protease ClpP (Brotz-Oesterhelt, Beyer et al. 2005). 
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Antibacterial activity can be exerted by activating or inhibiting ClpP, depending 
on the bacterium (Vass and Chien 2016). A synthetic derivative ADEP-4 was 
shown to activate ClpP in S. aureus, causing degradation of over 400 cellular 
proteins, and eradicating a culture of multidrug-tolerant persisters in vitro 
(Conlon, Nakayasu et al. 2013). ADEP-4 in combination with rifampicin was 
also able to sterilise murine chronic infection models containing persisters and 
biofilm (Conlon, Nakayasu et al. 2013).  
 
Phage and their products have been used to eradicate persisters directly. 
Endolysins, phage-encoded enzymes which degrade peptidoglycan, have been 
shown to have activity against persisters. Conjugates of antimicrobial peptides 
(AMPs) and endolysin were used to kill P. aeruginosa persisters, and 
endolysins alone can kill S. aureus persisters in a biofilm (Briers, Walmagh et 
al. 2014, Gutierrez, Ruas-Madiedo et al. 2014). 
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1.2 Burkholderia pseudomallei  
1.2.1 Bacteriology 
B. pseudomallei is a species of Gram negative, non-spore-forming, rod-shaped 
bacteria. The reference strain B. pseudomallei K96243 (a Thai clinical isolate) 
contains a 7.248Mbp genome, over two chromosomes of 4.075Mbp 
(chromosome 1) and 3.173Mbp (chromosome 2), with an average GC content 
of 68% (Holden, Titball et al. 2004). B. pseudomallei belongs to the 
Burkholderia genus, a group of over 40 diverse species, including 
environmental bacteria, opportunistic pathogens and obligate pathogens. 
B. pseudomallei is an environmental saprophyte commonly found in tropical 
areas such as Southeast Asia and Northern Australia. It has been isolated from 
soil, water and mud in endemic areas (reviewed by (Dance 2000, Cheng and 
Currie 2005)). The bacterium is able to survive in distilled water for many years 
(Pumpuang, Chantratita et al. 2011) and in desiccated soil for over 70 days 
(Larsen, Smith et al. 2013). B. pseudomallei has an array of resistance 
mechanisms to a range of antibiotics, reviewed by (Schweizer 2012). 
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1.2.2 Virulence factors 
B. pseudomallei is an opportunistic pathogen which causes the disease 
melioidosis. The bacterium is believed to use a number of virulence factors 
during infection of the host including: capsule polysaccharide (CPS), which may 
inhibit phagocytosis by preventing complement deposition (Reckseidler-
Zenteno, DeVinney et al. 2005); lipopolysaccharide (LPS), which contributes to 
serum resistance (DeShazer, Brett et al. 1998); a type 4 pilus, which enables 
adhesion to epithelial cells (Essex-Lopresti, Boddey et al. 2005); type 3 
secretion system (T3SS) -3, which secretes numerous effectors into target cells 
(reviewed by (Stevens, Haque et al. 2004, Allwood, Devenish et al. 2011)), 
contributing to processes such as invasion (Stevens, Friebel et al. 2003), 
escape from membrane vesicles (Stevens, Wood et al. 2002) and actin motility 
(Stevens, Wood et al. 2002); BimA, an autotransporter protein which 
manipulates host actin, enabling actin-based motility in host cells (Stevens, 
Stevens et al. 2005); and type 6 secretion system (T6SS) -1, which is involved 
in multi-nucleated giant cell (MNGC) formation and cytotoxicity  (Burtnick, Brett 
et al. 2011). Population level signalling may also influence the virulence of 
B. pseudomallei populations. For example, the BpsI–BpsR quorum sensing 
(QS) system regulates biofilm formation (Gamage, Shui et al. 2011).  Many 
reviews are available on virulence factors of B. pseudomallei, such as (Galyov, 
Brett et al. 2010, Allwood, Devenish et al. 2011, Wiersinga, Currie et al. 2012, 
Stone, DeShazer et al. 2014). 
 
Variant forms of virulence factors in B. pseudomallei have been linked to 
variability in disease outcome. For example, different forms of BimA exist in 
B. pseudomallei. The standard BimABp and variant BimABm both polymerise 
host actin, but the latter is less common, and has high sequence similarity to the 
BimA in B. mallei (Sarovich, Price et al. 2014). Neurological melioidosis is 
significantly more common in patients infected with B. pseudomallei with the 
BimABm than with BimABp-type B. pseudomallei, while the BimABp was 
associated with a greater probability of pneumonia (Sarovich, Price et al. 2014). 
These observations suggest that variant forms influence the contribution of 
virulence factors to disease. 
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1.2.3 B. thailandensis as a model for B. pseudomallei  
The closely related species B. thailandensis often co-exists with 
B. pseudomallei in the environment in endemic areas (Dance 2000). The 
genome of the prototype strain, B. thailandensis E264, consists of two 
chromosomes of 3.809Mb and 2.915Mb (Kim, Schell et al. 2005). These 
chromosomes are generally similar to the two chromosomes of B. pseudomallei 
(Yu, Kim et al. 2006). Despite the broad similarity, B. thailandensis is less able 
to cause disease in humans than B. pseudomallei, and does not require 
handling at BSL containment level 3 (CDC 2012). This has led to the use of 
B. thailandensis as a more tractable model for B. pseudomallei research for a 
range of areas such as T3SS-3, anaerobic respiration and soil survival 
(Jitprasutwit, Thaewpia et al. 2010, Andreae, Titball et al. 2014, Bishop and 
Rachwal 2014). The work reported here studied persister cells in 
B. thailandensis, as a model for B. pseudomallei persisters. 
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1.2.4 Persister cells in B. pseudomallei and B. thailandensis 
Several studies have investigated tolerance of B. thailandensis and 
B. pseudomallei to different antibiotics, using various strains and culture 
conditions (e.g. growth phase) (Hamad, Austin et al. 2011, Butt, Higman et al. 
2014, Hemsley, Luo et al. 2014, Nierman, Yu et al. 2015, Butt, Halliday et al. 
2016). Rather than report persister frequencies for every condition tested, this 
section will give an overview of trends and general patterns of persister cell 
formation and antibiotic tolerance in B. thailandensis E264 and B. pseudomallei 
(strain K96243, unless stated). 
 
Numerous environmental stresses increase the frequency of persisters, 
suggesting a role for stress responses in persister formation and antibiotic 
tolerance. Generally, stationary phase cultures have increased antibiotic 
tolerance compared with growing cultures. Increased persister frequencies were 
seen in stationary phase cultures for ceftazidime and ciprofloxacin in 
B. pseudomallei K96243 (Butt, Higman et al. 2014). Similarly, B. pseudomallei 
Bp82 (a select agent exempt strain) produces more persisters that can tolerate 
cefotaxime, gentamicin or  ciprofloxacin at stationary phase (Nierman, Yu et al. 
2015). Prolonged culture (>1 week) in aerobic or anaerobic conditions, which 
leads to various stresses such as pH stresses, results in cultures almost 
completely enriched (50-100%) for persisters (Hamad, Austin et al. 2011, 
Nierman, Yu et al. 2015). Other stresses which increase persister frequencies 
include nutrient starvation (incubation in distilled water) or pre-incubation with 
low concentrations (sub-MIC) of trimethoprim (Nierman, Yu et al. 2015).  
 
Oxygen also influences persister frequencies, with increased numbers under 
anaerobic conditions for a number of antibiotics. For B. pseudomallei, anaerobic 
conditions increase the number of persisters tolerant to chloramphenicol, 
ceftazidime and trimethoprim-sulfamethoxazole (Hamad, Austin et al. 2011). 
Anaerobically incubated B. thailandensis displays more persisters for 
ceftazidime (but not ciprofloxacin), compared with aerobic cultures (Hemsley, 
Luo et al. 2014). The gene expression profiles of B. thailandensis ceftazidime 
persisters (Hemsley, Luo et al. 2014) and anaerobic B. pseudomallei (Hamad, 
Austin et al. 2011) have a high level of similarity, providing a further link 
between adaptation to anaerobic conditions and tolerance to antibiotics 
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(Hemsley, Luo et al. 2014). Consistent with this, continuous aeration (shaking) 
of B. pseudomallei Bp82 reduces the number of persisters, resulting in no 
culturable survivors after treatment with cefotaxime or gentamicin (Nierman, Yu 
et al. 2015), and increasing the oxygen levels in cultures (either by introducing 
dissolved oxygen or modifying the oxygen gradient) improved antibiotic killing of 
anaerobically adapted B. thailandensis (Hemsley, Luo et al. 2014). In addition, 
nitroimidazoles, antibiotics activated under anaerobic conditions, are also 
sometimes effective against anaerobic B. pseudomallei, depending on duration 
of anaerobic exposure (Hamad, Austin et al. 2011).  
 
Numerous studies have identified molecular factors underling persister 
formation and antibiotic tolerance. Expression of the HicA toxin of the HicAB 
system inhibits growth of B. pseudomallei, leading to an increase in the number 
of persister cells tolerant to ceftazidime or ciprofloxacin (Butt, Higman et al. 
2014). Removal of this system increases susceptibility to ciprofloxacin (Butt, 
Higman et al. 2014). There are several other identified TA toxins in 
B. pseudomallei which affect bacterial growth (Butt, Muller et al. 2013); further 
work may indicate whether these play a role in persister cells. (p)ppGpp also 
appears to contribute to antibiotic tolerance in B. pseudomallei. A relA spoT 
B. pseudomallei strain is unable to produce (p)ppGpp (Muller, Conejero et al. 
2012) and displays a 1-log reduction in ceftazidime persister frequency (Claudia 
Hemsley, personal communication). Other cellular processes linked to persister 
cell formation include denitrification and arginine deimination. Transcription of 
genes encoding enzymes in these pathways is increased in ceftazidime tolerant 
persisters (Hemsley, Luo et al. 2014). Additionally, kynurenine formamidase 
(KynB), which generates 2-alkyl-4(1H)-quinolones (AQs), which are involved in 
QS, appears to play a role in persister cells. Removal of this enzyme from 
B. pseudomallei results in fewer persisters tolerant to ciprofloxacin (Butt, 
Halliday et al. 2016).  
 
These studies highlight the heterogeneity of persister cells in B. pseudomallei. 
For example, oxygen increases tolerance to a range of antibiotics, but not to 
ciprofloxacin (Hemsley, Luo et al. 2014). The deletion of the HicBA system 
decreases tolerance to ciprofloxacin, but not to ceftazidime (Butt, Higman et al. 
2014). These findings suggest that the formation of persister cells uses a 
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multitude of processes, and that different populations exist which vary in their 
tolerance to antibiotics. Further work is needed to improve knowledge and 
understanding of persister cells and antibiotic tolerance in B. pseudomallei and 
B. thailandensis. 
  
44 
 
1.3 Melioidosis  
1.3.1 Overview 
Melioidosis is the disease caused by infection with B. pseudomallei. Currently, 
the disease is endemic to 45 countries (figure 1.4), and it is estimated there are 
165000 cases per year, with 89000 fatalities annually (Limmathurotsakul, 
Golding et al. 2016). Various aspects of melioidosis including infection, clinical 
manifestations and treatment are well-reviewed elsewhere (White 2003, Cheng 
and Currie 2005, Wiersinga, van der Poll et al. 2006, Limmathurotsakul and 
Peacock 2011, Wiersinga, Currie et al. 2012, Dance 2014, Currie 2015). This 
section will provide a short overview (1.3.1) before focussing on aspects of 
melioidosis of particular relevance to this thesis (sections 1.3.2 and 1.3.3). 
 
Infection with B. pseudomallei usually occurs by inhalation, ingestion or 
percutaneous inoculation (White 2003, Currie 2015). Most infections are 
asymptomatic or subclinical, while some lead to melioidosis (clinical disease) 
(Currie 2015). Melioidosis is significantly more likely to develop following 
infection if the exposed person has one or more of several risk factors for 
melioidosis. These include diabetes mellitus, excessive alcohol intake, chronic 
kidney disease and chronic lung disease (Cheng and Currie 2005, Currie, Ward 
et al. 2010). In addition to host risk factors, size of the infecting load, bacterial 
strain virulence and infection route all influence the disease presentations that 
develop (Currie 2015).  
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Figure 1.4 – Strength of evidence for endemicity of melioidosis  
From (Limmathurotsakul, Golding et al. 2016) 
Reprinted by permission from Macmillan Publishers Ltd: Nature microbiology, 
(Limmathurotsakul, Golding et al. 2016), copyright (2016). 
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1.3.1.1 Clinical presentations 
Melioidosis is a highly protean disease, with many manifestations and several 
disease types (figure 1.5).  Clinical melioidosis commonly presents as 
pneumonia with or without bacteraemia. Other presentations include sepsis 
without an apparent focus, bone/joint infection and genitourinary infection 
(presentations reviewed elsewhere (White 2003, Cheng and Currie 2005, 
Currie, Ward et al. 2010, Currie 2015)). Abscesses are characteristic of the 
disease and may form on a wide range of organs (White 2003, Currie, Ward et 
al. 2010). The most common disease type is acute melioidosis, with an 
incubation period of 1-21 days and symptoms lasting less than 2 months 
(Currie, Fisher et al. 2000, Currie, Ward et al. 2010). Chronic, latent and 
recurrent disease types are discussed in section 1.3.2.  
 
Disease severity and mortality vary widely, with mortality rates of 14% in 
Northern Territory, Australia (Currie, Ward et al. 2010), 16% in Singapore (Lo, 
Ang et al. 2009), 22% in Southern Taiwan (Shih, Chuang et al. 2009), 25% in 
Queensland, Australia (Malczewski, Oman et al. 2005) and 43% in Northeast 
Thailand (Limmathurotsakul, Wongratanacheewin et al. 2010). Disease 
presentation and severity are associated with mortality. For example, septic 
shock is associated with a high rate of mortality (Currie, Ward et al. 2010, 
Limmathurotsakul, Wongratanacheewin et al. 2010). In a 20 year study in 
Australia, mortality rates of 50% were seen in patients with septic shock, while 
mortality was much less common in the absence of septic shock (Currie, Ward 
et al. 2010). That study also reported an increased rate of mortality in patients 
with one or more of the risk factors mentioned previously, such as diabetes 
mellitus (Currie, Ward et al. 2010). 
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Figure 1.5 – Clinical events after infection with B. pseudomallei 
Central chart: B. pseudomallei infection routes (blue boxes) are percutaneous 
inoculation, ingestion and inhalation. These lead to a number of clinical 
manifestations (white text) and natural history courses (red boxes). Bacteraemia 
can lead to disease in any organ, disseminated disease, severe sepsis and latent 
disease. Latent infections can reactivate to cause clinical melioidosis after a period 
of remission. 
 
Surrounding images: 
Various clinical manifestations of melioidosis. 
A) cutaneous melioidosis. 
B and C) lung abscesses in patient with acute pneumonia, detected by radiograph 
(B) and computed tomography (CT) scan (C). 
D) skin manifestations of disseminated melioidosis. 
E) abdominal CT scan showing splenic abscesses. 
F) aspirated pus from a patient with prostatic abscesses. 
G) CT scan showing abscesses. 
 
Reproduced with permission from (Wiersinga, Currie et al. 2012), Copyright 
Massachusetts Medical Society. 
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1.3.1.2 Diagnosis and treatment 
Melioidosis may be suspected based on patient risk factors for melioidosis, 
history of travel to endemic areas (where case is in non-endemic areas) or 
predicted risk of recreational or occupational exposure (Currie 2015). 
Identification of B. pseudomallei infection is essential for diagnosis and effective 
treatment. Culture of B. pseudomallei is the gold standard for a positive 
diagnosis, as it is highly sensitive and specific, especially when coupled with 
biochemical testing or microscopy (Wuthiekanun, Dance et al. 1990, Currie 
2015). Ashdown’s medium, the preferred growth medium for identification, gives 
identifiable colonies in 2-3 days (Wuthiekanun, Dance et al. 1990, Peacock, 
Chieng et al. 2005). B. pseudomallei may be cultured from blood, urine, pus or 
a range of other sites (Dance, Wuthiekanun et al. 1989, Wuthiekanun, Dance et 
al. 1990, Wuthiekanun, Suputtamongkol et al. 2001, Peacock, Chieng et al. 
2005). Other laboratory based methods for B. pseudomallei identification 
include real time PCR detection of the T3SS-1 (Kaestli, Richardson et al. 2012) 
and latex agglutination assays, which detect B. pseudomallei antigens with a 
range of antibodies (Amornchai, Chierakul et al. 2007). Portable testing kits, 
which give rapid results, have practical advantages over culture and other 
laboratory methods. Biochemical testing kits are generally effective in identifying 
B. pseudomallei (Dance, Wuthiekanun et al. 1989, Lowe, Engler et al. 2002), 
and a recently developed, portable lateral flow immunoassay (LFI) based on 
specific antibody detection of CPS is also being tested in endemic areas 
(Houghton, Reed et al. 2014). 
 
The standard regimen used to treat melioidosis is parenteral (intravenous) 
treatment with ceftazidime for 10-14 days, followed by oral treatment with 
trimethoprim-sulfamethoxazole for 12-20 weeks (Dance 2014, Currie 2015). 
Imipenem or meropenem may be used in the acute treatment phase in case of 
complications or ineffectiveness of ceftazidime, or in severe sepsis. 
Chloramphenicol and/or doxycycline may also be included in the oral treatment 
(Dance 2014, Currie 2015). Amoxicillin-clavulanate is substituted for 
trimethoprim-sulphamethoxazole in pregnant women and people intolerant to 
trimethoprim-sulphamethoxazole (Dance 2014, Currie 2015).   
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1.3.2 Persistent melioidosis 
While acute melioidosis is the most common presentation of melioidosis, there 
are other disease types, such as chronic, latent and recurrent infection. Chronic 
melioidosis refers to symptoms present for over 2 months, which occurs in ~11-
12% of melioidosis presentations in clinical areas (Limmathurotsakul, 
Chaowagul et al. 2006, Currie, Ward et al. 2010). Latent melioidosis refers to a 
period of months of years between infection with B. pseudomallei and 
presentation of melioidosis, which has reportedly been as long as 62 years 
(Ngauy, Lemeshev et al. 2005). Recurrent melioidosis is the presentation of 
melioidosis after treatment for previous active disease. Relapse is the term 
used when the same strain of B. pseudomallei is involved in the recurrent 
infection, and is more common than reinfection (episodes caused by different 
strains) (Desmarchelier, Dance et al. 1993, Limmathurotsakul, Chaowagul et al. 
2006). Chronic, latent and relapsed melioidosis can all broadly be described as 
persistent disease, where the pathogen exists in the host for an extended 
period of time, whilst avoiding removal by the host immune system or 
antibiotics.  
 
1.3.2.1 Sites of persistent infection 
B. pseudomallei is capable of infecting a wide range of organs, such as the 
lung, liver, spleen and skin (Wong, Puthucheary et al. 1995, Jones, Beveridge 
et al. 1996, Limmathurotsakul, Chaowagul et al. 2006, Wiersinga, Currie et al. 
2012). The bacterium is capable of establishing a long-term, stable population 
in many of these sites. Comparison of organ involvement in primary and 
relapsed melioidosis showed a high level of similarity, with the same organ 
often being involved in both disease episodes (Limmathurotsakul, Chaowagul et 
al. 2009). This suggests that B. pseudomallei can persist in an organ after 
causing active disease, then cause relapse at a later point. B. pseudomallei has 
been repeatedly cultured from the gastrointestinal (GI) tract of infected mice 
over a 60 day period, suggesting this may be a possible persistence site in 
melioidosis (Goodyear, Bielefeldt-Ohmann et al. 2012). Persistence is also 
evident in travellers returning to non-endemic areas, having visited endemic 
areas, who may present with melioidosis years later. These presentations 
commonly feature pneumonia and localised cutaneous melioidosis, 
50 
 
demonstrating persistence in the lung and skin (Saidani, Griffiths et al. 2015). 
Together, these observations demonstrate that persistent populations may be 
present in many different organs. 
 
Other sites of infection may also contribute to persistence, such as granulomas 
and abscesses, which are characteristic of persistent melioidosis. These sites 
are an attempt by the host to contain, but not eradicate the bacteria. Bacteria 
are prevented from spreading by surrounding layers of collagen, fibroblasts and 
immune cells, but B. pseudomallei is able to persist within host cells in these 
sites (Conejero, Patel et al. 2011). In addition, B. pseudomallei may persist in 
biofilms (Costerton, Stewart et al. 1999). Biofilms are bacterial communities 
where cells adhere to one another, and may adhere to surfaces. Biofilms have 
been detected in electron micrographs of lung tissue from melioidosis patients 
(Vorachit, Lam et al. 1995), demonstrating that they are present in vivo. Some 
of the ways in which a biofilm might contribute to persistent disease are 
discussed in the next section, as are other factors which contribute to 
persistence. 
 
1.3.2.2 Bacterial mechanisms of persistence 
The intracellular lifestyle of B. pseudomallei may contribute to persistent 
infection, by shielding the bacterium from immune effectors. B. pseudomallei 
can infect a wide range of phagocytic and non-phagocytic cells. Intracellular 
inhabitation may prevent clearance of bacteria from the host (Jones, Beveridge 
et al. 1996). An intracellular lifestyle also offers protection from humoral 
immunity, but exposes B. pseudomallei to cell mediated immunity, so the 
bacterium manipulates host immunity to survive and replicate within cells 
(reviewed by (Allwood, Devenish et al. 2011, Willcocks, Denman et al. 2016)) 
(figure 1.6). For example, B. pseudomallei LPS induces less nitric oxide (NO) 
and tumour necrosis factor alpha (TNF-α) production, compared with LPS from  
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Figure 1.6 – Model for intracellular lifestyle of B. pseudomallei 
B. pseudomallei can infect phagocytic cells by phagocytosis, and non-phagocytic 
cells by adhesion and uptake (involving the pilus subunit PilA, and adhesins such 
as BoaA).  
B. pseudomallei crosses the cell membrane into an endocytic vesicle. This 
internalisation process involves a number of bacterial factors such as T3SS-3 
(BopE, BipD, BsaQ) and the IrIR two-component system in non-phagocytic cells, 
and BopA (T3SS-3 effector) and RpoS (alternate sigma factor) in phagocytic cells. 
The bacterium disrupts the vesicle membrane, avoiding death by phagosome 
maturation or autophagy. The T3SS-3 plays a crucial role in escape from the 
vesicle. 
B. pseudomallei enters the cytoplasm, where it can replicate, and moves by 
manipulating host actin in a BimA-dependent manner. Intracellular growth involves 
metabolic pathways such as purine (PurM, PurN), histidine (HisF) and para-
aminobenzoate (PabB) metabolism.  
The bacterium interferes with host immune pathways, such as Janus kinases – 
signal transducers and activators of transcription (JAK-STAT). Additionally, 
B. pseudomallei LPS is a weak activator of intracellular interferon-β and -γ (IFN-β 
and IFN-γ). These processes lead to reduced activity of inducible nitric oxide 
synthase (iNOS) and lower levels of toxic NO.  
B. pseudomallei  triggers the formation of host cell membrane protrusions, which 
leads to fusion of membranes of adjacent cells. This results in a MNGC, which is 
thought to contribute to spread of infection. MNGC formation involves the T6SS-1, 
Hcp and RpoS. 
Virulence factors thought to play a role at each step are shown. 
Secretion system components are colour coded: effectors (purple), translators 
(black), structural components (red). Other factors are in black. 
Green arrows show time-progression. Red T-arrows show inhibitory processes. 
From (Allwood, Devenish et al. 2011) (CC BY). 
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other pathogens (Utaisincharoen, Tangthawornchaikul et al. 2000). This 
disrupts host killing of intracellular bacteria. In addition, B. pseudomallei is 
resistant to killing by complement, which contributes to survival outside of host 
cells and therefore persistence in the host (Ismail, Razak et al. 1988). 
Therefore, the bacterium has numerous strategies to enable survival in 
extracellular and intracellular environments within the host. 
 
The possible role for biofilms in melioidosis (Vorachit, Lam et al. 1995, 
Costerton, Stewart et al. 1999, Sawasdidoln, Taweechaisupapong et al. 2010, 
Limmathurotsakul, Paeyao et al. 2014) poses challenges for antibiotic 
treatment, as antibiotics are generally less effective against B. pseudomallei 
biofilms than against planktonic cells (Vorachit, Lam et al. 1993, Sawasdidoln, 
Taweechaisupapong et al. 2010). There are a number of mechanisms thought 
to contribute to the decreased susceptibility of biofilms to antibiotics. These 
include restricted or delayed penetration of the biofilm matrix by some 
antibiotics, degradation of antibiotics by bacterial enzymes in the matrix, and 
physiological heterogeneity of cells in the biofilm (reviewed by (Costerton, 
Stewart et al. 1999, Hoiby, Ciofu et al. 2011)). Therefore, biofilms can contribute 
to persistence by being able to survive in the presence of antibiotics. The ability 
of biofilms to shed replicating cells over a prolonged period of time can also 
contribute to chronic disease or relapse (Marrie, Nelligan et al. 1982, Costerton, 
Stewart et al. 1999). B. pseudomallei biofilms may also contribute to 
persistence by avoiding clearance by the immune system (Costerton, Stewart et 
al. 1999). In addition, biofilms of other bacteria have been shown to be more 
resistant to killing by phagocytosis and oxidative activity of the immune system 
than planktonic cells (Jensen, Kharazmi et al. 1990, Khoury, Lam et al. 1992, 
Costerton, Stewart et al. 1999). Therefore, there are many ways in which 
biofilms may enable persistence of B. pseudomallei in the host. Supporting a 
role for biofilm in persistent melioidosis, a comparison of biofilm formation in 
primary isolates from relapsing and non-relapsing melioidosis patients suggests 
that strains which produce high levels of biofilm were more likely to cause 
relapse (Limmathurotsakul, Paeyao et al. 2014). 
 
Conventional inherited antibiotic resistance could negatively affect the success 
rate of antibiotic treatment, and increase the risk of persistent infection. 
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Currently, resistance to melioidosis chemotherapy antibiotics is rare among 
clinical isolates from acute melioidosis (Schweizer 2012, Crowe, McMahon et 
al. 2014). However, resistance may be acquired during persistent melioidosis. 
Comparison of isolates from primary and relapsed melioidosis episodes 
indicates that antibiotic resistance can be acquired during persistent infection, 
leading to relapse (Jenney, Lum et al. 2001, Wuthiekanun, Amornchai et al. 
2011, Hayden, Lim et al. 2012). Acquired resistance has been linked to 
mutations affecting resistance mechanisms such as enzymatic inactivation of 
the antibiotic, target deletion, and efflux (Chantratita, Rholl et al. 2011, Sarovich, 
Price et al. 2012, Schweizer 2012, Podnecky, Rhodes et al. 2015).  
 
Separately from heritable resistance, genetically clonal B. pseudomallei from 
clinical samples can display a range of colony morphotypes in culture, due to 
different phenotypes (Chantratita, Wuthiekanun et al. 2007, Austin, Goodyear et 
al. 2015). These morphotypes form under different conditions, such as 
starvation, and are differentially associated with persistence in melioidosis. For 
example, Chantratita et al. identified a colony morphotype which was 
associated with high levels of biofilm and nonlethal, persistent infection of mice, 
featuring persistence in various organs (Chantratita, Wuthiekanun et al. 2007). 
Colony morphotypes have also been shown to vary in intracellular replication 
rates and sensitivity to ROS and antimicrobial peptides (Tandhavanant, 
Thanwisai et al. 2010). Other colony morphotypes have been shown to cause 
persistent infection in mice (Austin, Goodyear et al. 2015). Therefore phenotypic 
variation, without genetic change, can influence the ability of B. pseudomallei to 
cause persistent infection.  
 
Bacterial metabolism also contributes to persistence in melioidosis. Isocitrate 
lyase (ICL), which catalyses the first step of the glyoxylate bypass (described 
previously) enables metabolism of fatty acids in the host lung environment, and 
is required for persistent infection (van Schaik, Tom et al. 2009). Deletion of ICL 
did not affect survival in macrophages, but it did lead to more acute (rather than 
chronic) infections in mice (van Schaik, Tom et al. 2009). This suggests that ICL 
is involved in maintenance of persistent infection. 
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B. pseudomallei has been shown to form persister cells (Hamad, Austin et al. 
2011, Butt, Higman et al. 2014, Nierman, Yu et al. 2015). Given the evidence 
for a role for persisters in other persistent diseases (reviewed by (Fauvart, De 
Groote et al. 2011, Kint, Verstraeten et al. 2012)), it is possible that persisters 
contribute to persistent melioidosis, in concert with the factors described 
throughout this section.  Persisters may be present in infected cells and tissues, 
and sites such as granulomas, abscesses, and biofilms. These sites may exert 
a number of stresses on B. pseudomallei including low/no oxygen levels, 
nutrient stress, and during treatment of melioidosis, exposure to different 
antibiotics (Park, Myers et al. 1992, Simmen and Blaser 1993, Hamad, Austin et 
al. 2011, Anutrakunchai, Sermswan et al. 2015). These stresses have been 
suggested to increase the formation of B. pseudomallei persister cells and 
antibiotic tolerance for several antibiotics (Hamad, Austin et al. 2011, Nierman, 
Yu et al. 2015). In the current study, the effect of some of these stresses on 
persister frequencies was tested in the model organism B. thailandensis, with a 
range of antibiotics used to study tolerance. This was done in order to increase 
understanding of how clinically relevant conditions affect antibiotic tolerance of 
bacterial populations. 
 
1.3.2.3 Host factors which influence persistence 
As stated elsewhere, the focus of this thesis is bacterial processes, particularly 
persister cells, which may contribute to persistent melioidosis. However, the 
host plays a critical role in determining the outcome of B. pseudomallei infection 
(Cheng and Currie 2005, Currie 2015). Below is a brief overview of several host 
factors which can contribute to persistence of B. pseudomallei in the host. For 
reviews, please see (Cheng and Currie 2005, Currie 2015). 
 
As mentioned previously, most melioidosis patients have one or more of several 
identified risk factors, including diabetes mellitus, heavy alcohol use, and 
chronic kidney disease (reviewed by (Cheng and Currie 2005, Currie 2015)). 
These are all associated with deficiencies in the innate immune system, 
particularly neutrophil function (reviewed by (Cheng and Currie 2005, Currie 
2015)). This may contribute to persistence of B. pseudomallei in an infected, 
immunocompromised host, as the immune system is less able to clear the 
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bacteria. In the context of antibiotic treatment, it would increase dependence on 
the antibiotics for clearance of bacteria.  
 
The antibiotic regimen used to treat melioidosis plays a key role in determining 
whether persistent melioidosis will develop. Lower duration of antibiotic 
treatment, poor choice of antibiotics and poor compliance to chemotherapy are 
all associated with relapse (Currie, Fisher et al. 2000, Limmathurotsakul, 
Chaowagul et al. 2006). Therefore, use of a sub-optimal antibiotic treatment 
regimen contributes to persistence of the bacterium, by allowing more bacteria 
to survive.   
 
As mentioned in section 1.3.3.1, the host may try to contain, but not eradicate, 
B. pseudomallei in granulomas. The granulomas in lung infection are 
surrounded by barriers of fibroblasts and immune cells, which may offer 
protection from complete diffusion of antibiotics or immune cells, increasing the 
chances of a persisting population surviving in the host (Conejero, Patel et al. 
2011).   
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1.3.3 Antibiotic susceptibility 
Studies on clinical isolates from melioidosis patients have indicated that 
resistance to antibiotic used in chemotherapy is rare (<1% of isolates) which 
holds true for drugs such as ceftazidime (Wuthiekanun, Amornchai et al. 2011, 
Ahmad, Hashim et al. 2013, Crowe, McMahon et al. 2014), imipenem  (Smith, 
Wuthiekanun et al. 1996, Tan and Tan 2008, Ahmad, Hashim et al. 2013), and 
trimethoprim-sulphamethoxazole (Ahmad, Hashim et al. 2013, Dance, Davong 
et al. 2014) (although some reports indicated resistance to this antibiotic 
(Crowe, McMahon et al. 2014)). Despite susceptibility, treatment of melioidosis 
requires an extensive multi-component chemotherapy for several months.  
 
Many of the factors which contribute to persistence of B. pseudomallei in the 
host (see previous section) could negatively affect the efficacy of antibiotics in 
clearing infection. In combination with all the other factors, persisters may 
complicate antibiotic treatment by being less susceptible to killing than are non-
persisters. It should also be noted that persisters are not detected in 
conventional resistance tests (Brauner, Fridman et al. 2016). Persisters may 
also be able to re-generate a population after antibiotic killing of the majority, as 
this is a property of B. pseudomallei persisters in vitro (Hamad, Austin et al. 
2011, Butt, Higman et al. 2014, Hemsley, Luo et al. 2014, Nierman, Yu et al. 
2015). Persisters may therefore contribute to relapse or continued disease 
despite antibiotic treatment. In an immune compromised host, persisters may 
have extra relevance, as this increases dependence on the antibiotic treatment 
to kill persisters and other bacterial cells.  
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1.4 Project aims 
 Study the effects of different antibiotics, oxygen levels and growth phase 
on persister frequency in B. thailandensis. 
 Identify genes which influence persister cell formation and antibiotic 
tolerance. 
 Test compounds for persister eradicating activity.  
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Chapter 2: Materials and Methods 
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2.1 Bacterial strains  
All experiments used B. thailandensis strain E264 unless otherwise stated. 
Transposon mutagenesis used E. coli strain BW19851 containing plasmid pUT-
miniTn5km2, which was generated by chemical transformation of E. coli 19851 
with the pUT-miniTn5km2 plasmid (de Lorenzo, Herrero et al. 1990, Herrero, de 
Lorenzo et al. 1990). 
 
2.2 Bacterial storage 
2.2.1 Long-term storage 
Bacteria were stored for months or years at -80°C in 15% glycerol, in O-ring 
sealed cryovials.  
2.2.2 Fridge storage 
Bacterial streak plates were occasionally stored at 4°C for use in transposon 
mutagenesis or PCRs. E. coli was stored for up to two weeks. B. thailandensis 
was stored for up to 3 days. 
 
2.3 Bacterial growth 
2.3.1 Culture media 
Unless otherwise indicated, experiments were conducted in LB (product 
10638013, Fisher Scientific).  
Agar plates contained LB agar, which is LB with 1.5% Agar number 2 (product 
MC006, Lab M). Where reported, M9 minimal media contained: 1x M9 minimal 
salts (product M6030, Sigma-Aldrich), 2mM MgSO4, 30mM NaOAc, and 0.1mM 
CaCl2, adjusted to pH7. 
2.3.2 Recovery from freezer storage  
Freezer stocks were removed from the -80°C freezer, and a small amount of 
frozen culture was removed with a sterile loop and inoculated onto the surface 
of an LA plate. This plate was placed in a static 37°C incubator. The freezer 
stocks were returned to the freezer. 
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2.3.3 Growth of bacteria for assays 
Bacteria were scraped from a streak plate and re-suspended in LB. The 
OD600nm of this cell suspension was measured, and the sample was adjusted to 
OD600nm 1. The OD600nm 1 sample was added to 5ml LB in a 30ml universal at a 
1/20 dilution, to give a starting culture OD600nm of 0.05. These cultures were 
incubated at 37°C with 200rpm shaking. For stationary phase assays, bacteria 
were grown to OD600nm 4.5-5.5. For mid-log phase assays, bacteria were grown 
to OD600nm 0.3-0.6. 
 
2.4 Growth curve analysis  
Growth curve media was inoculated using overnight cultures or re-suspended 
colonies from a plate. Final OD600nm of inoculating culture was 0.05, unless 
indicated in the text. Flask cultures used 50ml LB in 250ml flasks, universal 
cultures used 5ml LB cultures in 30ml universal bottles, plate reader (Softmax 
pro-5, Versamax) cultures used 200μl LB cultures in 96 well assay plates. All 
assay cultures were incubated at 37°C. Flask and universal cultures used 
200rpm shaking, plate reader assays were static. At the time-points indicated in 
the text, the OD600nm was measured. 
When testing the effects of itaconate on growth, bacteria were incubated with 
concentrations of itaconate as indicated in the text. 
 
2.5 Antibiotics used 
All antibiotics used in this work are shown in table 2.1.  
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Antibiotic Stock solution Storage conditions 
Ampicillin 100mg/ml in water -20°C in solution 
Ceftazidime 10mg/ml in 0.1M NaOH N/A* 
Ciprofloxacin 1mg/ml in 0.1M NaOH -20°C in solution 
Co-trimoxazole 100mg/ml in DMSO -20°C in solution 
Gentamicin  100mg/ml in water -20°C in solution 
Imipenem 1mg/ml in water -20°C in solution 
Kanamycin 50mg/ml in water 4°C in solution 
Metronidazole 5mg/ml in 70% ethanol -20°C in solution 
Trimethoprim 10mg/ml in DMSO -20°C in solution 
Table 2.1 – Antibiotics used and storage conditions 
All antibiotics were supplied by Sigma-Aldrich. Storage conditions refers to storage 
of the antibiotic in a form to be used directly in an assay.  
For all antibiotics that required thawing prior to use (i.e. antibiotics stored at -20°C 
in 0.1M NaOH or water), once an aliquot had been thawed and used, any spare 
antibiotic was discarded, rather than re-frozen. Antibiotics which remained in the 
liquid state during storage (i.e. antibiotics stored in ethanol or DMSO, or at 4°C) 
could be removed from the fridge, used, and returned to cold storage, as there 
was no thawing process. 
* stock solutions of ceftazidime were not pre-made and stored as for the other 
antibiotics; ceftazidime powder was dissolved in 0.1M NaOH on the day of the 
assay, and discarded after use. The ceftazidime powder was stored at 4°C. 
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2.6 Determination of minimal inhibitory concentration 
2.6.1 Determining the MIC of a test population 
Assays were conducted in a 96-well plate. Antibiotics were prepared at a range 
of concentrations by two-fold serial dilution in LB. A test culture was adjusted to 
OD600nm 0.1, and added to the antibiotics to give a final culture density of 
OD600nm 0.0005 and antibiotics at a range of concentrations. Each antibiotic 
concentration had a minimum of three technical replicate wells. As controls, 
bacteria were incubated without antibiotic (positive control), and wells 
containing only LB (negative control) were prepared. 
This assay plate was place in a static 37°C incubator for 24 hours. Following 
incubation, assay plates were analysed at 595nm using a BioRad plate reader 
(600nm was not available), resulting in OD595nm absorbance values for each 
well in the plate.  
The average OD595nm for the LB-only wells was subtracted from all other wells, 
to account for the background absorbance value of the LB.  
The absorbance of the wells at each antibiotic concentration was plotted on a 
graph (with antibiotic concentration on the x-axis) and the MIC was identified as 
the lowest antibiotic concentration which gave no growth of the bacteria, i.e. no 
increase in OD595nm. 
2.6.2 Comparing the effects of different oxygen levels on MIC 
For MICs under different oxygen conditions, triplicate MIC plates were 
prepared. Each of the three replicate plates was incubated under a different 
oxygen condition for 24 hours. ‘Aerobic conditions’ consisted of incubation in a 
Sanyo incubator with normal air composition (~21% O2). ‘Microaerophilic 
conditions’ consisted of incubation in a Don Whitley MG500 workstation with air 
composition of: 2% H2, 10% CO2, 5% O2, N2 to 100%. ‘Anaerobic conditions’ 
consisted of incubation in a Don Whitley DG500 workstation with air 
composition of: 10% H2, 10% CO2, N2 to 100%. All incubators/cabinets were 
maintained at 37°C. After 24 hours, all three plates were removed from their 
respective cabinets/incubators and the plates were read on the BioRad plate 
reader, as above. 
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2.6.3 Inclusion of nitrate in MICs 
In order to enable growth of the bacteria in anaerobic conditions, 20mM sodium 
nitrate was included in the MICs. This was prepared as a 40mM stock, which 
was then diluted to 20mM upon mixing with the antibiotic and bacteria. All other 
conditions were the same as an anaerobic MIC. 
In order to test the effects of nitrate on antibiotic efficacy under aerobic 
conditions, an aerobic MIC assay was conducted, with parallel samples 
containing nitrate at a final concentration of 20mM. All other conditions were the 
same as an aerobic MIC. 
 
2.7 Persister frequency assays 
2.7.1 Determining the persister frequency of a test population 
A test culture was adjusted to OD600nm 0.2 in LB. An aliquot of this was set aside 
for t0 CFU measurement. Antibiotics to be used in the assay were adjusted to 
2x the assay concentration in LB. The remaining OD600nm 0.2 sample was 
combined with antibiotic in equal volumes, resulting in antibiotics at 1x assay 
concentration (indicated in the relevant text) and bacteria at a culture density of 
OD600nm 0.1, and 1ml samples were transferred to individual wells on a 24-well 
assay plate. This assay plate was placed in a static 37°C incubator.  
For t0 measurements, the bacterial suspension at OD600nm 0.2 was serially 
diluted tenfold in LB in a 96-well plate, and 3-5 10µl spots from 10-3 – 10-6 were 
dropped onto an LA plate. This plate was incubated at 37°C to allow colonies to 
grow for enumeration. 
At time-points during the assay (e.g. t24), the 24-well plate was removed from 
the incubator, and the relevant 1ml samples were transferred from the plate into 
1.5ml Eppendorf tubes. Except in the case of the final assay time-point, the 
assay plate was returned to the incubator. The Eppendorf tubes were 
centrifuged at 13,000rpm for 5 minutes to remove the antibiotic and culture 
media from the sample. The supernatant was removed and the resulting 
bacterial pellet was re-suspended in 1ml LB. A sample was taken from this and 
serially diluted tenfold in LB, and 10µl spots from several dilutions were dropped 
onto an LA plate. This plate was incubated at 37°C to allow colonies to grow for 
enumeration. 
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In the case of antibiotics which leave few culturable survivors (e.g. imipenem 
and ciprofloxacin), 10x concentrated samples were prepared, to increase the 
limit of colony detection, by re-suspending bacterial pellets in smaller volumes 
of LB.  
2.7.2 Comparing the effects of different oxygen levels on 
persister frequency 
For CFU assays under different oxygen conditions, triplicate plates were 
prepared. Each of the three replicate plates was incubated under a different 
oxygen condition for 24 hours, as described for MICs (aerobic, microaerophilic 
and anaerobic conditions). After 24 hours, all three plates were removed from 
their respective cabinets/incubators and 1ml samples were removed and 
processed as described for a normal persister assay. 
2.7.3 Testing the effect of itaconate on ceftazidime efficacy 
Bacteria (final OD600nm 0.1) were combined with ceftazidime and itaconate to 
give concentrations indicated in the text. No-itaconate and no-ceftazidime 
controls used LB as a substitute for the chemicals. The protocol was the same 
as for a normal persister frequency assay after this point.  
2.7.4 Testing the effect of co-trimoxazole and metronidazole in 
combination 
Bacteria were incubated in an anaerobic cabinet (at a final OD600nm 0.1) in the 
presence of one of the following 1) LB, 2) 320μg/ml cotrimoxazole, 3) 100μg/ml 
metronidazole or 4) 320μg/ml cotrimoxazole and 100μg/ml metronidazole.  
2.7.5 Measurements of culture turbidity during persister assays 
Where OD600nm at t24 are reported in the text, these were obtained from the re-
suspended bacteria used for CFU plating. 
2.7.6 Screening persister frequency assay survivors for 
antibiotic resistance 
Individual colonies from the t24 time-points of several persister frequency 
assays were screened for resistance to the antibiotic used in the assay, by 
testing the ability of the colony to grow on agar containing the antibiotic, at the 
same concentration. For example, colonies from t24 of a 40µg/ml ciprofloxacin 
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assay were tested using agar plates containing 40µg/ml ciprofloxacin. Colonies 
were picked individually and inoculated first onto an LA plate without antibiotic 
(to verify that the colony could be re-cultured), then onto an LA plate containing 
the antibiotic (which would only allow resistant mutants to grow), in the same 
position as the antibiotic-free LA plate. Both plates were incubated at 37°C. 
Colonies which gave growth on LA plates and LA plates containing antibiotic 
were judged to contain antibiotic resistant mutants. Colonies which could not 
grow on antibiotic plates, but could grow on plain LA plates, were judged not to 
contain mutants resistant to antibiotic at the concentration used in the assay. 
 
2.8 Transposon mutagenesis 
2.8.1 Introduction of transposon-containing plasmid by 
conjugation 
A single colony of E. coli 19851 pUT:mini-Tn5Km2 (called ‘donor’ in this 
section) was inoculated into 22ml LB in a 30ml universal, with 100µg/ml 
ampicillin and 30µg/ml kanamycin, and grown to ~OD600nm 0.6 overnight. 
B. thailandensis E264 (‘recipient’) was grown to OD600nm 1.6-2 overnight by 
inoculating a single colony into 10ml LB in a 30ml universal. Cultures were 
grown at 37°C, with 200rpm shaking. 
Overnight cultures of donor and conjugation strains were mixed in a ~1:3 
volume ratio. In parallel, conjugation-negative controls, with LB in place of one 
of the strains, were prepared. These conjugation mixtures were transferred to 
Eppendorf tubes. All tubes were centrifuged at 3,000rpm for 10 minutes. The 
supernatant was removed from all Eppendorfs, and the cell pellets were re-
suspended in LB (conjugation, donor-only control and recipient-only control). 
Each sample was aseptically spread over the surface of a separate LA plate, 
and the three plates were incubated at 37°C for 6 hours.  
2.8.2 Selection for B. thailandensis containing transposon 
After 6 hours of incubation at 37°C, bacterial growth was removed from all 
plates and re-suspended in LB. The OD600nm of the conjugation re-suspensions 
was measured and adjusted to different OD600nm values in LB (OD600nm 0.01 – 
0.00001). 100µl of these OD600nm-adjusted samples were spread over the 
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surface of LA plates containing 1mg/ml kanamycin and 100µg/ml gentamicin. 
Negative control conjugations were inoculated neat (100µl) onto 1mg/ml 
kanamycin and 100µg/ml gentamicin plates. These plates were incubated at 
37°C for 22-24 hours. Conjugation plates were then inspected for 200-1000 
colonies. Conjugation negative controls (B. thailandensis only or E. coli only) 
were checked for a lack of colonies on kanamycin and gentamicin. 
2.8.3 Detecting ampicillin resistance in transposon 
mutagenesis strains 
As an indicative test for the presence of the pUT plasmid following transposon 
mutagenesis, conjugated B. thailandensis was screened for resistance to 
100µg/ml ampicillin. Single colonies from the Gm100Km1000 selection plate 
were picked and inoculated first onto an LA plate, then onto a plate containing 
100μg/ml ampicillin. The plates were then incubated at 37°C, and were 
inspected the following day.  
2.8.4 Detecting miniTn5 mutants with increased ciprofloxacin 
resistance  
LA plates containing ciprofloxacin at several concentrations were prepared. 
Colonies from transposon mutagenesis (~1000 colonies) were pooled in LB and 
inoculated onto antibiotic plates. The same was done for a wild type culture. 
The plates were then incubated at 37°C, and were inspected over the next 3 
days. Mutant colonies which grew at a concentration which the wild type barely 
grew or could not grow were inoculated onto fresh ciprofloxacin plates to 
confirm the increased resistance.  
2.8.5 Generation of miniTn5 library 1B 
Approximately 36000 colonies (based on counts of 12 plates) from 45 
Gm100Km1000 plates were pooled in LB+15% glycerol. This was frozen in 
aliquots for future use. 
2.8.6 Persister assay screen for miniTn5 library 1B 
Input library: a 100μl frozen aliquot of Tn5 library 1B was inoculated into 50ml 
LB and grown at 37°C for 18h. Genomic DNA was extracted at this point from 3 
x 1ml samples, providing the 3 t0 replicates, T0-A, T0-B and T0-C (input 
samples). 
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Screen: The library culture was adjusted to OD600nm 0.2 and treated with 
40μg/ml ciprofloxacin or 400μg/ml ceftazidime for 24h at 37°C in aerobic 
conditions, as for a normal persister frequency assay. Antibiotic was removed 
after incubation and bacteria were re-suspended in LB. Samples were plated 
before and after antibiotic treatment to allow for CFU enumeration.  
Output libraries: The re-suspended bacteria from the screen were washed and 
inoculated into a fresh 50ml of LB. The fresh culture was grown at 37°C for 46-
47h, at which point the genomic DNA was extracted from 3 x 1ml samples per 
flask (giving Cef-1A, 1B and 1C from ceftazidime treated cultures, and Cip-1A, 
1B and 1C from ciprofloxacin treated cultures).  
 
2.9 DNA extraction  
2.9.1 Genomic DNA extraction 
Genomic DNA was extracted from overnight broth cultures using a Wizard 
Genomic DNA Purification Kit (Promega), as per the manufacturer’s 
instructions. DNA was eluted into water or resuspension buffer. 
2.9.2 Gel DNA extraction 
DNA was extracted from agarose gels using QIAquick or MinElute Gel 
Extraction kits (both Qiagen), as per the manufacturer’s instructions. DNA was 
eluted into water or buffer EB 
2.9.3 Plasmid DNA extraction 
Plasmid DNA was extracted from overnight broth cultures using a QiaPrep Spin 
Miniprep kit (Qiagen), as per the manufacturer’s instructions. Plasmid DNA was 
eluted into water or buffer EB. 
 
2.10 Primers used 
All primers used in this work are shown in table 2.2.  
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Primer name Sequence Use Source 
16S Fw AGTTTGATCCTGGCTCAGATTG 
Identification of 
B. thailandensis 
Sariqa Wagley 
16S Rv GAAGGTCCCCCGCTTTCAT 
Identification of 
B. thailandensis 
Sariqa Wagley 
KanF  CGACTGAATCCGGTGAGAAT Detection of MiniTn5 
Monika Bokori-
Brown 
KanR  CCGCGATTAAATTCCAACAT Detection of MiniTn5 
Monika Bokori-
Brown 
Bla3_Fw ACTGTTGGGCGCCATCTCCTTG Detection of pUT  This study 
Bla3_Rv CTCCGCTATCGCTACGTGACTG Detection of pUT  This study 
P7M1 GTCATTAAACGCGTATTCAGGCTGAC Arb-PCR (round one) 
Monika Bokori-
Brown 
ARB1 
GGCCACGCGTCGACTAGTCANNNNNNN
NNNGATAT 
Arb-PCR (round one) 
Monika Bokori-
Brown 
ARB3 
GGCCACGCGTCGACTAGTCANNNNNNN
NNNTGACG 
Arb-PCR (round one) 
Monika Bokori-
Brown 
ARB4 
GGCCACGCGTCGACTAGTCANNNNNNN
NNNACGCC 
Arb-PCR (round one) 
Monika Bokori-
Brown 
ARB5 
GGCCACGCGTCGACTAGTCANNNNNNN
NNNTACNG 
Arb-PCR (round one) 
Monika Bokori-
Brown 
P7U CTGCAGGCATGCAAGCTTCG 
Arb-PCR (round two), 
pglY PCR 
Monika Bokori-
Brown 
ARB2 GGCCACGCGTCGACTAGTAC Arb-PCR (round two) 
Monika Bokori-
Brown 
P7M  GCCGCACTTGTGTATAAGAGTC 
Sequencing of arb-PCR 
products, confirmation of 
pglY transposon 
insertion 
Monika Bokori-
Brown 
Pgly1 GCTTGTTGATCGCTCCCTTG pglY PCR This study 
Adapter1 (A1) GATCGGAAGAGCACACGTC*T 
Part of Adapter A1/P1, 
TraDIS library prep 
Nicola Senior 
Table 2.2 – Primers used in this work 
All primers except for HP12 were synthesised by Eurofins Genomics.  
An asterisk ‘*’ indicates phosphorothioate modification. 
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PCR1 
 
GTGACTGGAGTTCAGACGTGTGCTCTT
CCGATC*T 
 
Part of Adapter A1/P1, 
TraDIS library prep  
 
Nicola Senior 
MPX1 
CAAGCAGAAGACGGCATACGAGATATC
ACGGTGACTGGAGTT*C 
Multiplex PCR Nicola Senior 
MPX2 
CAAGCAGAAGACGGCATACGAGATCGA
TGTGTGACTGGAGTT*C 
Multiplex PCR Nicola Senior 
MPX3 
CAAGCAGAAGACGGCATACGAGATTTA
GGCGTGACTGGAGTT*C 
Multiplex PCR Nicola Senior 
MPX4 
CAAGCAGAAGACGGCATACGAGATTCA
GATCGTGACTGGAGTT*C 
Multiplex PCR Nicola Senior 
MPx5 
CAAGCAGAAGACGGCATACGAGATACA
GTGGTGACTGGAGTT*C 
Multiplex PCR Nicola Senior 
MPX6 
CAAGCAGAAGACGGCATACGAGATACT
TGAGTGACTGGAGTT*C 
Multiplex PCR Nicola Senior 
MiniTn5-3pr-3 
AATGATACGGCGACCACCGAGATCTAC
ACCTAGGCTGCGGCTGCACTTGTG 
Multiplex PCR Nicola Senior 
Syb_FP5 ATGATACGGCGACCACCGAG 
qPCR (adapter specific 
qPCR) 
Nicola Senior 
Syb_RP7 CAAGCAGAAGACGGCATACGAG 
qPCR (adapter specific 
and transposon specific 
qPCR) 
Nicola Senior 
MiniTn5-3pr-
Seq 
TAGGCTGCGGCTGCACTTGTGTA 
qPCR (transposon 
specific qPCR) and 
TraDIS transposon-
specific primer (MiSeq 
and Hiseq) 
Nicola Senior 
HP12 Property of Illumina  
TraDIS indexing primer 
(MiSeq and Hiseq) 
Illumina 
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2.11 Polymerase chain reaction 
2.11.1 Boilate preparation for colony PCR 
For PCRs that used a colony boilate, this was prepared as follows: a single 
colony was re-suspended in 30µl water. This was then boiled at 95-100°C for 2 
minutes, using a Stuart Block heater, to rupture the cells and release the DNA. 
The boilate was centrifuged for 2 minutes at 13000 rpm to pellet the boiled cells. 
The supernatant was then used in PCRs as a source of bacterial DNA. 
2.11.2 PCR-based identification of B. thailandensis or B. pseudomallei 
Transposon mutants were screened using primers 16S_Fw and 16S_Rv, to 
amplify ~200bp within the B. thailandensis 16S rRNA gene. PCR was 
performed using the HotStar PCR polymerase kit (Qiagen). Reactions were 
prepared to the final concentrations as follows: 1x HotStar PCR buffer, 1x Q-
solution, 0.4mM dNTPs, 1pmol/µl 16S_Fw, 1pmol/µl 16S_Rv, 1.25 units 
HotStar DNA polymerase and 2% (v/v) colony boilate. Samples were then run 
on program 16S, shown in table 2.3. B. thailandensis wild type and E. coli pUT-
miniTn5Km2 were included as positive and negative controls, respectively.  
2.11.3 Screening for the presence of the Km2 cassette in B. 
thailandensis by PCR 
Transposon mutants were screened using primers KanF and KanR, to amplify 
~500bp of the kanamycin resistance gene in the transposon. PCR was 
performed using the HotStar PCR polymerase kit (Qiagen). Reactions were 
prepared to the final concentrations as follows: 1x HotStar PCR buffer, 1x Q-
solution, 0.4mM dNTPs, 1pmol/µl KanF, 1pmol/µl KanR, 1.25 units HotStar 
DNA polymerase and 10% (v/v) colony boilate. Samples were then run on the 
HotStar Kan program as shown in table 2.4. E. coli pUT-miniTn5Km2 and 
B. thailandensis wild type were included as positive and negative controls, 
respectively.  
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Stage Temperature Duration  
Initial 
denaturation 
96 15:00  
Cycle – 
denaturation  
94 1:00 35 cycles 
Cycle – annealing 55 1:30 
Cycle – extension 72 1:30 
Final extension 72 7:00  
Hold 4 Hold  
Table 2.3 – 16S PCR program 
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Stage Temperature Duration  
Initial 
denaturation 
95 5:00  
Cycle – 
denaturation  
94 0:30 35 cycles 
Cycle – annealing 48 0:30 
Cycle – extension 72 0:45 
Final extension 72 5:00  
Table 2.4 – Kan PCR program 
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2.11.4 Screening for the presence of pUT plasmid in 
B. thailandensis by PCR 
Transposon mutants were screened using primers bla3_Fw and bla3_Rv, to 
amplify ~200bp within the ampicillin resistance gene on the pUT plasmid. PCR 
was performed using the HotStar PCR polymerase kit (Qiagen), to the final 
concentrations as follows: 1x HotStar PCR buffer, 1x Q-solution, 0.4mM dNTPs, 
1pmol/µl KanF, 1pmol/µl KanR, 1.25 units HotStar DNA polymerase and 10% 
(v/v) colony boilate. E. coli pUT-miniTn5Km2 and B. thailandensis wild type 
were included as positive and negative controls, respectively. Samples were 
amplified as shown in table 2.5. 
2.11.5 Arbitrary PCR to amplify Tn5-flanking region in 
B. thailandensis genome 
Two-stage arbitrary PCR was used to amplify a random fragment containing 
part of the tn5 sequence, and the flanking genomic DNA (Cuccui, Easton et al. 
2007). The first PCR step was prepared to the following final reagent 
concentrations: 1x AmpliTaq Gold master mix (including AmpliTaq Gold 
polymerase, Life Technologies, 4398881), 10% (v/v) 360 GC enhancer, 
10pmol/µl P7M1 (transposon-specific primer), 10pmol/µl arb1/arb3/arb4/arb5 
(one of four arbitrary primers) and 5% (v/v) template (genomic DNA to ~50-
300ng DNA), and amplified using the arb-PCR round one program (table 2.6).  
The product from this first reaction is then amplified in a second, nested PCR 
using the following final reagent concentrations:  1x AmpliTaq Gold master mix, 
10% (v/v) 360 GC enhancer, 10pmol/µl P7U, 10pmol/µl arb2 and 5% (v/v) 
template (product of previous reaction). The arb-PCR round two program is 
shown in table 2.7. 
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Stage Temperature Duration  
Initial 
denaturation 
95C 15min  
Cycle – 
denaturation  
94 30sec 35 cycles 
Cycle – annealing 57.7 30sec 
Cycle – extension 72 1min 
Final extension 72 10min  
Table 2.5 – Amp PCR program 
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Stage Temperature Duration  
Initial 
denaturation 
95 10:00  
Cycle A – 
denaturation  
95 0:30 6 cycles 
Cycle A – 
annealing 
30 0:30 
Cycle A – 
extension 
72 1:30 
Cycle B – 
denaturation  
95 0:30 30 cycles 
Cycle B – 
annealing 
45 0:30 
Cycle B – 
extension 
72 2:00 
Hold 4 Hold  
Table 2.6 – Arb-PCR program, round one 
 
76 
 
  
Stage Temperature Duration  
Initial 
denaturation 
95 10:00  
Cycle – 
denaturation  
95 0:30 35 cycles 
Cycle – annealing 45 0:30 
Cycle – extension 72 1:00 
Table 2.7 – Arb-PCR program, round two 
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2.11.6 PCR amplification of transposon-pglY junction 
Genomic DNA from B. thailandensis wild type or mutant A3 were amplified as 
follows: 1x HotStar PCR buffer, 1x Q-solution, 0.4mM dNTPs, 1pmol/µl pglY1, 
1pmol/µl p7U, 1.25 units HotStar DNA polymerase and 0.1μg genomic DNA. 
The PCR program is shown in table 2.8. 
2.11.7 PCR amplification of library DNA for TraDIS 
Parallel PCR was conducted with reactions prepared in 10 or more separate 
replicate tubes, using the Phusion high fidelity DNA polymerase kit (NEB). Each 
tube contained the following reagents: 1x GC buffer, 0.2mM dNTPs, 1 unit 
Phusion polymerase, 0.5μM MPX primer (one of MPX 1-6), 0.5μM primer 
miniTn5-3pr-3, 2% (v/v) adapter-ligated library DNA (template). The PCR 
program is shown in table 2.9. Reactions were pooled prior to clean-up. 
2.11.8 Gradient PCR 
Gradient PCR was carried out to optimise annealing temperatures for PCRs, as 
described in the text. Reactions were set up as described above, but with 
several replicate tubes, and each tube was placed in a gradient PCR machine 
(Techne, TC-512), which used a unique annealing temperature for each tube. 
2.11.9 PCR purification 
For clean-up of PCRs for sequencing, the Qiagen PCR purification kit was 
used, with the manufacturer’s instructions. DNA was eluted into water or buffer 
EB. 
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Stage Temperature Duration  
Initial 
denaturation 
95c 15min  
Cycle – 
denaturation  
94 30sec 35 cycles 
Cycle – annealing 57.5 30sec  
Cycle – extension 72 1min 
Final extension 72 10min  
Table 2.8 – PglY PCR program 
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Stage Temperature Duration  
Initial 
denaturation 
94 2min  
Cycle – 
denaturation  
94 30sec 22 cycles 
Cycle – annealing 54.8 20sec 
Cycle – extension 72 30sec 
Final extension 72 10min  
Table 2.9 – Transposon library amplification program 
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2.12 Agarose gel electrophoresis 
PCR products were separated using gel electrophoresis. 1% (w/v) agarose 
dissolved in 1 x Tris-acetate-EDTA (TAE) buffer was used to make the gels for 
electrophoresis, with 0.005% (v/v) Midori Green Advanced DNA stain (Nippon 
Genetics Europe GmbH) used for band visualisation. GeneRuler 100bp Plus or 
1kb Plus DNA ladder (Thermo Scientific) were used as size markers and 
loading dye (Thermo scientific) was added to samples before loading onto 
agarose gels. For size determination of PCR products 110V was used for 
approximately 30-40 minutes. Bands were imaged under UV light using a 
BioRad Gel Documentation Unit, using QuantityOne software. 
 
2.13 Determination of DNA concentration 
2.13.1 Nanodrop 
DNA concentration in PCR clean-up samples and genomic/plasmid DNA preps 
was measured using a NanoDrop 1000 spectrophotometer (Thermo Scientific), 
with ND1000 software. The machine was washed and blanked with water, 
before 2µl sample was measured as per manufacturer’s instructions. 
2.13.2 Qubit 
In order to obtain DNA concentrations in transposon library samples, 2μl was 
measured using a Qubit Fluorimeter and Qubit Fluorometric Quantitation 
reagents, by following manufacturer’s instructions (Sigma-Aldrich).  
2.13.3 Bioanalyser 
An Agilent DNA 7500 bioanalyser (Agilent Technologies) or Agilent D1000 
ScreenTape system (Agilent Technologies) was used to measure DNA 
fragment size and distribution during TraDIS library preps. DNA was analysed 
as per manufacturer’s instructions. 
2.13.4 qPCR 
2.13.4.1 Preparation of samples 
Test samples were diluted 10-4 for qPCR. This was carried out first by diluting to 
10-3 in EB buffer, then by diluting this suspension 1/10 in 0.1% Tween20, 
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resulting in a 10-4 dilution. DNA standards for qPCR were ordered from Kapa 
Biosystems (KK4904) and required no further preparation. 
2.13.4.2 Assay preparation 
An individual qPCR reaction contained the following: 1x Platinum SYBR Green 
qPCR SuperMix-UDG with ROX (Life Technologies, 11744), 0.1μM forward 
primer, 0.1 μM reverse primer, 4μl template DNA and water to 20ul. 
Primers used to detect transposon-containing DNA: MiniTn5-3pr-seq and 
Syb_RP7.  
Primers used to detect total (FCBR-containing) DNA (i.e. transposon-containing 
and non-transposon-containing): Syb_FP5 and Syb_RP7. 
Primers used for Kapa standards: Syb_FP5 and Syb_RP7. 
To minimise pipetting error, a master mix was prepared using all reagents 
except for the template DNA. 16μl of this master mix was distributed into each 
assay well of a 96 well assay plate (Life Technologies, product N8010560), then 
4μl template DNA (DNA standard or 10-4 sample) was added to the well. Wells 
were mixed by pipetting and centrifuged at 750rpm for 5 minutes to settle 
contents. Wells were sealed using optical strip caps (Agilent Technologies, 
product 401425). 
2.13.4.3 PCR amplification 
qPCR plates were amplified in a qPCR machine (MX3005P, Stratagene). The 
cycle used is shown in table 2.10. SYBR and ROX filters were used to measure 
each assay well, with ROX being used as the reference. 
2.13.4.4 Results analysis  
Ct values for all samples were obtained using MxPro software (Agilent 
Technologies) using automatic thresholding. Ct values for standards were used 
to construct a standard curve. The equation for the line was used to calculate 
the DNA concentration in a sample, based on its Ct values.  
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Stage Temperature Duration  
Initial denaturation 95°C 10min  
Cycle – 
denaturation  
95°C 10sec 40 cycles 
Cycle – annealing 60 or 65°C  30sec 
Table 2.10 – qPCR program 
Note that an annealing temperature of 60°C was used unless indicated in 
the text. When a 65°C annealing step was used, an extra extension step of 
30sec at 72°C was used in each cycle. 
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2.14 Library preparation for TraDIS 
2.14.1 Library DNA fragmentation 
DNA was diluted to give 1-5μg in 130μl buffer EB. This DNA was fragmented 
using an E220 focussed ultrasonicator (Covaris), with a fragmentation program 
of 110s, peak incident power (PIP) 105W, 5% duty factor, 200 cycles per burst. 
2.14.2 Size exclusion 
Fragmented DNA was processed using the GeneRead size selection kit 
(Qiagen, 180514) to remove <150bp fragments. DNA was transferred to a lo-
bind Eppendorf and treated as per manufacturer’s instructions. DNA was eluted 
in buffer EB. 
Fragmented DNA was run on the bioanalyser at this point to check 
fragmentation and confirm that small fragments were not present. 
2.14.3 End repair and adenylation  
End repair and adenylation of DNA fragments was performed using the 
NEXTflex rapid DNA sequencing kit (Bioo scientific, 5144), using the 
manufacturer’s instructions. 
2.14.4 Adapter ligation 
Adapter ligation of DNA fragments was performed using the NEXTflex rapid 
DNA sequencing kit (Bioo scientific, 5144), with 1.25μM annealed A1/P1 
adapter, using the manufacturer’s instructions. 
2.14.5 PCR amplification 
Adapter-ligated DNA libraries were amplified in a transposon specific parallel 
PCR. For each library, 10 or more individual reactions, containing a transposon 
specific primer (miniTn5-3pr-3) and an adapter specific MPX primer, were 
performed in parallel (see PCR methods section). These parallel reactions were 
then pooled, then purified and concentrated using AMPure XP beads (Beckman 
Coulter, A63880) with the NEXTflex protocol for a “no size selection clean-up” 
(Bioo scientific, 5144). 
Concentrated PCR amplified libraries were run on the bioanalyser to check the 
distribution of fragments and determine the appropriate region to size select. 
qPCR was used to determine DNA concentrations. 
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2.14.6 Size selection 
Size selection was performed using AMPure XP beads and the NEXTflex rapid 
DNA sequencing kit protocol. Size selected DNA was eluted from the beads in 
25µl resuspension buffer. 
Size selected DNA was run on the bioanalyser to check the distribution of 
fragments. qPCR was used to determine DNA concentrations and ratios of 
transposon containing DNA within the library as a whole. 
Size selected DNA libraries were given to the Exeter sequencing service for 
sequencing. 
 
2.15 Optimisation of library preparation 
2.15.1 Comparison of NEBNext and NEXTflex kits 
Fragmented DNA from 2μg of a test library (transposon library grown overnight 
in LB), after size exclusion using the GeneRead size selection kit (Qiagen, 
180514) was divided in half, and one sample (A) was prepared using the 
NEBNext kit, and the other (B) was prepared with the NEXTflex kit. The 
protocols were followed for end repair, adenylation and adapter ligation (with 
adapter substitution as previously described), using the manufacturers’ 
instructions. After the final clean-up, samples A and B were used for multiplex 
PCR with the transposon specific primer and MPX1 or 2. PCR amplified 
libraries were quantified by qPCR as previously described. 
2.15.2 optimisation of PCRs 
Gradient PCR was carried out using concentrations as described in section 
2.11.8, run on a gradient PCR program with different annealing temperatures 
tested. 
Phusion (NEB) and Jumpstart (Sigma) polymerase reactions were compared 
using concentrations as recommended by manufacturers, with primer 
concentrations as indicated in the text. 
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2.16 DNA sequencing 
2.16.1 Amplicon Sanger sequencing  
PCR products were sequenced by Source Biosciences (Nottingham, UK) to 
confirm the expected sequence had been amplified. Sequencing primers and 
template DNA were adjusted as per the sample requirements before sending to 
Source. 
2.16.2 MiSeq sequencing 
Sequencing was carried out on an M01625 MiSeq (Illumina) on nano run mode, 
using libraries diluted to 6pM + 10% PhiX control DNA. Primers MiniTn5-3pr-
seq3 and HP12 were used at 0.5μM. Sequencing was 150bp paired end.  
2.16.3 HiSeq sequencing 
Sequencing was carried out on an SN982 Hiseq 2500 (Illumina) on rapid run 
mode, using libraries diluted to 5pM + 2% PhiX control DNA. Primers MiniTn5-
3pr-seq3 and HP12 were used at 0.5μM. Sequencing was 100bp single end. 
 
2.17 Bioinformatics 
2.17.1 Primer design 
Primers were designed in Clone Manager. General primer parameters were 
specified, resulting in several candidate primer pairs. These pairs were checked 
for similar GC content and Tm, and each primer was checked for a lack of 
homology in negative control DNA using a nucleotide BLAST, as appropriate. 
2.17.2 Identification of Sanger sequencing data 
The .fasta file from the sequencing data was used as a query sequence for a 
nucleotide BLAST search (NCBI). When identifying known B. thailandensis 
sequences, this search was restricted to the B. thailandensis E264 genome or 
E. coli, as appropriate. 
2.17.3 Analysis of MiSeq data 
Data was received from the Exeter sequencing service in fastqc format. In order 
to approximate transposon-containing read frequency for each library/library 
pool, 500 reads were taken at random from the MiSeq data for sampling for the 
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transposon sequence TAAGAGTCAG (using the Find function in Microsoft 
Word). 
2.17.4 Analysis of Hiseq data 
Data was received from the Exeter sequencing service in fastqc format.  
2.17.4.1 transposon-containing read frequency  
For each library, 500 reads were taken at random for sampling for the 
transposon end sequence TAAGAGTCAG. 
2.17.4.2 Hit analysis  
Data was then processed by Ron Yang (University of Exeter) using the Distal 
Effect Model, to provide the number of transposon hits/insertions in each gene 
in the genome, for each library replicate.  
2.17.4.3 Noise removal 
T0 (input) samples: genes with transposon insertions in T0-A and T0-B were 
compared. Genes with 2 or more insertions in both of the libraries formed the 
“input list” and were used for further analysis.  
Cip-1 (output, ciprofloxacin treated) samples: genes with transposon insertions 
in Cip-1A, Cip-1B and Cip-1C were compared. Genes with 2 or more insertions 
in each of the three libraries formed the “output list” and were used for further 
analysis. 
2.17.4.4 List comparisons 
Input and output lists were compared using Microsoft Excel to determine which 
genes were present in both lists, or in only one list. Genes present in the input 
and output list formed the “survived treatment” list. Genes present in the input 
but not the output list formed the “lost in treatment” list. Genes present in the 
output but not the input list are described in the text. 
2.17.4.5 Investigation of TraDIS genes  
Following the list comparisons, all genes were searched for in KEGG (Kanehisa 
and Goto 2000), BLAST (Altschul, Gish et al. 1990), UniProt (Magrane and The 
Uniprot Consortium 2011) and the Burkholderia Genome Database (Winsor, 
Khaira et al. 2008). 
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2.18 Statistical analysis 
When comparing two values, an unpaired, parametric t-test assuming equal 
variance was used.  
A one-way ANOVA with Tukey’s multiple comparisons was used to compare 
three or more values. Dunnett’s multiple comparisons method was used when 
comparing multiple values against a control group. 
A p-value threshold of 0.05 was used to determine significance. 
 
2.19 Murine ceftazidime-metronidazole combination 
survival study (collaborator study) 
These assays were conducted at the London School of Hygiene and Tropical 
Medicine by Felipe Cia and Gregory Bancroft. Female BALB/c mice aged 6-8 
weeks were inoculated intra-nasally with B. pseudomallei 576 at approximately 
200 CFU. At 6h p.i., mice were treated with saline, 1200mg/kg bodyweight 
ceftazidime, or a combination of 1200mg/kg ceftazidime and 200mg/kg 
metronidazole. Mice were treated with this dose every 24h for 4 days, resulting 
in 5 treatments in total. In some assays, further daily treatments with 
metronidazole were provided, as indicated in the text. 
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Chapter 3: Characterisation of persister 
dynamics at the population level 
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3.1 Introduction 
In B. pseudomallei and B. thailandensis, it has been demonstrated that different 
persister fractions are exposed after treatment with drugs such as ceftazidime, 
sulfamethoxazole, tinidazole and ciprofloxacin (Hamad, Austin et al. 2011, Butt, 
Higman et al. 2014, Hemsley, Luo et al. 2014, Nierman, Yu et al. 2015). In order 
to increase understanding of persister cells and antibiotic tolerance in 
B. thailandensis, this study measured the number of culturable B. thailandensis 
cells after antibiotic treatment (persisters). Three factors were tested for their 
effect on persister frequencies in B. thailandensis: antibiotic used (and 
concentration), growth phase of bacterial culture, and oxygen level. 
 
For this study, drugs were chosen which are clinically relevant and have several 
cellular targets in susceptible cells: ceftazidime, ciprofloxacin, imipenem and 
trimethoprim. The different targets of these antibiotics will be useful in trying to 
understand possible persister tolerance mechanisms. Ceftazidime is a β-lactam 
antibiotic belonging to the third-generation cephalosporins. As mentioned in 
section 1.1.3, β-lactams targets cell wall synthesis by inhibiting the 
transpeptidases activity of PBPs, which produce and modify the peptidoglycan 
layer of the cell wall. Among the PBPs, ceftazidime has the highest affinity for 
PBP-3, which is involved in septum formation (Hayes and Orr 1983, Popham 
and Young 2003). Therefore ceftazidime results in cell filamentation and lysis 
(Hayes and Orr 1983). Ceftazidime is routinely used for the initial intravenous 
treatment phase of melioidosis chemotherapy (Dance 2014). 
 
Ciprofloxacin is a fluoroquinolone antibiotic that targets the type II 
topoisomerases DNA gyrase and topoisomerase IV, which control the topology 
of bacterial DNA. This interaction stabilises DSBs in the DNA, which causes 
inhibition of DNA replication and transcription, and cell death (LeBel 1988, 
Drlica, Malik et al. 2008, Kohanski, Dwyer et al. 2010). Ciprofloxacin is not 
routinely used to treat melioidosis, as it appears to be less effective than other 
drug treatments (Russell, Eley et al. 2000, Chetchotisakd, Chaowagul et al. 
2001). However, it was included in this study in order to build on previous 
research on B. thailandensis and B. pseudomallei (Butt, Higman et al. 2014, 
Hemsley, Luo et al. 2014, Nierman, Yu et al. 2015), and because ciprofloxacin 
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is one of the more commonly used drugs to study persisters (Keren, Kaldalu et 
al. 2004, Dorr, Vulic et al. 2010, Lechner, Patra et al. 2013).  
 
Imipenem is a carbapenem β-lactam antibiotic which, like ceftazidime, binds to 
PBPs, resulting in inhibition of peptidoglycan cross-linking in cell wall synthesis. 
However, imipenem differs from ceftazidime in PBP transpeptidase specificity. 
In E. coli, imipenem preferentially inhibits PBP-2, while affinity for PBP-3 is low 
(Hashizume, Ishino et al. 1984, Rodloff, Goldstein et al. 2006). PBP-2 is 
involved in cell elongation; inhibition of PBP-2 results in changes in cell 
morphology and lysis (Hashizume, Ishino et al. 1984, Popham and Young 2003, 
Rodloff, Goldstein et al. 2006). Imipenem may be used in the acute treatment 
phase of melioidosis chemotherapy under exceptional circumstances, such as 
ceftazidime ineffectiveness or complications (Currie 2015).  
 
Trimethoprim is an antibiotic that inhibits the bacterial dihydrofolate reductase 
(DHFR) enzyme. This enzyme is essential in the metabolic pathway that 
generates tetrahydrofolate, which is needed for synthesis of nucleic acids. 
Therefore trimethoprim causes inhibition of DNA synthesis (Burchall 1973, 
Capasso and Supuran 2014). Trimethoprim is often administered with the 
sulphonamide antibiotic sulphamethoxazole, which targets dihydropteroate 
synthetase, in the same folic acid synthesis pathway. The combination of the 
two drugs, co-trimoxazole, is used to treat various diseases, including 
melioidosis, where it is used in the oral eradication phase (Dance 2014). In this 
chapter, trimethoprim was studied in isolation in order to study antibiotic 
tolerance to a single antibiotic at a time. Studies in chapter 5 used the 
combination drug co-trimoxazole.  
 
The effect of growth phase on persister frequency and antibiotic tolerance has 
been studied in some other bacteria (Spoering and Lewis 2001, Keren, Kaldalu 
et al. 2004). However, little is known about the effect of growth phase on 
antibiotic tolerance in B. thailandensis. Understanding in this area may give 
insight into how growth phase affects antibiotic tolerance of in B. pseudomallei 
in persistent melioidosis. Comparison of stationary and mid-exponential phase 
B. pseudomallei from this lab suggests that, at least for ceftazidime and 
ciprofloxacin, B. pseudomallei adheres to the general pattern of increased 
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frequency of persisters at stationary phase (Butt, Higman et al. 2014). These 
tests were performed for B. thailandensis, using ceftazidime, ciprofloxacin, 
imipenem and trimethoprim.  
 
The availability of oxygen is important for bacterial viability and infectivity in 
vivo. Many bacterial pathogens will encounter diverse environments, ranging 
from oxygen-rich to low oxygen or anaerobic, as they spread through the 
infected host. In the course of human infection, B. pseudomallei encounters a 
variety of tissues, which may vary in oxygen content (Park, Myers et al. 1992, 
Wong, Puthucheary et al. 1995, Schaible, Schaffer et al. 2010). It is of interest 
to determine whether oxygen levels affect the persister frequency in the model 
organism B. thailandensis, as an indication of whether environmental oxygen 
conditions can affect antibiotic susceptibility of B. pseudomallei in infection. It 
has been shown that adaptation to anaerobic conditions increases the amount 
of ceftazidime-tolerant persister cells in a B. thailandensis culture (Hemsley, 
Luo et al. 2014). In this study, it was hypothesised that anaerobic adaptation of 
B. thailandensis might result in a higher persister frequency for various 
antibiotics under anaerobic conditions. Persister cell frequencies were therefore 
measured under different oxygen levels (aerobic, microaerophilic or anaerobic) 
for the above antibiotics. 
 
Following these studies, it was tested whether combinations of antibiotics 
showed additive potential to eliminate persisters, by adding a secondary 
antibiotic to a persister culture. This method has been used to characterise 
persister fractions in other bacteria including E. coli, S. aureus and 
M. tuberculosis (Hu, Coates et al. 2003, Hofsteenge, van Nimwegen et al. 2013, 
Lechner, Patra et al. 2013), demonstrating that a persister population tolerant to 
an antibiotic can be sub-divided based on tolerance or susceptibility to other 
drugs, suggesting the presence of multiple persister types. Studies in 
B. thailandensis have tested the susceptibility of ceftazidime persisters to 
ciprofloxacin and vice versa (Hemsley, Luo et al. 2014). These results 
demonstrated that a population of ceftazidime persisters vary in their tolerance 
to the fluoroquinolone ciprofloxacin, with most (>99%) being susceptible to the 
fluoroquinolone. In contrast, ceftazidime was only marginally effective against 
ciprofloxacin persisters (Hemsley, Luo et al. 2014). In this chapter, ceftazidime, 
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ciprofloxacin and imipenem were tested against persister cultures. This was 
done in order to investigate heterogeneity of antibiotic tolerance in 
B. thailandensis persisters, whether persisters are multi-drug tolerant, and 
identify what combinations of antibiotics are effective in reducing the size of the 
persister fraction. 
 
3.1.1 Aims and objectives 
- Study the effect of different antibiotics on the number of culturable 
B. thailandensis persister cells 
- Study the effect of oxygen levels on persister frequency 
- Study the effect of growth phase on persister frequency 
- Investigate cross-tolerance between persisters by treating a persister culture 
with a secondary antibiotic and measuring the persister frequency
93 
 
3.2 Stationary phase populations of B. thailandensis 
contain persister cells with reduced susceptibility to 
various clinically relevant antibiotics 
3.2 Persister cells in stationary phase cultures 
3.2.1 Growth of B. thailandensis in broth 
Growth of B. thailandensis was first measured in order to determine when the 
bacteria would reach stationary phase under culture conditions (figure 3.1). A 
method for generating stationary phase cells was then defined; inoculation of 
B. thailandensis E264 into a 30ml universal containing 5ml of culture, at a 
starting OD600nm of 0.05, incubated at 37°C with 200rpm shaking for >12 hours 
would result in stationary phase bacteria, at an OD600nm of >3. For all stationary 
phase experiments described below, bacteria had been incubated for 16-18h, 
and had reached an OD600nm of between 4.5 and 5.5. 
 
3.2.2 MICs of stationary phase cultures 
Stationary phase cultures were tested using several antibiotics: ciprofloxacin, 
ceftazidime, imipenem and trimethoprim. This was done with MIC assays using 
a stationary phase inoculum, in order to determine what concentrations of 
antibiotic could inhibit growth upon re-culture of the stationary phase bacteria. 
The MIC values for ceftazidime, ciprofloxacin, imipenem and trimethoprim are 
given in table 3.1.  
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Figure 3.1 – Growth of B. thailandensis E264 in LB 
Bacteria were inoculated into LB at a starting OD600nm of 0.05, which was then 
divided into 5ml aliquots in 30ml universal bottles. These cultures were incubated at 
37°C, with 200rpm shaking. At the time-points indicated, the universals were 
removed from the incubator and the OD600nm was measured. Error bars show 
standard deviation of 2 assays. 
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Antibiotic MIC (μg/ml) 
Ceftazidime  8-16 
Ciprofloxacin 2 
Imipenem 1 
Trimethoprim 16 
Table 3.1 – Minimal inhibitory concentrations towards stationary phase 
B. thailandensis E264 
Stationary phase bacteria were diluted and mixed with serial dilutions of 
antibiotic in a microtitre plate, resulting in a culture density of OD600nm 0.0005 
and antibiotics at a range of concentrations. The plate was incubated under 
aerobic conditions at 37°C, for 24h, then OD595nm was measured. The MIC was 
determined as the lowest concentration of antibiotic which inhibited growth. 
Averages for at least 3 assays are reported. 
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3.2.3 Persister frequency assays of stationary phase cultures 
Stationary phase bacteria were incubated with antibiotics and the CFU/ml was 
measured at several time-points, in order to try to determine persister 
frequencies. Using the MIC values, these assays were performed at ≥10x MIC 
(table 3.2). For consistency with previous work in B. thailandensis (Butt, Higman 
et al. 2014, Hemsley, Luo et al. 2014), 400μg/ml ceftazidime or 40μg/ml 
ciprofloxacin was used. Imipenem and trimethoprim were used at 
concentrations of 100x MIC.  
 
Results of the CFU/ml measurements of antibiotic treated cultures are shown in 
figure 3.2. The average frequencies (+/- standard deviation) of surviving 
culturable bacteria/persisters, after exposure to each antibiotic, at 24 hours 
were: ceftazidime, 3.0x10-2 (+/- 2.7x10-3); ciprofloxacin, 1.3x10-4 (+/- 1.2x10-4); 
imipenem, 1.4x10-6 (+/- 1.1x10-6); and trimethoprim, 2.4x10-2 (+/- 1.2x10-2). 
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Antibiotic 
Concentration used in 
persister frequency 
assay (µg/ml) 
Multiple of MIC  
Ceftazidime  400 25-50 
Ciprofloxacin 40 10-20 
Imipenem 100 100 
Trimethoprim 1600 100 
Table 3.2 – concentrations of antibiotics used in persister frequency 
assays, in relation to MICs 
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Figure 3.2 – CFU/ml measurements of stationary phase B. thailandensis E264 
after treatment with antibiotic for the time indicated  
A stationary phase culture was adjusted to OD600nm of 0.2 and mixed in equal 
volumes with antibiotic at 2x the assay concentration, resulting in a final culture 
density of OD600nm 0.1 and antibiotics at the following concentrations: 400μg/ml 
ceftazidime (A), 40μg/ml ciprofloxacin (B), 100μg/ml imipenem (C) and 1.6mg/ml 
trimethoprim (D). Samples were incubated in 1ml aliquots in a 24 well plate, under 
aerobic conditions (at 37°C, static incubation), for 24 hours. CFUs were 
enumerated before (t0) antibiotic treatment and after incubation for the time 
indicated. Error bars indicate standard deviation of at least 3 assays.  
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3.2.3.1 Effect of solvents on CFU/ml 
The assays above used antibiotics dissolved in water (imipenem), NaOH 
(ceftazidime and ciprofloxacin) or DMSO (trimethoprim). Water and DMSO were 
tested to see whether they could affect the number of culturable bacteria, in the 
absence of antibiotic. 
 
In the previous assays, trimethoprim powder was dissolved in DMSO prior to 
use; the final DMSO concentration in assays with 1600μg/ml trimethoprim was 
6.4%. The assays with 100μg/ml imipenem contained 10% water. Therefore, 
CFU/ml measurements were conducted on cultures treated with 6.4% DMSO or 
10% water (figure 3.3) and compared with LB-treated controls.  
 
DMSO treated samples had significantly fewer CFU/ml compared with controls 
at t2 (~43% of control CFU/ml, p<0.05, one-way ANOVA with Dunnett’s multiple 
comparisons). DMSO treated samples were no different from controls at any 
other time-points tested (t4, t6, t24), while water treated samples were no 
different from controls at any time-points tested (t2, t4, t6, t24) (p>0.05 one-way 
ANOVA with Dunnett’s multiple comparisons). 
 
Ceftazidime and ciprofloxacin were dissolved in NaOH, resulting in 4mM NaOH 
being present in 400μg/ml ceftazidime or 40μg/ml ciprofloxacin. The effects of 
4mM NaOH were not tested, as ceftazidime or ciprofloxacin dissolved in NaOH 
have previously been used, at the same concentrations, in work with 
B. thailandensis persisters in this lab (Hemsley, Luo et al. 2014). Hemsley et al. 
reported persister frequencies of stationary phase cultures of ~10-2 for 
ceftazidime and 10-5-10-4 for ciprofloxacin after 24h.  
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Figure 3.3 – CFU/ml measurements over time of B. thailandensis in 24 well 
plate with LB, LB and DMSO, or LB and water 
A stationary phase culture was adjusted to OD600nm of 0.2 and mixed in equal 
volumes with LB containing solvents at 2x the assay concentration, resulting in a 
final culture density of OD600nm 0.1 and solvents at the following concentrations: 
6.4% (v/v) DMSO or 10% (v/v) water. Samples were incubated in 1ml aliquots in a 
24 well plate, under aerobic conditions (at 37°C, static incubation), for 24 hours. 
CFUs were enumerated before incubation (t0) and after incubation for the time 
indicated. Error bars show standard deviation of at least 2 assays. * p<0.05, one-
way ANOVA with Dunnett’s multiple comparisons against LB control. 
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3.2.3.2 Effect of different antibiotic concentrations on persister frequency 
Persister frequencies in other bacteria have been shown to be independent of 
the drug concentration for a range of antibiotics (Brooun, Liu et al. 2000, 
Spoering and Lewis 2001, Hansen, Lewis et al. 2008, Sharma, Brown et al. 
2015). In order to test this for B. thailandensis, the persister frequency was 
measured following treatment with different concentrations of each antibiotic 
(figure 3.4). For all of the antibiotics tested, there was no significant difference in 
persister frequencies between treatments at ≥10x the MIC.  
 
For ceftazidime, only one replicate was available for the untreated control, so 
this could not be included in the statistical analysis. However, there was no 
difference between the persister frequencies for any of the ceftazidime 
concentrations tested (p>0.05, one-way ANOVA, figure 3.4A). 
 
For ciprofloxacin, persister frequencies were similar at 10x MIC and 20x MIC 
(p>0.05, one-way ANOVA, figure 3.4B), while imipenem persister frequencies 
were similar at 10x MIC and 100x MIC (p>0.05, one-way ANOVA, figure 3.4C). 
 
Although trimethoprim appeared to show a dose-dependent increase in the 
number of culturable survivors, this was not statistically significant (p>0.05, one-
way ANOVA, figure 3.4D). 
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Figure 3.4 – Effect of different concentrations of antibiotic on persister 
frequency 
A stationary phase culture was adjusted to OD600nm of 0.2 and mixed in equal 
volumes with antibiotic at 2x the assay concentration, resulting in a final culture 
density of OD600nm 0.1 and antibiotics at the following concentrations: ceftazidime 
(A, performed by Claudia Hemsley) at 80μg/ml (5-10x MIC), 200μg/ml (12.5-25x 
MIC) or 400μg/ml (25-50x MIC); ciprofloxacin (B) at 20μg/ml (10x MIC) or 
40μg/ml (20x MIC); imipenem (C) 1μg/ml (1x MIC), 10μg/ml (10x MIC) or 
100μg/ml (100x MIC); or trimethoprim (D) at 160μg/ml (10x MIC), 800μg/ml (50x 
MIC) or 1600μg/ml (100x MIC). Bacteria were also incubated in the presence of 
LB without antibiotic (0μg/ml antibiotic). Samples were incubated in 1ml aliquots 
in a 24 well plate, under aerobic conditions (at 37°C, static incubation), for 24 
hours. CFUs were enumerated before (t0) and after (t24) incubation. Error bars 
indicate standard deviation of at least 2 assays. * indicates p<0.05 with one-way 
ANOVA with Tukey’s multiple comparisons. 
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3.2.4 The surviving culturable bacteria do not display heritable 
antibiotic resistance  
Colonies which survived 24h of antibiotic treatment (figure 3.2) were individually 
screened for resistance to the antibiotic used, as for other reports (Butt, Higman 
et al. 2014, Hemsley, Luo et al. 2014, Nierman, Yu et al. 2015). None of the 
colonies screened (n>45 colonies for each antibiotic) were able to grow in the 
presence of the antibiotic used to treat the bacteria in the persister frequency 
assay/kill curve (plate images in figure 3.5 A-D, data summarised in table 3.3), 
indicating that antibiotic resistance was not responsible for the survival of the 
majority of the culturable population. 
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Figure 3.5 – Growth of culturable survivors on non-selective agar plates and 
agar containing antibiotic  
Colonies were picked from plates of the t24 time- points of antibiotic treatment 
assays, shown in figure 3.2, and inoculated first onto an LA plat e (left of each 
image), then onto a plate containing the same antibiotic used in the original assay 
(right of each image). Plates were incubated at 37°C for 1-3 days. Antibiotics used in 
each plate were 400μg/ml ceftazidime (A), 40μg/ml ciprofloxacin (B), 100μg/ml 
imipenem (C) and 1.6mg/ml trimethoprim (D).  
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Antibiotic 
(concentration) 
Number of 
colonies tested 
Frequency of 
susceptible 
colonies (%) 
Frequency of 
resistant mutants 
(%) 
ceftazidime 
(400μg/ml) 
55 100 0 
ciprofloxacin 
(40μg/ml) 
55 100 0 
imipenem 
(100μg/ml) 
55 100 0 
trimethoprim 
(1.6mg/ml) 
47 100 0 
Table 3.3 – Frequency of colonies displaying antibiotic 
resistance after 24 hours of antibiotic treatment.  
Data from figure 3.5. 
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3.3 Persister cells in mid-exponential cultures 
3.3.1 MICs of mid-exponential phase cultures 
Using the growth curve data from figure 3.1, mid-exponential growth was 
identified at OD600nm 0.3-0.5. Cultures inoculated to OD600nm 0.05 in 5ml LB, and 
grown for 3.5-5h usually fell within this range. MIC assays were conducted 
using a mid-exponential phase inoculum, in order to determine which 
concentrations of antibiotic could inhibit growth upon re-culture of the mid-
exponential phase bacteria. MICs are shown in table 3.4. There was no 
statistically significant difference between MICs (p>0.05, using one-way ANOVA 
with Tukey’s multiple comparisons) for stationary phase and mid-exponential 
phase, for any antibiotic tested (figure 3.6), suggesting that the growth phase of 
the inoculating culture does not affect the MIC.  
 
3.3.2 Persister frequency assays of mid-exponential cultures 
Mid-exponential cultures were sub-cultured in the presence of antibiotics, and 
the frequency of culturable bacteria was measured over several time-points. 
Due to similarity in MICs, the same concentrations of antibiotics were used as 
for stationary phase cultures (previously shown, section 3.2.3). Results are 
shown in figure 3.7 A-D. 
 
The average frequencies (+/- standard deviation) of surviving culturable 
bacteria/persisters, after exposure to each antibiotic, at 24 hours were: 
ceftazidime, 7.9x10-6 (+/- 6.6x10-6); ciprofloxacin, 3.8x10-6 (+/-2.3x10-6); 
imipenem, 1.6x10-6 (+/-1.9x10-6); and trimethoprim, 1.6x10-4 (+/-1.6x10-4). 
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Antibiotic MIC (μg/ml) 
Ceftazidime 8 
Ciprofloxacin 4 
Imipenem 2 
Trimethoprim 16-32 
Table 3.4 – Minimum inhibitory concentrations for mid-exponential phase 
B. thailandensis E264 
Mid-exponential phase bacteria were diluted and mixed with serial dilutions of 
antibiotic in a microtitre plate, resulting in a culture density of OD600nm 0.0005 
and antibiotics at a range of concentrations. The plate was incubated under 
aerobic conditions at 37°C, for 24h, then OD595nm was measured. The MIC was 
determined as the lowest concentration of antibiotic which inhibited growth. 
Averages for at least 3 assays are reported. 
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Figure 3.6 – Effect of growth phase on MIC 
Stationary phase and mid-exponential phase cultures were diluted to OD600nm 0.0001 
and incubated with serial dilutions of antibiotic for 24h, then OD595nm was measured. 
The MIC was determined as the lowest concentration of antibiotic which inhibited 
growth. Averages for at least 3 assays are reported. 
Error bars indicate standard deviation of at least 4 assays. 
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Figure 3.7 – CFU/ml measurements of mid-exponential phase 
B. thailandensis E264 after treatment with antibiotic  
A mid-exponential phase culture was adjusted to OD0.2 and mixed in equal 
volumes with antibiotic at 2x the assay concentration, resulting in a final culture 
density of OD600nm 0.1 and antibiotics at the following concentrations: 400μg/ml 
ceftazidime (A), 40μg/ml ciprofloxacin (B), 100μg/ml imipenem (C) and 1.6mg/ml 
trimethoprim (D). Samples were incubated in 1ml aliquots in a 24 well plate, under 
aerobic (37°C, static incubation), for 24 hours. CFUs were enumerated at the 
time-points indicated. Please see methods for full details. Error bars indicate 
standard deviation of at least 2 assays.  
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3.4 Effect of oxygen on antibiotic susceptibility of 
stationary phase B. thailandensis 
3.4.1 Oxygen levels have little effect on MIC  
Stationary phase B. thailandensis was inoculated into MIC assay plates, and 
incubated under one of three different oxygen levels: aerobic (normal air, ~21% 
O2), microaerophilic (~5% O2) or anaerobic (0% O2). Results for aerobic and 
microaerophilic conditions are shown in table 3.5. There was no significant 
difference in MICs (p>0.05, using one-way ANOVA with Tukey’s multiple 
comparisons) in aerobic, microaerophilic or anaerobic conditions (figure 3.8). 
 
B. thailandensis cannot grow anaerobically without an alternate electron 
acceptor, sodium nitrate was therefore included in the anaerobic assay plates 
(Andreae, Titball et al. 2014) so that growth inhibition could be studied. In order 
to test for any direct effects of nitrate on antibiotic activity, aerobic MICs were 
conducted with and without 20mM sodium nitrate. No statistically significant 
difference in MIC (p>0.05, using one-way ANOVA with Tukey’s multiple 
comparisons) was seen between the control and added nitrate samples (figure 
3.9).  
 
 
  
111 
 
 
 
 
  
Antibiotic 
Aerobic MIC 
(μg/ml) 
Microaerophilic MIC 
(μg/ml) 
Anaerobic MIC 
(μg/ml) 
Ceftazidime 4-8 8-16 8 
Ciprofloxacin 2 2-4 4 
Imipenem 2 2 2 
Trimethoprim 16 16 16-32 
Table 3.5 – summary of MIC values for aerobic, microaerophilic and 
anaerobic B. thailandensis 
Stationary phase bacteria were diluted and mixed with serial dilutions of 
antibiotic in a microtitre plate, resulting in a culture density of OD600nm 
0.0005 and antibiotics at a range of concentrations. The plate was 
incubated under in aerobic, microaerophilic or anaerobic conditions at 
37°C, for 24h, then OD595nm was measured. The MIC was determined as 
the lowest concentration of antibiotic which inhibited growth. Averages for 
at least 3 assays are reported. Anaerobic assays included 20mM sodium 
nitrate. 
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Figure 3.8 – effect of oxygen levels on MIC 
Stationary phase cultures were diluted and incubated with serial dilutions 
of antibiotic under aerobic, microaerophilic, or anaerobic conditions with 
20mM sodium nitrate. OD595nm was measured after 24h. Averages of at 
least 2 assays are reported, with error bars indicating standard deviation.  
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Figure 3.9 – effect of 20mM sodium nitrate on MIC under aerobic 
conditions 
Bacterial cultures were incubated with serial dilutions of antibiotic for 
24h, in the presence or absence of 20mM sodium nitrate, under 
aerobic conditions. After 24h, the OD595nm was measured. The MIC 
was determined as the lowest concentration of antibiotic which 
inhibited re-growth of stationary phase bacteria. Averages for at least 2 
assays are reported. 
Error bars indicate standard deviation.  
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3.4.2 Effect of oxygen on CFU/ml 
In order to determine whether the CFU/ml of B. thailandensis would be affected 
by oxygen conditions, independently of antibiotics, the CFU/ml of 
B. thailandensis was tested following 24h incubation under aerobic, 
microaerophilic or anaerobic conditions. No antibiotics were included in these 
assays. Incubation in microaerophilic conditions resulted in a significant higher 
CFU/ml compared with cultures incubated in aerobic or anaerobic conditions 
(figure 3.10). Incubation in anaerobic conditions resulted in a significantly lower 
CFU/ml compared with cultures incubated in aerobic or anaerobic conditions 
(figure 3.10). 
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Figure 3.10 – Effect of oxygen on CFU/ml counts of B. thailandensis 
A stationary phase culture was adjusted to OD600nm of 0.1. 1ml samples were 
transferred to individual wells on three 24-well assay plate. Samples were 
incubated in 1ml aliquots in a 24 well plate, under aerobic, microaerophilic or 
anaerobic conditions (all 37°C static incubation), for 24 hours. CFUs were 
enumerated before (t0) and after (t24) incubation. Error bars indicate 
standard deviation of at least 3 assays. * indicates p<0.05 with one-way 
ANOVA with Tukey’s multiple comparisons. 
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3.4.3 Reduced oxygen levels increase the persister frequency 
of B. thailandensis to several antibiotics 
In order to test the effect of oxygen levels on antibiotic tolerance, the frequency 
of culturable bacteria was measured following antibiotic treatment (persisters) 
under aerobic, microaerophilic or anaerobic conditions.  
 
For ceftazidime, the frequency of culturable survivors was inversely 
proportionate to oxygen levels. Microaerophilic conditions resulted in 
significantly more survivors than aerobic conditions, and anaerobic conditions 
resulted in more survivors than microaerophilic conditions (figure 3.11 A). The 
same trend was observed for imipenem (figure 3.11 C) as for ceftazidime. 
However, the effect of oxygen was more pronounced; there was a ~100x 
increase in culturable survivors from aerobic to microaerophilic, and another 
~100x increase from microaerophilic to anaerobic (~1% survivor frequency). For 
trimethoprim, there was a statistically significant increase in survivors from ~2% 
in aerobic conditions to ~22% in anaerobic conditions (figure 3.11 D). 
Ciprofloxacin (figure 3.11 B) was the only drug tested which did not 
demonstrate a statistically significant difference in CFUs for any of the oxygen 
conditions. Overall the results indicate that all antibiotics tested, except for 
ciprofloxacin, result in more culturable survivors under anaerobic conditions, 
despite no change in MIC. 
 
In order to test whether the increased survival under anaerobic conditions was 
due to increased antibiotic resistance, colonies that grew after 24h exposure to 
400µg/ml ceftazidime or to 40µg/ml ciprofloxacin treatment under aerobic, 
microaerophilic or anaerobic conditions were streaked onto LA plates containing 
antibiotic (400µg/ml ceftazidime or 40µg/ml ciprofloxacin). Of 20 colonies per 
condition which were screened, all grew on LA, but none on LA plates 
containing antibiotic (data not shown), suggesting that antibiotic resistance is 
not increased under anaerobic conditions. 
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Figure 3.11 – Effect of oxygen levels on persister frequency during 
incubation of stationary phase B. thailandensis with antibiotics  
A stationary phase culture was adjusted to OD600nm 0.2 and mixed in equal 
volumes with antibiotic at 2x the assay concentration, resulting in a final culture 
density of OD600nm 0.1 and antibiotics at the following concentrations: 400μg/ml 
ceftazidime (A), 40μg/ml ciprofloxacin (B), 100μg/ml imipenem (C) and 1.6mg/ml 
trimethoprim (D). Samples were incubated in 1ml aliquots in a 24 well plate, 
under aerobic, microaerophilic or anaerobic conditions (all 37°C static 
incubation), for 24 hours. CFUs were enumerated before (t0) and after (t24) 
incubation. Error bars indicate standard deviation of at least 3 assays. * indicates 
p<0.05 with one-way ANOVA with Tukey’s multiple comparisons. 
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3.5 Susceptibility of antibiotic-treated cultures to 
further antibiotic treatment 
3.5.1 ceftazidime-treated cultures  
In order to investigate the presence of different persister populations within a 
single culture, the susceptibility of a drug tolerant persister population to 
treatment with a second antibiotic was tested. Bacteria were treated with 
ceftazidime for 24 hours, at which time a second antibiotic was added and the 
cells incubated for a further 24 hours. The resulting survivor frequencies are 
shown in figure 3.12.  
 
The survivor frequency following 48h incubation (Figure 3.12, point B) with 
ceftazidime was no different from the frequency following 24h incubation with 
ceftazidime (A). Adding ceftazidime to ceftazidime-treated cultures also had no 
effect on the number of survivors (C). When ciprofloxacin or imipenem was 
added to the ceftazidime treated cultures there was a significant reduction in the 
number of culturable cells, compared with ceftazidime-treated frequencies. The 
further addition of ciprofloxacin (D) or imipenem (F) resulted in a secondary 
reduction to ~1% of the population of ceftazidime-treated cultures. There was 
no significant effect of adding trimethoprim (H), or any of the solvents used to 
dissolve the antibiotics (NaOH for ceftazidime and ciprofloxacin, E, water for 
imipenem, G, DMSO for trimethoprim, I). 
 
 
 
 
 
  
* * 
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Figure 3.12 – Effect of secondary antibiotic treatment on ceftazidime-treated 
cultures 
A stationary phase culture was adjusted to OD600nm 0.2 and mixed in equal volumes with 
ceftazidime at 2x the assay concentration, resulting in a final culture density of OD600nm 0.1 
and 400μg/ml ceftazidime. Samples were incubated in 1ml aliquots in a 24 well plate, 
under aerobic conditions (at 37°C, static incubation), for 24 hours. After 24h incubation, the 
plate was removed from the incubator and 1ml extracts were centrifuged to remove 
antibiotic, before CFU enumeration (A: total 400μg/ml ceftazidime, containing 4mM 
NaOH). 
 
Antibiotics or solvents were added to the remaining samples at t24, for a further 24h 
incubation before CFU enumeration. Additions at t24 were as follows: 
B: No antibiotic added (total 400μg/ml ceftazidime containing 4mM NaOH);  
C: 400μg/ml ceftazidime added (total 800μg/ml ceftazidime, containing 8mM NaOH);  
D: 40μg/ml ciprofloxacin added (total 400μg/ml ceftazidime and 40μg/ml ciprofloxacin, 
containing 8mM NaOH);  
E: 4mM NaOH added (total 400μg/ml ceftazidime, containing 8mM NaOH);  
F: 100μg/ml imipenem added (total 400μg/ml ceftazidime and 100μg/ml imipenem, 
containing 4mM NaOH and10% water);  
G: 10% water added (total 400μg/ml ceftazidime, containing 4mM NaOH and10% water).  
H: 1.6mg/ml trimethoprim added (total 400μg/ml ceftazidime and 1.6mg/ml trimethoprim, 
containing 4mM NaOH and 6.4% DMSO); 
I: 6.4% DMSO added (total 400μg/ml ceftazidime, containing 4mM NaOH and 6.4% 
DMSO); 
The plate was returned to the incubator after the t24 time-point for another 24h incubation. 
Following this incubation (total 48h incubation), CFU were enumerated. Results are shown 
as log10 of CFU divided by the starting CFU. 
 
Error bars indicate standard deviation of at least 2 assays. * indicates p<0.05 with one-way 
ANOVA with Tukey’s multiple comparisons. 
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3.5.2 ciprofloxacin-treated cultures  
Having tested several antibiotics on ceftazidime treated cultures, similar 
experiments were conducted on ciprofloxacin-treated cultures, to investigate 
whether ciprofloxacin tolerant cells were susceptible to further antibiotic 
treatment. Results are shown in figure 3.13. Bacteria were treated with 
ciprofloxacin for 24 hours, at which time a second antibiotic was added and the 
cells incubated for a further 24 hours. The resulting survivor frequencies are 
shown in figure 3.13.  
 
The survivor frequency following 48h incubation with ciprofloxacin (figure 3.13, 
point B) was significantly lower than the frequency following 24h incubation with 
ciprofloxacin (A). Adding ciprofloxacin (C), NaOH (D), imipenem (E), or water 
(F) to ciprofloxacin-treated cultures at 24h had no additional effect on the 
number of survivors.  
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Figure 3.13 – Effect of secondary antibiotic treatment on ciprofloxacin-
treated cultures 
A stationary phase culture was adjusted to OD600nm 0.2 and mixed in equal 
volumes with ciprofloxacin at 2x the assay concentration, resulting in a final 
culture density of OD600nm 0.1 and 40μg/ml ciprofloxacin. Samples were incubated 
in 1ml aliquots in a 24 well plate, under aerobic conditions (at 37°C, static 
incubation), for 24 hours. After 24h incubation, the plate was removed from the 
incubator and 1ml extracts were centrifuged to remove antibiotic, before CFU 
enumeration (A: total 40μg/ml ciprofloxacin, containing 4mM NaOH).  
 
Antibiotics or solvents were added to the remaining samples at t24, for a further 
24h incubation before CFU enumeration. Additions at t24 were as follows:  
B: No antibiotic added (B, total 40μg/ml ciprofloxacin, containing 4mM NaOH);  
C: 40μg/ml ciprofloxacin added (C, total 80μg/ml ciprofloxacin, containing 8mM 
NaOH);  
D: 4mM NaOH added (D, total 40μg/ml ciprofloxacin, containing 8mM NaOH); 
E: 100μg/ml imipenem added (purple diamond, “48h ciprofloxacin with 24h 
imipenem” total 40μg/ml ciprofloxacin and 100μg/ml imipenem, containing 4mM 
NaOH and 10% water);  
F: 10% water added (F, total 40μg/ml ciprofloxacin, containing 4mM NaOH and 
10% water).  
The plate was returned to the incubator after the t24 time-point for another 24h 
incubation. Following this incubation (total 48h incubation), CFU were 
enumerated. Results are shown as log10 of CFU divided by the starting CFU. 
 
Error bars indicate standard deviation of at least 2 assays. * indicates p<0.05 with 
one-way ANOVA with Tukey’s multiple comparisons. 
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3.6 Discussion 
Much of the understanding of persisters has come from studies of model 
organisms such as E. coli (Korch, Henderson et al. 2003, Balaban, Merrin et al. 
2004, Keren, Kaldalu et al. 2004, Keren, Shah et al. 2004, Shah, Zhang et al. 
2006) and P. aeruginosa (Spoering and Lewis 2001, Keren, Kaldalu et al. 2004, 
Murakami, Ono et al. 2005). However, in recent years studies have been 
undertaken in other species, resulting in the identification of persisters in 
pathogenic bacteria such as S. mutans (Leung and Levesque 2012), Vibrio 
cholerae (Dorr, Davis et al. 2015) and Borrelia burgdorferi (Sharma, Brown et 
al. 2015). These findings demonstrate that the capacity for antibiotic tolerance is 
a widespread phenomenon in bacteria (Cohen, Lobritz et al. 2013, 
Maisonneuve and Gerdes 2014). Given that persister cells have previously 
been reported in B. pseudomallei and B. thailandensis (Hamad, Austin et al. 
2011, Hemsley, Luo et al. 2014, Nierman, Yu et al. 2015), this study tested the 
effect of different environmental conditions, that might be encountered in vivo, 
on the frequency of B. thailandensis persisters.   
 
The approach taken was based on measurements of number of culturable cells 
(CFU/ml) of antibiotic treated cultures over several time-points, which is 
commonly used to detect persisters (Keren, Kaldalu et al. 2004, Lewis 2007, 
Lechner, Lewis et al. 2012, Sharma, Brown et al. 2015). It is important to note 
that the method used in this thesis measures the frequency of culturable 
planktonic cells. B. thailandensis may also able to exist in a sessile/biofilm state 
in these plates, and adhere to the plates (Ed Galyov, personal communication). 
Strongly adherent cells may not have been detected in the current assay. To 
study antibiotic tolerance of persisters in sessile/biofilm cultures, the biofilm 
viability assays previously reported for other Burkholderia species are 
recommended (Van Acker, Sass et al. 2013, Anutrakunchai, Sermswan et al. 
2015).  
  
In a planktonic culture containing persisters, treatment with an antibiotic results 
in two phases of decline in the number of culturable bacteria over time. The first 
phase is a drop in culturable bacteria as a result of killing of non-persister cells 
by the drug. The second phase appears as a ‘plateau’ or more level stage, 
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when cells are killed at a slower rate. The bacterial cells that survive the first 
phase of killing are termed persisters (Lewis 2007). These experiments 
identified B. thailandensis persisters for several antibiotics as a surviving 
culturable fraction after antibiotic treatment, which did not grow in the presence 
of antibiotics. Some persister fractions declined over the course of the assay, 
but, in general, there was a surviving persister fraction at the end of the assay. 
The evidence of persister populations of various sizes for different antibiotics 
suggests a range of different persister types, with different susceptibility to 
antibiotics, emphasising the widespread nature of persister cells and antibiotic 
tolerance in this bacterium (Hemsley, Luo et al. 2014, Nierman, Yu et al. 2015). 
Persisters identified in the kill curves were confirmed not to possess heritable 
antibiotic resistance (section 3.2.3), a trait further used to separate persisters 
from antibiotic resistant mutants (Bigger 1944, Kint, Verstraeten et al. 2012).  
 
The persisters identified are not an artefact of antibiotic doses, as the persister 
frequency was independent of drug concentration (section 3.2.4) at all supra-
MIC concentrations tested (i.e. dose-independent rather than dose-dependent) 
(Abel Zur Wiesch, Abel et al. 2015). However, the result for trimethoprim should 
be noted (figure 3.4D). The number of culturable cells at 100x MIC was over 
100-fold greater than at 10x MIC. The result is substantial despite not being 
statistically significant (perhaps due to high variation). As mentioned previously, 
a limitation of the assays used in this report to enumerate persisters, is that they 
only test planktonic cells. Therefore CFU measurements could be influenced by 
planktonic cells (easy to extract and culture) becoming sessile and adherent to 
the assay plates (making them harder to extract), or vice versa. The increased 
CFU at higher trimethoprim concentration may be due to the release of 
adherent/sessile cells into the media, enabling their extraction and culture. 
Nonetheless, the general results for the various drug concentrations suggests 
that the persisters tested are dose-independent, and not an artefact of drug 
concentration (Abel Zur Wiesch, Abel et al. 2015).  
 
It was found that the growth phase of the inoculating culture significantly affects 
the B. thailandensis persister frequency, with more persisters detected when a 
stationary phase culture is treated with ceftazidime, ciprofloxacin or 
trimethoprim (compared with a mid-exponential phase culture). This is in 
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agreement with studies for B. pseudomallei, where stationary phase cultures 
have been shown to contain more persisters tolerant to ceftazidime and 
ciprofloxacin, compared with exponential phase cultures (Butt, Higman et al. 
2014), and studies for other bacteria with different antibiotics (Spoering and 
Lewis 2001, Keren, Minami et al. 2011, Lechner, Lewis et al. 2012, Goneau, 
Yeoh et al. 2014). Imipenem tolerance was not affected by growth phase in the 
conditions tested, this is in agreement with the report that imipenem killing of 
E. coli is not proportional to growth rate (Cozens, Markiewicz et al. 1989). The 
origin of the small fraction of cells which are less susceptible to imipenem at 
either growth phase is unclear. Altogether, these observations further implicate 
stationary phase and nutrient stress in persister formation in Burkholderia. This 
is important as bacteria may be in a stationary phase-like (non-growing) state 
and/or be nutrient stressed in vivo, in sites such as biofilm (Costerton, Stewart 
et al. 1999, Anutrakunchai, Sermswan et al. 2015). The effects of growth phase 
on tolerance to imipenem or trimethoprim should be tested in B. pseudomallei in 
order to see whether these antibiotics follow the same trends seen for 
B. thailandensis.  
 
Persisters were detected for ciprofloxacin and imipenem in mid-exponential 
phase cultures (demonstrated by biphasic kill curves), the origin of these 
persisters is unclear. It is possible they formed during growth to mid-exponential 
phase, or that they were carried over from the stationary phase inoculum 
(Balaban, Merrin et al. 2004). This could potentially be clarified by adapting the 
methodology of Keren et al., who studied persisters in exponential phase E. coli 
cultures. This would involve repeatedly culturing B. thailandensis to mid-
exponential phase, and measuring the persister frequencies after each 
passage. If persisters are not produced in exponential phase, then the 
repeatedly cultured bacterial population should lose persisters after a sufficient 
number of passages  (Keren, Kaldalu et al. 2004). Based on the observations 
reported here, repeated culture to OD600nm 0.3-0.5 would be needed for this 
experiment. This experiment would help to understand what growth conditions 
lead to persister formation in B. thailandensis. In contrast with the results for 
imipenem or ciprofloxacin, mid-exponential phase cultures treated with 
ceftazidime or trimethoprim did not produce a clear biphasic killing pattern. 
However, there was still a culturable sub-population at the end of the assay 
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(24h). These surviving cells are clearly the least susceptible cells in the 
population, and may be persisters of some kind. 
 
Another factor that was found to influence persister frequencies in 
B. thailandensis was oxygen. It has been reported that oxygen tension is an 
important determinant of success of a pathogen in infecting a host and causing 
disease (Park, Myers et al. 1992). This study therefore aimed to test whether 
oxygen levels could affect the number of culturable B. thailandensis, and the 
susceptibility of the bacterium to antibiotics. Although the MIC was unaffected 
by oxygen levels, an increased frequency of ceftazidime persisters was 
observed under anaerobic conditions.  This observation is in agreement with 
that reported by Hemsley et al. In that paper, it was shown that ceftazidime 
tolerant persister cells had a similar gene expression profile to anaerobic 
B. pseudomallei, and showed the up-regulation of anaerobic respiration 
pathways such as the arginine deamination and nitrate reduction pathways. The 
results suggest that antibiotic tolerance in B. thailandensis is associated with a 
distinct transcriptome profile, and switching to this profile can occur under 
anaerobic conditions (Hemsley, Luo et al. 2014). It is possible that a similar 
mechanism of anaerobic transcriptome adaptation is occurring to produce 
ceftazidime tolerance in this study, given the similarity in persister assay 
conditions. Also in agreement with that paper, this study reported no change in 
ciprofloxacin persister frequencies under different oxygen levels. 
 
An increase in persister frequencies under anaerobic conditions was seen for 
imipenem and trimethoprim. Given that changes in gene expression under 
anaerobic conditions can increase tolerance to ceftazidime for B. thailandensis 
(Hemsley, Luo et al. 2014), it would be interesting to measure the 
transcriptomes of trimethoprim or imipenem treated cultures. Comparison of 
gene expression data between different persister types from anaerobic 
conditions would help further understand how oxygen levels affect persister 
formation. These anaerobic persister types could also be further characterised 
by their susceptibility to other antibiotics. Anaerobic ceftazidime persisters have 
been shown to be mostly susceptible to ciprofloxacin, as ciprofloxacin kills 
independently of oxygen tension (Hemsley, Luo et al. 2014). It is unclear 
whether or not imipenem and trimethoprim persisters would also be susceptible 
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to ciprofloxacin under anaerobic conditions, as is the case for ceftazidime. 
Additionally, treatment of anaerobic ceftazidime persisters with trimethoprim or 
imipenem under anaerobic conditions would help test whether the ceftazidime-
tolerant and imipenem- (or trimethoprim-) tolerant persister populations consist 
of separate populations or whether there is overlap. 
  
This work suggests that the amount of oxygen present can influence the 
presence of B. thailandensis tolerant to the clinically relevant drugs ceftazidime, 
imipenem and trimethoprim. If the pattern of increased persister frequencies in 
oxygen limitation also occurs in B. pseudomallei, then this may be of clinical 
significance. It is known that the oxygen tension can vary across the human 
body (Park, Myers et al. 1992), and that B. pseudomallei can infect a range of 
tissues (Wong, Puthucheary et al. 1995). Therefore B. pseudomallei may 
encounter oxygen depleted environments in host tissues. In addition to natural 
variation in host tissues, infection with B. pseudomallei often causes abscess 
formation; abscesses may contain very little oxygen (Hamad, Austin et al. 
2011). Furthermore, B. pseudomallei is known to form biofilms, and may inhabit 
biofilms in vivo (Vorachit, Lam et al. 1995, Costerton, Stewart et al. 1999, 
Limmathurotsakul, Paeyao et al. 2014). Biofilms vary in oxygen conditions, with 
the oxygen level generally dropping further into the biofilm, resulting in a 
hypoxic or even anaerobic centre (Costerton, Stewart et al. 1999, Yoon, 
Hennigan et al. 2002). 
 
These results highlight the need for antibiotics that can kill anaerobic bacteria. 
Previous chemicals with demonstrated efficacy against persister cells, under 
anaerobic conditions, include drugs which do not require a certain oxygen 
tension for efficacy, such as ciprofloxacin (Hemsley, Luo et al. 2014), or a drug 
which targets anaerobic bacteria, such as the nitroimidazoles (Lofmark, Edlund 
et al. 2010, Hamad, Austin et al. 2011). The results also raise the question of 
whether anaerobic persister types (e.g. imipenem-tolerant anaerobic persisters) 
can be reduced by introducing dissolved oxygen, as has been shown for 
ceftazidime persisters (Hemsley, Luo et al. 2014). In summary, numerous 
strategies can be incorporated into these assays to try to reduce the number of 
persisters under anaerobic conditions. 
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These findings demonstrate that persisters are present in varying frequencies 
under various conditions, suggesting that persister cells in B. thailandensis are 
heterogeneous in their formation. More research into the mechanisms of 
persister cell formation under various conditions is warranted. The HicAB TA 
system influences formation of ceftazidime and/or ciprofloxacin tolerant 
B. pseudomallei persisters (Butt, Higman et al. 2014), while other TA systems 
inhibit growth, but have yet to be tested for effects on persister formation (Butt, 
Muller et al. 2013). Perhaps different toxins cause formation of different 
persister types (e.g. different formation conditions, different drug tolerances). 
This has been reported for other organisms, such as M. tuberculosis, where 
different RelE homologues are associated with formation of individual persister 
types (Singh, Barry et al. 2010). Likewise, transcriptome analysis of 
B. thailandensis ceftazidime persisters has provided insight into metabolic 
processes involved in formation of these persisters (Hemsley, Luo et al. 2014), 
but other antibiotic-tolerant persister types might feature different gene 
expression profiles. 
 
Given the findings that B. thailandensis persisters can vary in formation 
conditions (some under anaerobic, some in stationary phase), it was 
hypothesised that they might also vary in drug tolerances. Cross-tolerance 
between persisters was investigated, by treating a persister culture with a 
secondary antibiotic and measuring the change in persister frequency. It was 
found that most ceftazidime persisters were killed, or lost culturability, by 
ciprofloxacin or imipenem, but not trimethoprim, and that ciprofloxacin persisters 
were not affected by imipenem. In all cases there were bacteria which survived 
treatment with multiple drugs. These results indicate that there are different 
persister types within a single persister population e.g. ceftazidime-
tolerant/susceptible, imipenem-tolerant/susceptible, consistent with the findings 
for ceftazidime treated B. thailandensis cultures (Hemsley, Luo et al. 2014). The 
results point to relatively specific tolerance mechanism/s which affect tolerance 
to at least one, but not all tested antibiotics. A persister population tolerant to 
one antibiotic can demonstrate heterogeneity in its tolerance or susceptibility to 
other drugs. This builds on the concept of heterogeneity of persisters in 
B. thailandensis, suggesting that they are heterogeneous in their tolerance to 
antibiotics. 
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It is interesting that most of the ceftazidime persisters are susceptible to 
imipenem. Ceftazidime and imipenem both target the PBPs; however, 
ceftazidime has strongest affinity for PBP-3 (Hayes and Orr 1983), whereas 
imipenem has affinity for PBP-2 (Hashizume, Ishino et al. 1984). Differential 
availability of the PBP targets could theoretically confer tolerance to one drug 
but not the other. Interestingly, transcriptional data for ceftazidime tolerant 
B. thailandensis indicated significantly increased gene expression of PBP-2 in 
ceftazidime tolerant cells, compared with stationary phase culture (Hemsley, 
Luo et al. 2014). If this leads to increased PBP-2 in ceftazidime persisters, then 
this might explain how ceftazidime-tolerant persisters can be susceptible to 
imipenem. The finding of imipenem efficacy against ceftazidime persisters is 
also important from a melioidosis treatment perspective. Ceftazidime and 
imipenem are commonly used to treat melioidosis individually, but not in 
combination. This work supports a new research avenue aimed at determining 
whether combining imipenem and ceftazidime can improve treatment of 
persisters in persistent melioidosis. The next step would be to confirm the 
efficacy of the combined antibiotics in B. pseudomallei. 
 
In contrast with the finding for ceftazidime persisters, ciprofloxacin persisters 
were not susceptible to imipenem. This may suggest that the ciprofloxacin 
persisters have fewer drug targets available, compared with ceftazidime 
persisters, so are not susceptible to imipenem. Tolerance to fluoroquinolones 
has previously been attributed to inactivity of DNA gyrase (Goneau, Yeoh et al. 
2014). Inactivation of DNA gyrase would be expected to have downstream 
effects on transcription, which might result in fewer drug targets for other 
antibiotics (such as imipenem) (Kwan, Valenta et al. 2013, Goneau, Yeoh et al. 
2014). Other drugs should be tested against both ceftazidime and ciprofloxacin 
persisters for comparison of their level of multidrug tolerance.  
 
The ciprofloxacin-tolerant, imipenem-tolerant persisters (figure 3.12) are one of 
several MDT persister populations detected in this study. Another type was the 
ceftazidime-tolerant, trimethoprim-tolerant fraction in figure 3.11.Such 
populations could be tested with a further antibiotic treatment stage to identify 
drug susceptibilities. Notwithstanding the (low) frequency of MDT persisters, the 
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results of the two-stage antibiotic treatment assays suggest potential anti-
persister strategies which may warrant further testing in B. pseudomallei. For 
example, ceftazidime and imipenem are two clinically relevant drugs which 
resulted in a low persister frequency when B. thailandensis was treated with the 
two antibiotics sequentially. 
 
Global down-regulation of drug targets, resulting from dormancy, has previously 
been proposed as the primary mechanism for multi-drug tolerance in persisters 
(Lewis 2007, Wood, Knabel et al. 2013). This does not appear to explain the 
persisters that are tolerant to one antibiotic but susceptible to all other drugs 
tested (this study and (Lechner, Patra et al. 2013, Goneau, Yeoh et al. 2014)). 
However, dormancy is believed to confer tolerance to multiple drugs (Keren, 
Shah et al. 2004, Lewis 2007), so may explain the multi-drug tolerant persisters 
seen in some of the assays reported here. Whether or not these persisters are 
dormant is an important question. It would be technically difficult to address 
given the low frequency of persisters, and likely abundance of dead/lysed cells 
and VBNCs, but theoretically, methods such as the -omics (e.g. transcriptomics, 
proteomics) could be used, provided persisters can be isolated (Shah, Zhang et 
al. 2006, Orman and Brynildsen 2013, Van Acker, Sass et al. 2013). The AP 
method (described previously) has been used to study persister metabolism 
without prior isolation. However, this method may not be possible for 
B. thailandensis, as it is resistant to aminoglycosides (Podnecky, Rhodes et al. 
2015).  
 
Taking all the data from this chapter together, this work supports the idea that, 
as for other bacteria, B. thailandensis persisters are heterogeneous. A persister 
frequency measurement may in fact represent persisters of various types. The 
various persister types seen may have formed under different conditions, have 
different antibiotic tolerances, and presumably vary in their molecular makeup. 
Some persisters form in stationary phase, and others form under anaerobic/low-
oxygen conditions, with their frequency also depending on the antibiotic used. 
There were persisters that were tolerant to single antibiotics, while some were 
tolerant to multiple antibiotics. A single mechanism of antibiotic tolerance, such 
as dormancy, does not appear to explain all of the different persister types in 
the assays reported here. These results complicate antibiotic treatment and 
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studies of persisters in B. thailandensis, but several trends have been observed 
which shed light on this complicated phenotype. Further work is warranted to try 
to understand the molecular mechanisms underlying persister formation and 
antibiotic tolerance in B. thailandensis. In addition, it may be possible to use the 
information obtained here to develop anti-persister strategies. Successful 
strategies could be tested against B. pseudomallei. 
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Chapter 4: Transposon mutagenesis 
and sequencing of B. thailandensis 
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4.1 Introduction 
Transposons are mobile pieces of DNA (transposable elements, or TEs), which 
are capable of moving within a genome. In a process called transposition, which 
is catalysed by a transposase enzyme, the transposon is inserted into a site in 
the genome (McClintock 1950, Munoz-Lopez and Garcia-Perez 2010). In 
bacteria, transposons move via replicative (a duplication process in which the 
original transposon is retained, and a copy is inserted into a new site), or 
conservative transposition (an excision of the transposon from the old site, and 
transfer to the new site) (Griffiths, Miller et al. 2000, Munoz-Lopez and Garcia-
Perez 2010). 
  
The ability of transposons to integrate into host genomes has been exploited as 
a tool for generating random mutations, a process known as transposon 
mutagenesis (Munoz-Lopez and Garcia-Perez 2010). The transposon is 
introduced into a target bacterium, and is transposed into a theoretically random 
site in the target genome, disrupting the genome. Insertion of a transposon into 
a gene can disrupt gene expression, this is called insertional inactivation 
(Munoz-Lopez and Garcia-Perez 2010).  Following mutagenesis, a transposon 
library (a collection of transposon mutants) is screened for a phenotype of 
interest, enabling genes responsible for that phenotype to be identified.  
 
An advantage of transposon mutagenesis over targeted mutagenesis 
approaches is that it can be used to probe the whole genome, making it a 
potentially valuable tool to study persister cells and antibiotic tolerance, a 
complicated phenomenon where many genes may be involved (Lewis 2012, 
Fasani and Savageau 2013, Prax and Bertram 2014). Transposon mutagenesis 
has mainly been used to study genes associated with persisters in E. coli (Hu 
and Coates 2005, Li and Zhang 2007, Bernier, Lebeaux et al. 2013, Shan, 
Lazinski et al. 2015), although persisters in P. aeruginosa and S. aureus have 
also been recently studied using transposons (De Groote, Verstraeten et al. 
2009, Manuel, Zhanel et al. 2010, Wang, Chen et al. 2015). A goal of this 
project was to use transposon mutagenesis to study the molecular basis of 
persister cell formation and antibiotic tolerance in B. thailandensis. Transposon 
mutagenesis has previously been shown to be a useful tool to study genotype-
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phenotype interactions in B. thailandensis and B. pseudomallei, for a range of 
phenotypes (examples (Gallagher, Ramage et al. 2013, Bishop and Rachwal 
2014, Moule, Hemsley et al. 2014, Lu, Xu et al. 2015, Moule, Spink et al. 
2015)). However, at the time of this thesis, there are no published reports of 
transposon mutant libraries being studied for altered persister frequencies in 
B. thailandensis.  
 
The approach taken was to mutagenise B. thailandensis using miniTn5Km2, 
which was introduced on plasmid pUT-miniTn5Km2 (de Lorenzo, Herrero et al. 
1990, Herrero, de Lorenzo et al. 1990). In this system, the miniTn5 transposon 
is transferred from the plasmid into the target genome (figure 4.1). The 
transposon is subsequently maintained in the genome, while the rest of the 
plasmid is unable to replicate, and is lost from the target cell. This method has 
been previously used to mutagenise B. thailandensis (Monika Bokori-Brown, 
unpublished data, and (Andreae, Titball et al. 2014)). However, it was 
necessary to verify that mutagenesis was successful in this work by checking 
for transposon insertion. Subsequently, miniTn5 mutants were tested in two 
phenotypic assays. The first was a screen for increased antibiotic resistance 
using a method previously used for S. aureus (Blake and O'Neill 2013). The 
transposon insertion site was identified in a mutant with increased resistance to 
ciprofloxacin, in order to verify that transposon mutagenesis could be used to 
identify links between phenotypes and genomic insertions in B. thailandensis. 
The second was a screen aimed at identifying the genes that contribute 
(positively or negatively) to formation of persister cells and antibiotic tolerance. 
This used a high-throughput sequencing (HTS) method (i.e. TraDIS) to study all 
the genes in the genome (figure 4.2) in a library treated with antibiotics 
(ceftazidime or ciprofloxacin). It was hypothesised that comparison of genes 
present in an antibiotic treated culture with an untreated culture will indicate 
genes which may positively regulate antibiotic tolerance (may be absent from 
antibiotic treated culture due to transposon insertion), and genes which 
negatively regulate antibiotic tolerance (may be present in both cultures). 
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4.1.1 Aims and objectives 
Identify genes associated with antibiotic resistance and antibiotic tolerance 
(persister cell formation and antibiotic tolerance) 
- Generate transposon mutants in B. thailandensis 
- Identify genes involved in antibiotic resistance  
- Identify genes associated with persister cell formation 
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Figure 4.1 – Schematic of transposon mutagenesis.  
Starting from top panel: 
B. thailandensis (black cell) contains two chromosomes (blue circles). 
Conjugation: conjugation with E. coli pUT-miniTn5Km2 introduces the 
pUT-miniTn5Km2 plasmid (red circle), which contains the miniTn5 
transposon (yellow box). Ampicillin resistance is encoded by the plasmid, 
kanamycin resistance is encoded by the transposon. 
Transposition: The plasmid encodes a transposase enzyme, which excises 
the transposon from the plasmid, and inserts it into a random site in the 
genome (de Lorenzo, Herrero et al. 1990, Goryshin and Reznikoff 1998, 
Reznikoff 2008). 
Replication: The plasmid requires the Pir protein for replication (de 
Lorenzo, Herrero et al. 1990, Herrero, de Lorenzo et al. 1990), so is lost 
from the Pir-negative B. thailandensis during cell replication. 
The result is a mutant which has a single transposon insertion, which is 
now kanamycin resistant, which lacks the plasmid. 
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Figure 4.2 – overview of transposon library screening and 
sequencing 
A pool of mutants is tested for a phenotype of interest using a screen, in 
the case of this report, ceftazidime or ciprofloxacin treatment. Individual 
mutants will change in frequency according to the effect of the transposon 
insertion on that phenotype (e.g. a mutation which increases tolerance to 
ciprofloxacin in the assay should lead to an increase in the frequency of 
that mutant). Sequencing the libraries before and after screening (using 
TraDIS) will enable the mutants in each treatment group to be compared.  
Figure adapted from (Chaudhuri, Morgan et al. 2013) (CC BY). 
Modification: Replaced screen with data from two persister frequency 
assays from chapter 3 (ceftazidime and ciprofloxacin). 
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4.2 MiniTn5 mutagenesis selects for B. thailandensis 
which contains the transposon 
The plasmid pUT-miniTn5Km2 (de Lorenzo, Herrero et al. 1990) was used to 
generate transposon mutants in B. thailandensis by conjugation. E. coli strain 
19851 was used to transfer the plasmid. Conjugated bacteria were selected on 
agar containing 100μg/ml gentamicin and 1mg/ml kanamycin (Gm100Km1000), 
resulting in 400-800 colonies per plate. After obtaining colonies, tests were 
conducted to confirm that these bacteria were B. thailandensis containing the 
transposon. 
 
4.2.1 Identification of B. thailandensis by PCR 
In order to exclude the possibility that colonies on the Gm100Km1000 plates 
were antibiotic resistant E. coli from the conjugation, PCRs were conducted 
using primers 16S_Fw and 16S_Rv, which amplify a 195bp fragment within the 
16S rRNA gene of B. thailandensis. The PCR was positive for B. thailandensis 
control cultures and negative for E. coli. Individual colonies after transposon 
mutagenesis were tested, and 100% were positive for the B. thailandensis 16S 
rRNA gene (n=40 colonies tested), indicating that they were B. thailandensis 
and not E. coli (representative gel in figure 4.3).  
 
The PCR products were sequenced and searched in BLAST. This showed high 
similarity to the reported B. thailandensis 16S rRNA gene sequence (>95% 
identity, e<10-40), but no similarity to the E. coli 19851 genome sequence or the 
pUT-miniTn5 plasmid sequence (no significant alignment, BLAST). This 
confirmed that the DNA amplified in the PCR belongs to B. thailandensis and 
not E. coli or the pUT plasmid.  
 
Together, the results suggest that colonies re-grown after transformation were 
B. thailandensis. 
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Figure 4.3 – Agarose gel of PCR to amplify a 195bp fragment within 
B. thailandensis 16S rRNA 
Lane order (L-R): 
1 – DNA ladder. Ladder fragment size is given in bp next to the gel. 
2 – Template: E. coli pUT-miniTn5Km2 colony boilate (negative DNA control). 
3 – Template: B. thailandensis colony boilate (positive DNA control). 
4 – Template: water (negative control). 
5-10 – Template: pUT-miniTn5Km2 conjugation colony boilates (6 colonies in 
total). 
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4.2.2 Detection of miniTn5 in B. thailandensis colonies 
PCR was used to detect the transposon within colonies that grew after 
mutagenesis. Primers KanF and KanR were used, which amplify 544bp within 
the kanamycin resistance gene in the transposon.  
 
The PCR yielded a product using the positive control E. coli pUT-miniTn5Km2, 
while B. thailandensis wild type was negative. Genomic DNA from 5 colonies 
(100%) gave a positive result (figure 4.4), as did 15 tested colonies (colony 
boilates, 100%, not shown). This suggests that colonies re-grown after 
transformation contain the transposon. 
  
140 
 
 
 
  
Figure 4.4 – Representative gel of PCR to amplify a 544bp fragment within 
the miniTn5 kanamycin resistance gene 
Lane order (L-R): 
1 – DNA ladder. Ladder fragment size is given in bp next to the gel. 
2-6 – Template: genomic DNA from pUT-miniTn5Km2 conjugation colony (6 
colonies in total). 
7 – Template:  genomic DNA from B. thailandensis colony(negative DNA 
control). 
8 – Template: purified pUT miniTn5Km2 (positive DNA control). 
9 – Template: water (negative control). 
141 
 
4.2.3 The pUT-miniTn5Km2 plasmid is lost after tn5 insertion 
The pUT-miniTn5Km2 plasmid cannot replicate in Pir-negative bacteria such as 
B. thailandensis, therefore conjugated bacteria are expected to contain the 
transposon but not the rest of the plasmid (de Lorenzo, Herrero et al. 1990, 
Herrero, de Lorenzo et al. 1990). This was confirmed experimentally, by 
demonstrating that the original plasmid had been lost in the mutagenised 
B. thailandensis.  
 
A microbiological plate screen was first used, to attempt to detect the plasmid 
within bacteria, as the pUT-miniTn5Km2 plasmid encodes a β-lactamase. The 
hypothesis was that mutagenised bacteria would not be able to grow on agar 
containing ampicillin. E. coli pUT-miniTn5Km2 was included as a positive 
control, while wild type B. thailandensis colonies was expected not to grow 
(negative control). 
 
All of the E. coli pUT-miniTn5Km2 (positive control) colonies were able to grow 
on100μg/ml ampicillin plates as expected (figure 4.6). Wild type B. thailandensis 
colonies were also able to grow on ampicillin (43% at 48h), showing that strains 
without the plasmid were not growth inhibited in this assay. For the conjugated 
B. thailandensis colonies, 7% had grown after 24h incubation and 46% had 
grown after 48h (figure 4.5). Therefore this method could not reliably 
differentiate plasmid-positive and plasmid-negative strains.  
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Figure 4.5 – ampicillin resistance of colonies obtained after conjugation 
Single colonies were picked from pUT-miniTn5Km2 conjugation plates 
(Conjugation) and streak plates of donor E. coli pUT-miniTn5Km2 and recipient 
B. thailandensis E264, and re-streaked onto LA plates or  LA plates containing 
100μg/ml ampicillin (amp100). All colonies grew on LA (not shown). The 
percentage of colonies that grew on LA or LA+amp100, compared with those 
that did not grow on LA+amp100 after 24h or 48h incubation at 37°C is shown. 
Data from one assay. Number of colonies screened: 55 conjugation colonies, 
29 donor colonies, 26 recipient colonies. 
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It was hypothesised that PCR could be used to screen for the presence of the 
pUT-miniTn5Km2 plasmid instead. Primers Bla3_Fw and Bla3_Rv were 
designed, which recognised part of the β-lactamase gene, with an expected 
product size of 198bp. Bioinformatics confirmed that the primer recognition 
sequences were not present in the B. thailandensis or E. coli genomes (data not 
shown). In order to test the activity of the new primers at different annealing 
temperatures, a gradient PCR was conducted (figure 4.6). An annealing 
temperature of 57.7°C gave optimal yield, and was used for subsequent 
reactions. 
 
The PCR was positive for E. coli pUT-miniTn5Km2 and negative for 
B. thailandensis wild type controls, showing that plasmid positive and negative 
bacteria can be distinguished using this method (figure 4.7). Of six tested 
transposon mutants, all gave a negative result with primers Bla3_Fw and 
Bla3_Rv (figure 4.7). This suggests that colonies re-grown after transformation 
do not contain the plasmid. 
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Figure 4.6 – Gradient PCR, using primers Bla3_Fw and Bla3_Rv 
A boiled colony of E. coli 19851 pUT-miniTn5Km2 was amplified using primers 
Bla3_Fw and Bla3_Rv, with a range of annealing temperatures as indicated 
below: 
Lane order (L-R): 
1 – DNA ladder. Ladder fragment size is given in bp next to the gel. 
2 – Annealing temperature = 57.7°C, 
3 – Annealing temperature = 58.5°C, 
4 – Annealing temperature = 59°C, 
5 – Annealing temperature = 60.3°C, 
6 – Annealing temperature = 61.9°C, 
7 – Annealing temperature = 62.6°C, 
8 – Annealing temperature = 63.9°C, 
9 – Annealing temperature = 65.1°C. 
All temperatures accurate to within 0.3ºC. 
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Figure 4.7 – PCR to amplify the ampicillin resistance gene of the pUT-
miniTn5Km2 plasmid 
Colony boilates were used in a PCR reaction with primers Bla3_Fw and 
Bla3_Rv. 
Lane order (L-R) 
1 – DNA ladder. Ladder fragment size is given in bp next to the gel. 
2-7 – Template: pUT-miniTn5Km2 conjugation colony boilates (6 colonies in 
total). 
8 – Template: B. thailandensis E264 wild type colony boilate (negative control). 
9 – Template: E. coli pUT-miniTn5Km2 colony boilate (positive control). 
10 – Template: water (negative control). 
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4.3 Antibiotic resistance screen of transposon mutants  
Prior to the persister assay screen and TraDIS, a small transposon library 
(~1000) mutants was screened for ciprofloxacin resistance. Identification of 
transposon insertion sites in mutants with increased resistance was done in 
order to link genotype with phenotype.  
4.3.1 Phenotypic screen for increased ciprofloxacin resistance 
A transposon library of ~1000 mutants was inoculated onto LB plates containing 
ciprofloxacin. Mutants that were able to grow on 4μg/ml ciprofloxacin (2x MIC) 
plates, on which the wild type could not grow, were picked and streaked onto 
4μg/ml ciprofloxacin plates to confirm the increased resistance (data not 
shown). From these plates, seven mutants were obtained which showed 
increased ciprofloxacin resistance in a preliminary MIC assay (figure 4.8). Of 
these, mutant A3 was used for further study. The other mutants were stored at -
80°C for potential future studies.  
 
In additional experiments, mutant A3 reproducibly demonstrated a significantly 
higher (~2x) MIC compared with wild type E264 (unpaired t-test assuming equal 
variances, figure 4.9A). In these assays, mutant A3 demonstrated significantly 
higher OD595nm after 24h in the presence of 2μg/ml ciprofloxacin, in comparison 
with the wild type (unpaired t-test assuming equal variances, figure 4.9B). It also 
displayed a higher OD595nm at 3μg/ml, but the difference between mutant and 
wild type was not statistically significant (p = 0.0674, unpaired t-test between 
wild type and mutant A3 at 3μg/ml). These data suggest that mutant A3 is more 
resistant to ciprofloxacin than is the wild type. 
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Figure 4.8 – Increased ciprofloxacin resistance for seven 
transposon mutants, compared with wild-type B. thailandensis 
Assay used cultures of seven transposon mutants (A1-7) that grew on 
4μg/ml ciprofloxacin plates, and wild type (WT) B. thailandensis. 
Stationary phase bacteria were diluted and mixed with serial dilutions of 
antibiotic in a microtitre plate, resulting in a culture density of OD600nm 
0.0005 and antibiotics at a range of concentrations. The plate was 
incubated under aerobic conditions at 37°C, for 24h, then OD595nm was 
measured. For each mutant, the OD595nm for ciprofloxacin treated wells 
was divided by the OD595nm for control wells (bacteria incubated without 
antibiotic), in order to account for different levels of growth after 24h by 
the different mutants. The MIC was determined as the lowest 
concentration of antibiotic which inhibited growth. Data from one assay, 
with error bars indicating standard deviation of 3 technical replicates. 
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Figure 4.9 – Increased ciprofloxacin resistance in miniTn5 mutant A3 
Stationary phase bacteria were diluted and mixed with serial dilutions of 
ciprofloxacin in a microtitre plate, resulting in a culture density of OD600nm 0.0005 
and ciprofloxacin at a range of concentrations. The plate was incubated under 
aerobic conditions at 37°C, for 24h, then OD595nm was measured. The MIC was 
determined as the lowest concentration of antibiotic which inhibited growth. 
Averages for three assays are reported. Error bars indicate standard deviation. 
A) Average of the three MIC results. * indicates p<0.05 using two-tailed t-test. 
B) Average of the three OD595nm readings (from the three assays in 4.9A), after 
24h ciprofloxacin treatment at the concentrations indicated. * indicates p<0.05 
using two-tailed t-test. 
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4.3.2 Identification of transposon insertion site in miniTn5 
mutants with increased ciprofloxacin resistance 
Genomic DNA was purified from mutant A3, and the transposon flanking region 
was amplified using arbitrary-PCR, which resulted in a 500-700bp product 
(figure 4.10). This product was sequenced using primer arb2, which reads from 
the flanking genomic DNA into the transposon. After read clean-up, the 
sequence data contained 498 genomic DNA residues, followed by 61 
transposon residues. 
 
A BLAST search of the genomic DNA from the sequencing read identified a 
high level of identity (99% matching residues, e=0) with the B. thailandensis 
gene BTH_I0115 (pglY) on chromosome 1. This suggested that the transposon 
insertion site was within the pglY gene. The last residue of pglY (before the 
transposon) was at chromosome position 2179790 (chromosome 1, accession 
number CP008785.1). The transposon is therefore between residues 2179790 
and 2179791 (figure 4.11). 
 
In order to confirm the presence of miniTn5 in the pglY gene in mutant A3, 
primer PglY_1 was designed, which annealed 173bp downstream of the 
expected transposon insertion site, in gene pglY. A PCR was conducted using 
this primer and primer p7U, which bound within the transposon. If the 
transposon is present, the primers were expected to amplify a product of 232bp 
(59bp transposon DNA plus 173bp genomic DNA) (figure 4.12A). As shown in 
figure 4.14B, PglY_1 and P7U1 generated a product of between 200-300bp, 
demonstrating that there is a transposon insertion in the pglY gene in mutant 
A3. There was no product with the wild type, as expected (figure 4.12B). The 
PCR product from mutant A3 was sequenced; a BLAST search of the 
sequencing product had a high level of identity with the pglY gene (99% 
matching residues, e=0), confirming that the insertion is in this gene.  
 
Arbitrary PCR was also performed on genomic DNA purified from the other 
mutants identified in section 4.3.1 (and shown in figure 4.8): mutants A1, 2, 4, 5, 
6, 7. Sequencing of these PCR products indicated single transposon insertions 
in each mutant. One mutant (A1) had an insertion in BTHII_0270, which 
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encodes an uncharacterised protein, 4 mutants (A2, A4, A5, and A7) had 
insertions in BTHII_2068, which encodes dihydrodipicolinate synthetase family 
protein, and one mutant (A6) had an insertion in BTH_I1311, which encodes 3-
methyl-2-oxobutanoate hydroxymethyltransferase (PanB).  
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Figure 4.10 – arbitrary PCR to amplify transposon flanking region in 
miniTn5 mutant A3 
Genomic DNA from wild type B. thailandensis E264 or tn5 mutant A3 were 
amplified with a two-step arbitrary PCR. Several different random primer pairs 
were used for amplifications in the first round of PCR (see below), whereas the 
same nested primer pair (arb2 and p7U) was used for all amplifications in the 
second round of PCR. Products from the second round were run on an agarose 
gel to visualise results. 
Lane order (L-R): 
1 – DNA ladder. Ladder fragment size is given in bp next to the gel. 
2 – Template: B. thailandensis wild type gDNA. First round primers: P7M1 and 
arb1. 
3 – Template: B. thailandensis wild type gDNA. First round primers: P7M1 and 
arb3. 
4 – Template: B. thailandensis wild type gDNA. First round primers: P7M1 and 
arb4. 
5 – Template: B. thailandensis wild type gDNA. First round primers: P7M1 and 
arb5. 
6 – Template: B. thailandensis miniTn5 mutant A3. First round primers: P7M1 
and arb1. 
7 – Template: B. thailandensis miniTn5 mutant A3. First round primers: P7M1 
and arb3. 
8 – Template: B. thailandensis miniTn5 mutant A3. First round primers: P7M1 
and arb4. 
9 – Template: B. thailandensis miniTn5 mutant A3. First round primers: P7M1 
and arb5. 
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Figure 4.11 – Representation of miniTn5-pglY junction in mutant A3 
The pglY gene is shown in green, the miniTn5 transposon is in blue. The pglY gene is 
interrupted by the transposon, which has inserted 965bp downstream from the start of 
pglY. After the end of the transposon, there is the remaining 2719bp of the pglY gene.  
Total gene length is 3684bp, total transposon length is 1641bp. The terminal 3 base 
pairs are shown for each section.  
Chromosomal positions of pglY are as follows: start of gene at position 2178826, end 
of gene at position 2182509. Transposon insertion is between position 2179790 and 
2179791.  
The arb2 sequencing read from figure 4.10 (red arrow) read from right to left (opposite 
orientation to gene and transposon) and contained 498 residues of pglY (from right 
hand side of gene) and 61 residues of the transposon. 
Not to scale. 
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Figure 4.12 – PCR to confirm the transposon insertion site in pglY 
A) Schematic representation of possible PCR outcomes with primer P7U and 
pglY1. If the pglY gene (green) contains the transposon (blue), there will be an 
amplification of a 232bp product (left figure). If there is no transposon, primer 
P7U will not be able to anneal, so will not create a product with pglY1 (right 
figure). The terminal 3 nucleotides of the primers and primer recognition sites are 
shown. Not to scale. 
 
B) Analysis of actual PCR products by agarose gel electrophoresis. DNA was 
amplified using primers p7U (transposon specific) and pglY1 (pglY gene 
specific). 
Lane order (L-R): 
1 – DNA ladder. Ladder fragment size is given in bp next to the gel. 
2 – empty. 
3 – Template: B. thailandensis E264 wild type genomic DNA. 
4 – empty. 
5 – Template: B. thailandensis miniTn5 mutant A3 genomic DNA. 
6 – empty. 
7 – Template: water  
 
 
 
 
 
 
A) 
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4.3.3 Further characterisation of pglY miniTn5 mutant 
4.3.3.1 Growth rate analysis 
In order to test whether there was a growth phenotype of the pglY mutant, the 
growth rate (by measuring OD600nm over several time-points) was tested and 
compared with the wild type. The mutant grew more slowly and to a lower 
OD600nm than the wild type (figure 4.13).  
 
4.3.3.2 Bioinformatic analysis 
In an attempt to try and understand the role of the pglY /BTH_I0115 gene and 
the PglY protein, bioinformatic searches were conducted using the gene and 
protein sequences. Outside of B. thailandensis E264, the pglY nucleotide 
sequence had a perfect match for B. thailandensis strain 2002721643, in the 
pglY gene in chromosome I. There was a weak alignment with the genome of 
Kibdelosporangium sp. MJ126-NF4, in the pglY gene, which encodes a 
bacteriophage resistance protein (table 4.1). The PglY protein sequence aligned 
with 100 protein sequences from other bacteria, including several phage 
defence/resistance proteins (table 4.2). Taking the bioinformatics results 
together, this suggests that PglY is involved in phage resistance.  
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Figure 4.13 – growth of B. thailandensis wild type and miniTn5-pglY 
mutant in LB 
Bacteria were inoculated into LB at a starting OD600nm of 0.0005, which was 
then divided into 200μl aliquots in a 96 well plate. These cultures were 
incubated at 37°C, without shaking. ODs were recorded automatically using 
a plate reader every 30 minutes. Data from one experiment are shown. 
Error bars show standard deviation from 4 technical replicates. Data from 
28h incubation rather than 24h is shown, in order to demonstrate mutant A3 
reaching stationary phase.  
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Description Max 
score 
Total 
score 
Query 
coverage 
E 
value 
Identity Accession 
ID 
B. thailandensis 
2002721643 
chromosome I, complete 
sequence 
6802 6802 100% 0.0 100% CP009601.1 
B. thailandensis E264, 
chromosome 1, complete 
sequence 
6802 6802 100% 0.0 100% CP008785.1 
B. thailandensis 
2002721723 
chromosome 1, complete 
sequence 
6802 6802 100% 0.0 100% CP004097.1 
B. thailandensis E264, 
chromosome I, complete 
sequence 
6802 6802 100% 0.0 100% CP000086.1 
Kibdelosporangium sp. 
MJ126-NF4, complete 
genome 
58.4 58.4 1% 0.001 88% LN877229.1 
 Table 4.1 – alignment of pglY gene sequence 
The pglY gene sequence was searched in nucleotide BLAST, using optimisation for 
highly similar sequences (MEGABLAST).  
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Protein  Organism 
Max 
score 
Total 
score 
Query 
coverage 
Identity Accession ID 
Hypothetical 
protein 
B. mimosarum 2369 2369 100% 95% WP_028211990.1 
Hypothetical 
protein 
WS62_13745 
Burkholderia sp. 
ABCPW-14  
2332 2332 100% 94% KVD69282.1 
Hypothetical 
protein 
B. pseudomallei 2330 2330 100% 94% WP_043294106.1 
Hypothetical 
protein 
Acidovorax 
oryzae 
2303 2303 100% 93% WP_026434334.1 
Hypothetical 
protein 
Candidatus 
competibacter 
denitrificans 
1707 1707 100% 71% WP_048671262.1 
PglY 
Nitrococcus 
mobilis 
967 967 83% 49% WP_005004488.1 
Phage 
resistance 
protein 
Comamonas 
aquatica  
952 952 80% 49% WP_045266902.1 
Hypothetical 
protein 
AW10_02765 
C. 
accumulibacter 
sp. BA-92  
951 951 81% 49% EXI78850.1 
Phage 
resistance 
protein 
Azohydromonas 
australica 
944 944 94% 45% WP_028998074.1 
Phage 
resistance 
protein 
Diaphorobacter 
sp. J5-51  
938 938 80% 49% WP_047351120.1 
 Table 4.2 – alignment of PglY protein sequence 
The PglY protein sequence was searched in protein BLAST. Top 10 alignments of 
100 are reported. All E values were 0.0. 
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4.4 Generation of transposon mutant library 1B 
Next a TraDIS study was undertaken to try to identify genes involved in 
tolerance to ceftazidime or ciprofloxacin. In order to generate a larger 
transposon library for TraDIS, the transposon mutagenesis protocol was scaled 
up to give 45 plates of mutagenised bacteria, with an average of ~800 colonies 
per plate (n=12 plates counted). This provided approximately 36000 mutants 
across all plates.  
  
All colonies on these plates were pooled to give library 1B. 20 colonies from this 
library were checked using the previously described 16S-specific and 
transposon specific PCRs (described in sections 4.2.1 and 4.2.2, respectively), 
to confirm that they were B. thailandensis miniTn5 mutants. This resulted in 
100% positive results for all 20 colonies with both PCRs (representative gels in 
figures 4.14 and 4.15), indicating that the library contained B. thailandensis 
miniTn5 mutants. The library was stored at -80°C in media containing 15% 
glycerol. 
 
In order to calculate coverage (frequency of transposon insertions) of the 
genome, the following formula was used: 
 N = C x ln(1-p) / ln (1-f) 
Where N = number of mutants, C = coverage (number of transposon insertions 
per gene), p = probability and f = fraction (proportion of genome). (Provided by 
Richard Saint, DSTL, by personal communication). 
 
B. thailandensis E264 has 5717 genes, therefore f = 1/5717. For 90% 
confidence, p = 0.9. N = 36000 (minimum) based on experimental data. 
Inserting these parameters into the equation above gives: 
 36000 = C x ln(1-0.9) / ln (1-(1/5717)) 
therefore C = 2.73. 
This indicates that there is a 90% probability that miniTn5 library 1B contains, 
on average, at least 2.73 transposon insertions per gene. 
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Figure 4.14 – Agarose gel showing representative results of 
B. thailandensis-specific PCR of miniTn5 library 1B 
Using primers 16S_Fw and 16S_Rv, as for figure 4.3.  
Lane order (L-R): 
1 – DNA ladder. Ladder fragment size is given in bp next to the gel. 
2-6 – Template: pUT-miniTn5Km2 conjugation colony boilates (5 colonies in 
total). 
7-8 – Template: B. thailandensis wild type colony boilate (2 colonies in total). 
9-10 – Template: E. coli pUT-miniTn5Km2 colony boilate (2 colonies in total). 
11 – Template: water 
 
 
 
 
 
160 
 
 
  
Figure 4.15 – Agarose gel showing representative results of 
transposon-specific PCR of miniTn5 library 1B 
Using primers KanF and KanR, as for figure 4.4. 
Lane order (L-R): 
1 – DNA ladder. Ladder fragment size is given in bp next to the gel. 
2 – Template: B. thailandensis wild type colony boilate. 
3-8 – Template: pUT-miniTn5Km2 conjugation colony boilates (6 colonies 
in total). 
9 – Template: E. coli pUT-miniTn5Km2 colony boilate. 
10 – Template: water. 
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4.5 Persister frequency assay screen of transposon 
library 1B 
In order to conduct a selection process for persister mutants, the library was 
first grown from a freezer stock, which produced turbidity in a flask after 18h 
incubation, indicating that the transposon library could be recovered from 
freezer storage and grown in broth. Genomic DNA was extracted from this 
culture in triplicate, to produce the library DNA samples T0-A, T0-B and T0-C. 
 
The library culture was treated with 400μg/ml ceftazidime or 40μg/ml 
ciprofloxacin for 24 hours (incubated statically at 37ºC in 24 well assay plates, 
as for all persister frequency assays). The CFU/ml measurements before and 
after treatment are reported in figure 4.16.  
 
Surviving bacteria after ceftazidime or ciprofloxacin treatment were washed and 
re-cultured in fresh LB. This was done in order to select for bacteria that could 
re-grow after antibiotic treatment, as well as to dilute the dead/lysed/non-
culturable cells in the antibiotic treated culture. DNA was extracted, in triplicate, 
from these sub-cultures after 42h, resulting in the samples Cef-1A, Cef-1B and 
Cef-1C (after ceftazidime treatment and re-growth) and Cip-1A, Cip-1B and Cip-
1C (after ceftazidime treatment and re-growth).  
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Figure 4.16 – CFU/ml measurements of a B. thailandensis miniTn5 
library before and after treatment with ceftazidime or ciprofloxacin  
An 18h culture of miniTn5 library 1B grown in broth (50ml LB in a 250ml flask) 
with 200rpm shaking was adjusted to OD600nm 0.2 and mixed in equal volumes 
with antibiotic at 2x the assay concentration, resulting in a final culture density 
of OD600nm 0.1 and antibiotics at the following concentrations: 400μg/ml 
ceftazidime or 40μg/ml ciprofloxacin. Samples were incubated in 1ml aliquots 
in a 24 well plate, under aerobic conditions (at 37°C, static incubation), for 24 
hours. CFUs were enumerated before (t0/input) antibiotic treatment and after 
24h incubation. Library construction and screening was performed once, error 
bars indicate standard deviation of technical replicates. 
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4.6 Preparation of libraries for sequencing 
An overview of the process used to prepare genomic DNA from the transposon 
library samples for TraDIS is shown in figure 4.17. 
4.6.1 Optimisation of sequencing library preparation  
Prior to preparing the libraries for sequencing, several assays were conducted 
on a test library, to test aspects of the library preparation process, and optimise 
the yield of transposon-containing DNA.  
4.6.1.1 Comparison of NEXTflex and NEBNext kits for end repair, A-tailing 
and adenylation of fragmented library DNA 
Several commercial kits are available for preparation of DNA libraries for 
sequencing. The DNA yields of a transposon library, prepared using the 
commercial kits NEBNext DNA Library Prep Reagent Set for Illumina (NEB) or 
NEXTflex Rapid DNA-Seq Kit (Newmarket Scientific), were compared. A 
fragmented sample of 2μg of library DNA was split in half and prepared with 
NEBNext reagents or NEXTflex reagents (using manufacturer’s instructions) in 
parallel, resulting in two samples of adapter-ligated DNA. After a PCR to amplify 
transposon-containing DNA, a qPCR was performed to determine the 
concentration of the transposon-containing DNA. It was found that the NEXTflex 
method gave a higher transposon-containing DNA concentration in the qPCR, 
compared with the NEBNext method (table 4.3). NEXTflex was therefore used 
for all subsequent library preps. 
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Figure 4.17 – Method used for library preparation for sequencing 
Sequencing is optimal on small fragments of DNA (150-1000bp), rather than 
whole genomes. Therefore genomic DNA from transposon libraries was 
fragmented, resulting in DNA fragments, some of which contain the 
transposon-genome junction. Fragments were then repaired and adapters 
ligated to all fragments. A PCR was carried out using a primer specific for 
transposon DNA, and another primer specific for the adapter sequence. 
This PCR is needed to 1) increase the abundance of transposon-containing 
fragments, 2) add flow cell binding regions, which enable fragments to 
cluster in the sequencer, 3) attach a 6-7 nucleotide barcode, so that all 
fragments from that library have a 6-7 nucleotide sequence that can be 
identified post-sequencing (“de-multiplexing”). Size selection was carried out 
on PCR amplified libraries in order to standardise fragment size for 
sequencing.  
Adapted by permission from Macmillan Publishers Ltd: Nature Reviews 
Microbiology, (van Opijnen and Camilli 2013) copyright (2013). 
Modification: HITS, Tn-Seq and INSeq library preparation processes 
removed. Size selection moved to after PCR. 
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  Kit Tn-DNA (pM) 
NEBNext 745.7 
NEXTflex 1104.8 
Table 4.3 – Transposon-containing DNA yields for 
NEBNext and NEXTflex kits 
2μg library genomic DNA was fragmented by ultra-sonication 
then divided into two equal volumes. Both halves of the sample 
were end-repaired, A-tailed and adapter-ligated, one using 
NEB Next, one using NEXTflex. Concentration of transposon-
containing DNA was determined by qPCR with primers 
miniTn5-3pr-seq and Syb_RP7. Results from one library prep. 
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4.6.1.2 Optimisation of PCR conditions 
Two PCR polymerases were tested, with different primer concentrations, 
chosen based on manufacturers recommendations and previous library 
preparations (Nicola Senior, personal communication). Phusion polymerase 
gave >50x more DNA compared with Jumpstart polymerase (figure 4.18A), and 
a primer concentration of 0.5µM lead to slightly improved yield compared with 
2μM primer. Phusion polymerase with 0.5μM of each primer was therefore for 
future library preparations. 
 
A gradient PCR was conducted to test the effect of different annealing 
temperatures on yield from NEXTflex prepared template DNA using Phusion 
polymerase. Results were analysed by qPCR (figure 4.18B). It was found that 
54.8°C was the optimal annealing temperature, and was therefore used for 
future reactions.  
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Figure 4.18 – optimisation of yield from transposon-specific PCR 
A) an adapter-ligated test library was amplified using Jumpstart or Phusion 
polymerase, as per manufacturers’ instructions.  
B) an adapter-ligated test library was amplified using Phusion polymerase in a 
gradient PCR, using several different annealing temperatures (accurate to within 
0.3ºC). 
qPCR with adapter-specific primers Syb_FP5 and Syb_RP7 was used to 
quantify the yield of adapter-containing DNA in both figures. Results from one 
library prep. 
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4.6.1.3 Trial size selection of test library 
After conducting the PCR amplification stage on a test DNA library, a trial size 
selection (for 350-500bp fragments, which are optimal for library preparation) 
was conducted. TapeStation measurements (figure 4.19) of the library before 
and after size selection indicate that the size selection method was effective in 
obtaining a concentrated sample fragment distribution of 350-500bp (compare 
B1 and C1 in figure 4.19A, or upper and lower traces in figure 4.19B). Size 
region analysis of this data indicated that 116nM DNA of a suitable size for 
sequencing (150-1000bp) is available for this test library, with an average 
fragment size of 419bp. 
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Figure 4.19 – Efficacy of bead based size selection method, using test 
library 
The library was analysed by TapeStation (Agilent), using an aliquot taken 
before size selection, and an aliquot from the size selected library. 
A1 = ladder, B1 = non-size-selected DNA, C1 = DNA selected at 350-500bp, 
D1= empty lane. 
A) Electropherogram. Upper (~1500bp) and lower (~25bp) markers were 
included. The lower marker was not detected in B1 due to non-marker DNA 
of a similar size. 
B) Bioanalyser traces. Upper trace = non-size-selected DNA (B1), lower 
trace = DNA selected at 350-500bp (C1). Upper (1500bp) and lower (25bp) 
markers were included. The lower marker was not detected in B1 due to 
non-marker DNA of a similar size.  
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4.6.2 Preparation of persister assay libraries for sequencing 
4.6.2.1 Samples 
Genomic DNA was extracted from the ceftazidime- and ciprofloxacin-treated 
libraries (Cef-1 and Cip-1) in triplicate, resulting in the generation of samples 
Cef-1A, Cef-1B, Cef-1C, Cip-1A, Cip-1B and Cip-1C. Genomic DNA was also 
extracted from the input sample (T0), in triplicate, to produce T0-A, T0-B and 
T0-C. The sequencing library preparation workflow was then conducted for the 
nine libraries. 
  
4.6.2.2 Bioanalyser traces of fragmented DNA  
DNA was fragmented to ~500bp as described in methods. Bioanalyser was 
used to confirm that fragments of the desired size had been generated. 
Bioanalyser readings indicated that all samples had given an approximately 
normally distributed spread of fragments of different sizes, with an average size 
of 400-600bp (figure 4.20 and table 4.4). 
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Figure 4.20 – Bioanalyser traces of fragmented DNA libraries 
Genomic DNA from the 3 treatment cultures (input, ceftazidime or ciprofloxacin 
treated) was purified, and three replicates of each gDNA extract were fragmented, 
then purified to remove <150bp fragments.  
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Library Size range Average 
size 
ng/μl nM 
T0-A 150-1000bp 576 25.99 78.7 
T0-B 150-1000bp 561 26.58 80.8 
T0-C 150-1000bp 569 35.89 109.2 
Cef-1A 150-1000bp 429 21.74 91.4 
Cef-1B 150-1000bp 452 36.6 145.1 
Cef-1C 150-1000bp 463 43.06 166.9 
Cip-1A 150-1000bp 472 46.13 176.4 
Cip-1B 150-1000bp 499 62.27 222.7 
Cip-1C 150-1000bp 499 41.53 148.7 
Table 4.4 – Summary of bioanalyser traces of fragmented DNA libraries 
DNA concentrations between 150-1000bp are shown. 
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4.6.2.3 PCR and size selection of libraries  
PCR was carried out with a transposon-specific primer (MiniTn5-3pr-3), and one 
of 6 adapter specific primers (MPX1-6). The 6 MPX primers each add a different 
barcode sequence. These barcodes will be used for identification of the libraries 
during sequencing. The use of one of the MPX primers resulted in each library 
having one of 6 barcodes: ATCACG (libraries T0-A and T0-C), CGATGT 
(libraries T0-B and Cef-1C), ACAGTG (Cip-1A), ACTTGA (Cip-1B), TTAGGC 
(Cip-1C and Cef-1A), and TCAGATC (Cef-1B). The PCR also adds the flow-cell 
binding regions (FCBR) to all amplified fragments, which are needed for 
adhesion to the sequencing cell. The FCBR will also be used for library qPCR 
quantitation (next section). 
 
Libraries amplified by PCR were checked by bioanalyser to determine the size 
of the DNA fragments, in order to determine what size range would be used for 
size selection. Following fragmentation of the DNA to 400-600bp fragments, 
then addition of adapters, and PCR amplification of a part of the fragment, it 
was calculated that the average transposon-containing fragment would be 
approximately 400-600bp. The bead-based size selection method has several 
possible size selection ranges: 350-500bp, 400-600bp and 500-700bp. 
 
The most concentrated range for each library is shown in table 4.5 (after PCR 
columns). Each library had >25nM DNA in its most concentrated range. Despite 
this high concentration, there were also fragments outside of this range, which 
could interfere with sequencing and reduce the concentration of transposon-
containing fragments. Size selection was therefore carried out to enrich for 
fragments of the desired size. 
 
Size selection of all nine libraries resulted in >10nM DNA (table 4.5, after size 
selection column). This was >25% of the concentration before size selection in 
all libraries (compare before and after size selected DNA concentrations); some 
DNA is expected to be lost during size selection. However, the average 
fragment size (400-500bp) and the bioanalyser traces (data not shown) suggest 
that the size selection process has increased the relative concentration of DNA 
in the intended size ranges, by excluding very small and very large fragments. 
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Library After PCR After size 
selection 
Most concentrated 
size selection range 
DNA concentration 
in this range (nM) 
DNA 
concentration in 
size selected 
range (nM) 
T0-A 350-500 29.8 18.1 
T0-B 400-600 27.8 16.4 
T0-C 350-500 47.7 23.9 
Cef-1A 350-500 66.2 42.5 
Cef-1B 350-500 114 31.8 
Cef-1C 400-600 91.6 39.7 
Cip-1A 350-500 96.6 25.5 
Cip-1B 350-500 108.4 53.5 
Cip-1C 400-600 82.6 79.4 
 Table 4.5 – Summary of Bioanalyser data for PCR amplification and size 
selection steps of library preparation  
After PCR amplification, libraries were studied by Bioanalyser, in order to 
determine suitable size ranges for size selection. The relevant size selection 
ranges of interest are 350-500bp, 400-600bp and 500-700bp. The most 
concentrated range is given for each PCR amplified library, as well as the DNA 
concentration within this range. 
After size selection, libraries were studied by Bioanalyser, in order to determine 
final library DNA concentrations. Within the size selection ranges (350-500bp or 
400-600bp) chosen, the DNA concentration is given.  
For example, t0-A had 29.8nM DNA between 350-500bp. After size selection 
there was 18.1nM DNA in this range.  
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4.6.2.4 Transposon-containing DNA concentrations of size selected 
libraries 
The bioanalyser traces give concentrations of total DNA in the libraries. qPCR 
was used to determine relative concentrations of transposon-containing and 
non-transposon-containing DNA in the size selected libraries.  
 
Primers miniTn5-3pr-seq and syb_RP7 were used to quantify the fragments 
which contained transposon. Primers syb_FP5 and syb_RP7 were used to 
quantify all (FCBR-containing) fragments (i.e. total transposon-containing and 
non-transposon-containing fragments) (figure 4.21).  
 
qPCR results for both primer pairs are shown in table 4.6 (qPCR initial result 
columns). These concentrations were obtained based on the size of the qPCR 
standards (452bp), so were adjusted to account for the average size of DNA 
fragments in the libraries (which was obtained by Bioanalyser), as follows: 
 
Size adjusted DNA concentration = non-adjusted concentration (from qPCR) x 
(Size of qPCR standard / average size of library fragments). 
(Calculation provided by Dr Karen Moore). 
 
Using library T0-A as an example: 
Size adjusted transposon-containing DNA concentration = 6.97nM x (452bp / 
438bp) = 7.19nM. 
 
This calculation was conducted for all libraries, and final size-adjusted 
transposon-containing and total DNA concentrations are shown in table 4.6.  
All input (T0) and Cip-1 libraries had good (<10:1) ratios of transposon-
containing fragments to total FCBR-containing fragments, with >1nM 
transposon-containing DNA fragments. For the Cef-1 libraries, the ratios were 
lower (400:1 – 250:1). All libraries had >100pM transposon-containing DNA 
fragments. 
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Figure 4.21 – Schematic of qPCR primers  
Following PCR, all DNA fragments are expected to contain FCBR. 
qPCR with miniTn5-3pr-seq and syb_RP7 was used to detect transposon-
containing DNA fragments. 
qPCR with syb_FP5 and syb_RP7 was used to detect total DNA fragments 
(transposon containing and non-transposon containing) 
 
DNA fragments containing transposon (A) will yield a product for both 
transposon-specific and FCBR-specific qPCRs.  
DNA fragments which do not contain transposon DNA (B) will yield a product for 
FCBR-specific but not transposon-specific qPCRs. 
 
FCBR = flow-cell binding region. A = adapter. 
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Library Average 
fragment 
size 
Transposon-
containing fragments 
FCBR-containing 
fragments (total 
fragments)  
Ratio 
transposon: 
FCBR 
containing 
fragments 
qPCR 
initial 
result 
(nM) 
Adjusted 
DNA 
concentration 
(nM) 
qPCR 
initial 
result 
(nM) 
Adjusted 
DNA 
concentration 
(nM) 
T0-A 438 6.97 7.19 45.04 46.47 1:6.46 
T0-B 476 2.14 2.03 14.55 13.82 1:6.80 
T0-C 432 2.21 2.32 15.94 16.68 1:7.20 
Cef-1A 463 0.21 0.21 54.31 53.02 1:258 
Cef-1B 469 0.22 0.21 58.40 56.29 1:270 
Cef-1C 491 0.12 0.11 53.75 49.48 1:450 
Cip-1A 467 6.98 6.76 48.76 47.19 1:6.98 
Cip-1B 484 10.98 10.25 69.53 64.94 1:6.34 
Cip-1C 484 16.61 15.52 102.78 95.99 1:6.19 
Table 4.6 – Summary of size selected libraries 
Bioanalyser was used to provide the average size of DNA fragments. 
The concentration of transposon-containing fragments was obtained by qPCR with primers 
miniTn5-3pr-seq and syb_RP7. 
The concentration of FCBR-containing fragments was obtained by qPCR with primers 
syb_FP5 and Syb_RP7. Following PCR, all DNA fragments are expected to contain FCBR. 
For all qPCR results with both primer sets, the average size was used to adjust the qPCR 
DNA concentration. This is in bold for clarity.  
The final ratio of size adjusted transposon-containing fragments to all FCBR-containing 
fragments is shown in bold for clarity. 
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4.7 MiSeq sequencing of libraries 
To trial the sequencing of a single library, prior to a Hiseq run of multiple 
libraries in a pool, library Cip-1C was analysed using a MiSeq. The library was 
read with a transposon specific primer (MiniTn5-3pr-seq), which sequenced the 
transposon-genome junctions, and an indexing primer (HP12), which read the 
library barcode (schematic overview in figure 4.22). The library was sequenced 
in a pool with 24 other libraries belonging to other users. 1.6x105 reads were 
mapped to library Cip-1C using the barcode (i.e. 1.6x105 reads were sequenced 
by both the transposon specific primer MiniTn5-3pr-seq and the indexing primer 
HP12).  
 
The reads were tested for the presence of the Transposon End Sequence 
(TES, sequence TAAGAGTCAG). When the transposon inserts into genomic 
DNA, the TES is the transposon DNA at the junction between transposon and 
genomic DNA. Therefore all reads from DNA fragments containing transposon 
insertions should contain the TES. It was expected that most or all of the reads 
from the transposon specific primer miniTn5-3pr-seq contain the TES.  
 
Although 1.6x105 reads were sequenced with the transposon-specific primer, 
not all reads contained the TES. Of a sample of 500 reads, 57% (284/500) 
contained the TES. Since reads from DNA fragments containing transposon 
insertions should contain the TES, the result may indicate some non-specific 
activity of the primer, or some sequencing error, for the remaining 43% of reads.  
 
A second MiSeq run was conducted, with several libraries, to test whether de-
multiplexing would work for multiple libraries in a pool. 6x104 reads were 
successfully sequenced from the transposon primer, and over 5000 reads per 
library pool were de-multiplexed using the barcodes (figure 4.23). A sample of 
500 reads was tested from each library pool for the presence of the TES 
(TAAGAGTCAG), reported in table 4.7. Frequencies were lower than for the 
previous MiSeq run, however, all library pools (except for Cef-1C) contained at 
least 1000 transposon-containing reads with a frequency of 11-31%. 
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Together, the two MiSeq runs indicated that the libraries could be sequenced 
using the transposon-primer and the indexing primer. De-multiplexing is 
possible for libraries in a pool, and should be possible in for a pool of libraries in 
the HiSeq. 
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Figure 4.22 – Schematic figure to show sequencing of DNA fragments 
Target fragments will contain (left to right in figure): 
- Flow cell binding region (FCBR, red), added during PCR 
- Adapter (orange), added during adapter ligation 
- Transposon DNA, including the Transposon End Sequence (TES) TAAGAGTCAG 
- Genomic DNA 
- Flow cell binding region (FCBR, red), containing one of 6 index barcodes, added 
during PCR 
 
Transposon sequencing primer MiniTn5-3pr-seq will recognise the transposon using 
the sequences shown and sequence 100bp in the following direction: TES, Genomic 
DNA. Therefore all reads from this primer should start with the TES, followed by 
genomic DNA. 
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Figure 4.23 – MiSeq result: number of de-multiplexed reads identified to 
each pool of 1 or 2 libraries 
6 pools containing a single library, or two libraries sharing a barcode, were run 
on the MiSeq. The barcode primer was used to read the barcodes, enabling 
the sequencing reads to be matched to the correct library pool. Results from 1 
MiSeq run. 
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Libraries Frequency of de-
multiplexed reads 
containing TES (%) 
Extrapolated number of 
de-multiplexed reads 
containing transposon 
T0-A, T0-C 31.2 4856 
T0-B, Cef-1C 13.8 1481 
Cip-1A 21.0 1414 
Cip-1B 18.8 1355 
Cip-1C, Cef-1A 11.2 1521 
Cef-1B 4.2 297 
Table 4.7 – MiSeq result: number of de-multiplexed reads 
containing transposon end sequence 
500 reads de-multiplexed to each library/library pool were checked 
for the transposon end sequence TAAGAGTCAG. Results are 
given as % of 500 reads (frequency of transposon sequence in de-
multiplexed reads). This frequency was then multiplied by the total 
number of de-multiplexed reads, to give the total number of de-
multiplexed reads containing TES, per library. 
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4.8 HiSeq sequencing of libraries  
After the success of the MiSeq runs, a Hiseq run was carried out on all libraries. 
This was done to provide more reads and enable larger pools to be sequenced. 
 
4.8.1 Pooling of libraries 
Libraries were pooled according to barcode compatibility (libraries with a 
common barcode must be in separate pools), into two pools.  
Pool 1 contained T0-A (barcode: ATCACG), T0-B (CGATGT), Cip-1A 
(ACAGTG), Cip-1B (ACTTGA) and Cip-1C (TTAGGC), i.e. 5 libraries.  
Pool 2 contained T0-C (barcode: ATCACG), Cef-1A (TTAGGC), Cef-1B 
(TCAGATC) and Cef-1C (CGATGT), i.e. 4 libraries. 
 
4.8.2 HiSeq sequencing 
The two pools were clustered and sequenced using a HiSeq system. Each 
sequencing cluster (~1000 copies of 1 DNA fragment) was sequenced with two 
primers: a transposon-specific primer (MiniTn5-3pr-seq), which will be used to 
determine the genome DNA flanking the transposon, and an indexing primer, 
which will be used to identify the barcode of the read (described in section 
4.6.2.3) and hence match the read to the correct library. This used the same 
primers as for the MiSeq (figure 4.22) 
 
As was the case with the MiSeq results, pool 1 sequenced well with the 
transposon-specific primer (81.71% of reads with signal-noise ratio >Q30 (read 
quality cut-off)). However, sequencing with the indexing primer featured a lot of 
noise (0.37% of reads with signal-noise ratio >Q30). This suggests over-
clustering of DNA in the sequencer. Nonetheless, 9.4x105 reads from pool 1 
were de-multiplexed to the correct libraries, resulting in over 104 de-multiplexed 
reads per library (figure 4.24). From 500 randomly selected reads from each 
library, 16-24% of reads contained the Transposon End Sequence (TES) 
TAAGAGTCAG, resulting in over 2000 TES-containing reads per library (table 
4.8). 
 
Pool 2 sequenced with the transposon-specific primer (89.04% of reads with 
signal-noise ratio >Q30), however the quality of sequencing with the index 
184 
 
primer was too low to read the barcodes and enable de-multiplexing of any 
reads (0.02% of reads with the index primer had signal-noise ratio >Q30). This 
low indexing quality indicates over-clustering of DNA in the sequencer. 
Therefore no reads are available for any libraries in pool 2.  
185 
 
  
Figure 4.24 – HiSeq result: number of de-multiplexed reads identified to 
each library in pool 1 
Sequencing was carried out using a transposon specific primer and an indexing 
primer. The transposon specific primer MiniTn5-3pr-seq anneals to a 
recognition site in the transposon, and sequences out from the transposon (10 
nucleotides TAAGAGTCAG) into the flanking gene. The indexing primer HP12 
anneals to the adapter and sequences the 6-7 nucleotide barcode specific to 
each library (figure 4.22). When libraries are sequenced in a pool (as above), 
sequencing of the barcodes enables the correct transposon reads to be 
mapped to each library (“de-multiplexing”). The number of reads for each 
library, for which the barcode was identified, is shown. 
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Libraries Frequency of de-
multiplexed reads 
containing 
transposon (%) 
Extrapolated number 
of de-multiplexed 
reads containing 
transposon 
T0-A 23.6 4186 
T0-B 22.8 3536 
Cip-1A 16.6 3746 
Cip-1B 21.8 2720 
Cip-1C 18.2 4671 
Table 4.8 – HiSeq result: number of de-multiplexed reads containing 
transposon in pool 1 
500 reads de-multiplexed to each library were checked for the transposon 
sequence TAAGAGTCAG. Results are given as % of 500 reads (frequency of 
transposon sequence in de-multiplexed reads). This frequency was then 
multiplied by the total number of de-multiplexed reads (figure 4.24), to give the 
total number of de-multiplexed reads containing transposon, per library. 
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4.9 Analysis of HiSeq data 
Reads were processed using the Distal Effect Model (Ron Yang, personal 
communication), providing the frequency of unique transposon insertions for 
every gene in the genome.  
 
4.9.1 Transposon insertions are randomly distributed within 
either chromosome, but more common in chromosome 1 
Within each chromosome of the input library, the cumulative number of unique 
insertions at the end of each gene (using genome position) was calculated, as 
for previous analyses (Shan, Lazinski et al. 2015). This resulted in a strong 
linear relationship (R2 = 0.88 on chromosome 1, R2 = 0.97 on chromosome 2) 
between position and total number of unique insertions, indicating that the 
cumulative number of transposon insertions is positively correlated with number 
of bp observed (genome position). This indicates that transposon insertions are 
mostly random in each chromosome (figure 4.25A and B).  
 
Some hot-spots were suggested by these graphs and the transposon insertion 
data. For example, the genes in regions 22481-139812bp and 2935055-
3152675bp on chromosome 1, and 32379-94246bp and 2445016-2483971bp 
on chromosome 2 appeared to have more transposon insertions. However, the 
average size of transposon-containing genes is larger in these regions, which 
may result in more insertions per gene. To account for this, for each gene, the 
number of mutants in that gene was divided by the size of the gene (figure 
4.25C and D). Again there was a strong positive correlation between genome 
position and cumulative number of insertions, with even greater R2 values (R2 = 
0.91 on chromosome 1, R2 = 0.98 on chromosome 2), indicating that accounting 
for gene size improved the distribution (figure 4.28C and D).  
 
There were 1310 unique insertion sites in the genome in the input library (both 
technical replicates), of which 1089 were in chromosome 1 (1 unique insertion 
per 3495bp) and 221 were in chromosome 2 (1 unique insertion per 13158bp). 
These insertions were in 340 genes in chromosome 1 (average ~3.2 insertions 
per gene) and 115 genes in chromosome 2 (average ~1.9 insertions per gene). 
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Most of the genes (3004/3344 genes in chromosome 1, 2258/2373 genes in 
chromosome 2) did not have transposon hits in at least one of the T0 libraries.  
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Figure 4.25 – Transposon insertion distribution in input pool 
A and B) x axis shows genome position, and the y axis shows the total number of 
unique transposon insertions. A: chromosome 1, B: chromosome 2. 
C and D) x axis shows gene number (each gene with transposon insertions was 
assigned a number from 1-340 in chromosome 1, and 1-115 in chromosome 2 in 
ascending order of genome position), and the y axis shows the total number of 
unique transposon insertions/bp (for each gene with transposon insertion/s, the 
number of unique insertions was divided by the number of bp in the gene, giving the 
insertions/bp for that gene. This value was then cumulated over the whole 
chromosome, as shown on the y-axis). C: chromosome 1, D: chromosome 2. 
 
Linear regression analysis data:  
A) Chromosome 1: y = 1.4x10-3X - 2329.2, R2 = 0.8778.  
B) Chromosome 2: y = 7x10-5X + 19.546, R2 = 0.9726.  
C) Chromosome 1: Y = 2.347x10-7X - 0.04002, R2 = 0.908.  
D) Chromosome 2: Y = 9.221x10-8X + 0.02247, R2 = 0.9805. 
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4.9.2 Noise removal  
In order to reduce the amount of false negatives in the data, only genes with 
more than one unique insertion site in both input libraries were included in 
further analysis. There were 148 genes with two or more unique insertions in 
both input libraries (T0-A and T0-B) (figure 4.26A). Of these, 138 genes are on 
chromosome 1, 10 are on chromosome 2. These genes formed the “input” list. 
For the ciprofloxacin treated libraries Cip-1A, Cip-1B and Cip-1C, there were 31 
genes with two or more unique insertions (figure 4.26B). Of these, 27 were on 
chromosome 1, 4 were on chromosome 2. These genes formed the “output list”. 
 
4.9.3 Comparison of input and output library genes 
The input and output lists were compared, in order to determine which mutated 
genes were present in both lists, and which were absent from one list (figure 
4.27).  
 
Comparison of input and output lists resulted in 119 genes present in the input 
list but not the output list (figure 4.27). These were genes present before the 
antibiotic assay but not after the assay. This comparison provided the “lost in 
treatment” list, with the top 15 genes shown in table 4.9. The mutants were 
ordered by number of transposon insertions in the input population. For 
reference, the full gene list is provided in appendix table 1.  
 
There were 29 genes common to both lists (figure 4.27). This provided the 
“survived treatment” list, with the top 15 genes shown in table 4.10. The genes 
were ordered by number of unique transposon insertion sites in the 
ciprofloxacin output population. For reference, the full gene list is provided in 
appendix table 2. 
 
There were 2 genes which were present in the output list but not the input list, 
suggesting these genes were more highly represented after antibiotic treatment 
(figure 4.27). These were BTH_II1788 (average 2 insertions), which encodes 
glutaminase, and BTH_II2252 (average 2 insertions), which encodes carbon 
starvation protein A (from BGD, (Winsor, Khaira et al. 2008)).  
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Figure 4.26 – comparison of replicate libraries 
Numbers represent number of genes with two or more unique transposon insertions 
that are present in one or more library replicates. Overlap indicates genes with 
transposon insertions in multiple replicates.  
A) input (T0) libraries . * indicates genes common to all replicates, which were used 
to create the input list. 
B) output (Cip) libraries . * indicates genes common to all replicates, which were 
used to create the output list. 
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Figure 4.27 – comparison of input and output lists 
Numbers represent number of genes with two or more unique transposon insertions 
that are present in one or both library lists. 
LT: the 119 genes present in the input list but not the output list were used to create 
the “lost in treatment” list. 
ST: the 29 genes common to both lists were used to create the “survived treatment” 
list. 
The 2 genes present in the output list but not the input list were BTH_II1788, and 
BTH_II2252, as described in the text. 
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Gene name 
Tn insertions in 
input list 
Protein annotation 
BTH_I2723 13.5 Filamentous hemagglutinin 
BTH_I2738 11 
Conserved hypothetical 
protein 
BTH_I2702 10 Lipoprotein, putative 
BTH_II0083 9.5 
Acetyltransferase domain 
protein 
BTH_I1442 8.5 
Conserved hypothetical 
protein 
BTH_I2595 8.5 
Threonyl-tRNA synthetase 
(ThrS) 
BTH_I2633 7.5 Valyl-tRNA synthetase (ValS) 
BTH_I0113 7.5 
Protein kinase domain-
containing protein 
BTH_I3301 7 
Proline dehydrogenase/delta-
1-pyrroline-5-carboxylate 
dehydrogenase 
BTH_I0112 6.5 Hypothetical protein 
BTH_I0096 6 Hypothetical protein 
BTH_I0002 6 
Sodium/hydrogen exchanger 
family protein 
BTH_I2661 5.5 
  
Alanyl-tRNA synthetase 
(AlaS) 
BTH_I2719 5.5 DNA helicase II 
BTH_I3135 5.5 Resolvase TnpR 
Table 4.9 – top 15 genes of “lost in treatment” list: genes present in input 
list but not in output list 
Tn hits in input list are shown as an average of the two replicate libraries T0-A 
and T0-B. Protein annotation information from Universal Protein Resource 
(UniProt) (Magrane and The Uniprot Consortium 2011), Kyoto Encyclopedia of 
Genes and Genomes (KEGG) (Kanehisa, Sato et al. 2016) or Burkholderia 
Genome Database (BGD) (Winsor, Khaira et al. 2008) is provided for each gene. 
 
194 
 
 
 
   
Gene 
Tn insertions 
in input list 
Tn 
insertions 
in output 
list 
Protein annotation 
BTH_I2739 53 15 DNA mismatch repair protein 
BTH_I0114 37 12 Hypothetical protein 
BTH_I2743 21.5 10 
Type I restriction system adenine 
methylase 
BTH_I3143 21.5 7.3 
Helicase domain containing 
protein 
BTH_I2742 21.5 7.3 
Type I restriction-modification 
system specificity determinant 
BTH_I2691 20.5 6.3 Fis family transcriptional regulator 
BTH_I2740 26.5 6 
Type I restriction-modification 
system endonuclease 
BTH_I1443 24.5 6 Superfamily I DNA/RNA helicase 
BTH_I2698 20.5 5.3 Hypothetical protein 
BTH_I0093 14.5 5 ATPase 
BTH_I3136 19 5 Conserved hypothetical protein 
BTH_I2701 23 5 Conserved hypothetical protein 
BTH_I0097 6.5 5 Conserved hypothetical protein 
BTH_II0082 17.5 5 Hypothetical protein 
BTH_I2741 14.5 4.3 Hypothetical protein 
Table 4.10 – top 15 genes of “survived treatment” list: genes present in 
input list and output list 
Tn hits in input list are shown as an average of the two replicate libraries T0-A and 
T0-B. Tn hits in output list are shown as an average of the three replicate libraries 
Cip-1A, Cip-1B and Cip-1C. Protein annotation information from Universal Protein 
Resource (UniProt) (Magrane and The Uniprot Consortium 2011), Kyoto 
Encyclopedia of Genes and Genomes (KEGG) (Kanehisa, Sato et al. 2016) or 
Burkholderia Genome Database (BGD) (Winsor, Khaira et al. 2008) is provided for 
each gene. 
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4.10 Discussion 
It is widely recognised that persister cells are a complex phenomenon, with 
many pathways having been linked to formation of persister cells and antibiotic 
tolerance, including various TA systems, (p)ppGpp and the SR, the SOS 
response and quorum sensing (Korch, Henderson et al. 2003, Spoering, Vulic 
et al. 2006, Moker, Dean et al. 2010, Nguyen, Joshi-Datar et al. 2011, Gerdes 
and Maisonneuve 2012, Prax and Bertram 2014). This complexity is 
compounded by the fact that there are most likely persister mechanisms that 
have yet to be discovered (Shan, Lazinski et al. 2015). Genome-wide 
approaches are warranted to investigate multiple pathways simultaneously and 
increase the chances of finding important persister genes. HTS of transposon 
mutants has previously been used to study other processes such as growth  
(van Opijnen, Bodi et al. 2009), virulence (Gawronski, Wong et al. 2009, 
Langridge, Phan et al. 2009), intestinal colonisation (Goodman, McNulty et al. 
2009) and sporulation (Dembek, Barquist et al. 2015), and it has potential for 
identification of persister genes. Transposon mutagenesis has previously been 
used to identify genes involved in persister cell formation and antibiotic 
tolerance in E. coli, P. aeruginosa and S. aureus (Hu and Coates 2005, Manuel, 
Zhanel et al. 2010, Wang, Chen et al. 2015). However, with the exception of a 
publication released during this project (Shan, Lazinski et al. 2015), there are no 
published reports of HTS being used to compare a transposon library before 
and after treatment that selects for persisters (i.e. antibiotic treatment and re-
culture), with the aim of identifying persister genes. The main aim of this chapter 
was to use HTS of a transposon library (i.e. TraDIS) to study genes linked to 
persister cell formation and antibiotic tolerance in B. thailandensis.  
 
The first aim of this chapter was therefore to generate transposon mutants in 
B. thailandensis using miniTn5. Consistent with previous reports (Andreae, 
Titball et al. 2014), it was shown that the mutagenesis method reliably produces 
transposon mutants in B. thailandensis, by verifying that the transposon is 
present in the genome of mutagenised cells, while the plasmid used to deliver 
the transposon is absent after mutagenesis. Tests by others using pUT-
miniTn5Km2 have shown that transposon insertion is random in 
B. thailandensis (Monika Bokori-Brown, personal communication) and in 
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B. pseudomallei (Cuccui, Easton et al. 2007, Moule, Hemsley et al. 2014), 
producing unique mutants.  
 
The first phenotypic test of a transposon library was conducted to identify genes 
involved in ciprofloxacin resistance. This used a method adapted from Blake 
and O’Neill, which was based on inoculating a pooled library onto plates 
containing antibiotic. This was done with the hope of finding novel genes related 
to ciprofloxacin susceptibility and resistance, and also because genes identified 
in this assay could be a potential reservoir for acquired antibiotic resistance 
(Blake and O'Neill 2013). This study was used as a trial run for library 
phenotypic screening and gene/mutant identification, rather than a 
comprehensive whole-genome screen, therefore it was limited to 1000 mutants. 
This method was successful in identifying several mutants with increased 
resistance, of which mutant A3 appeared to be the most promising (showed the 
highest resistance).  
  
Mutant A3 had a transposon inserted into the pglY gene. This suggests that 
disruption of pglY gene is responsible for the phenotype seen (increased 
ciprofloxacin resistance). However, the possibility of a transposon-independent 
mutation, such as spontaneous mutation in another part of the genome, or 
downstream effects of transposon insertion on other genes, cannot be 
excluded. BTH_I0115 (pglY) is in an operon with BTH_I0116 (pglZ), so it is 
possible that the miniTn5 insertion in pglY could affect pglZ expression. 
Therefore complementation of the miniTn5-pglY mutant with a wild type pglY 
gene would be needed to confirm the role of the pglY mutation in increased 
ciprofloxacin resistance. Nonetheless, this method successfully identified the 
transposon insertion site in a mutant of interest, linking genotype to phenotype.  
 
In Streptomyces coelicolor, the protein PglY belongs to the bacteriophage 
growth limitation (PGL) system, which prevents phage growth. It was shown to 
be essential for phage resistance, and it is thought to function as an ATPase, 
which powers the system (Sumby and Smith 2002, Hoskisson, Sumby et al. 
2015). Therefore, pglY may encode a protein involved in phage defence. How 
this is linked to ciprofloxacin resistance is unclear.  
197 
 
In other bacteria, fluoroquinolones have been suggested to induce phage-
mediated lysis (Lopez, Domenech et al. 2014, Bearson and Brunelle 2015), and 
resistance to fluoroquinolones is correlated with fewer functional/inducible 
phages in S. pneumoniae (Lopez, Domenech et al. 2014). Therefore, it is 
expected that mutations that disrupt phage defences might decrease 
fluoroquinolone resistance, rather than increase it. If the pglY mutant in this 
work has impaired phage defence, this could be an indication of a novel 
negative effect of phage resistance on ciprofloxacin resistance. Phage limitation 
assays have been used to study PGL mutants in S. coelicolor (Sumby and 
Smith 2002, Hoskisson, Sumby et al. 2015); these could be used to test the 
level of activity of the PGL system in a pglY mutant, to try and understand the 
link between phage defence and ciprofloxacin resistance in B. thailandensis. 
 
Having used transposon mutagenesis to study genes involved in antibiotic 
resistance, the next aim of this chapter was to use transposon mutagenesis to 
study the molecular basis of persister cell formation in B. thailandensis. Library 
1B was generated, which contained approximately 36,000 mutants. Libraries of 
this size (104-105 mutants) have previously been used for genome-wide 
phenotypic screens and/or sequencing in B. thailandensis (Gallagher, Ramage 
et al. 2013, Lu, Xu et al. 2015). The transposon library was sequenced using 
TraDIS, before and after antibiotic (ceftazidime or ciprofloxacin) challenge, with 
the aim of identifying mutants which could survive antibiotic treatment, and 
those that could not.  
 
Unfortunately, no data was available for the ceftazidime treated libraries, as the 
Hiseq was unable to de-multiplex the sequence reads from pool 2. The 
probable reason for this is the high content of ‘background’ (non-transposon-
containing) DNA (qPCR data, section 4.6.2.4) which over-clustered in the 
sequencer, and interfered with cluster identification. Over-clustering was 
indicated by the poor cluster identification throughout the flow cell and a low 
read quality score (0.02 % of reads >Q30). The origin of the high level of 
background DNA (particularly in the Cef-1A-C libraries) is unclear, as the library 
preparation process selects for DNA which contains the transposon. In future 
library preparations, monitoring of the ratio of transposon-containing to 
background DNA (such as by qPCR) should occur throughout library 
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preparation. This may help identify sources of background DNA and implement 
strategies to minimise the generation of background DNA and its impact on 
clustering and sequencing. 
 
Pool 1 also demonstrated over-clustering, but some transposon fragments 
could still be sequenced and de-multiplexed for each library. For these libraries, 
few genes had transposon insertions (9% of the genes in the genome were 
present in both input populations, while 91% of genes were absent from at least 
one of the two input populations). Essential genes would be expected to be 
absent from the input library (van Opijnen and Camilli 2013). However, previous 
TraDIS studies in B. thailandensis indicated that approximately 7% of all genes 
are essential for growth in rich media (Baugh, Gallagher et al. 2013). This 
suggests that most of the genes missing from the input library (approximately 
84% of all genes) are not essential, and were probably not represented in the 
initial mutant library. Like library 1B, previous transposon libraries in 
B. thailandensis have used 104 – 105 mutants (Gallagher, Ramage et al. 2013, 
Lu, Xu et al. 2015), therefore there may be a problem with diversity of library 1B 
such that some mutants are generated but not sequenced. Possible factors 
which may reduce mutant diversity and genome coverage of the library, and 
mitigation strategies for future experiments, are discussed below. 
 
Library 1B was frozen after mutagenesis, due to time constraints on performing 
back-to-back mutagenesis with up-scaling, screening and DNA extraction. 
Additionally, it was done to provide a library stock which could be used for 
multiple experiments, or have more mutants added as required. However, this 
process probably affected library diversity; mutants affected by freezer storage 
may be lost. Furthermore, a growth phase is then required to recover the 
mutants from freezer storage, which may alter library mutant diversity due to 
different growth rates and competition between mutants in the library (van 
Opijnen and Camilli 2013). In future, when making a library, freezing the library 
should be avoided if possible. The library can then be screened/sequenced 
straight after mutagenesis, as the mutagenesis suspension should be dense 
enough for genomic DNA extraction. If a library is to be frozen, it should contain 
many more mutants to allow for some loss of diversity. Recently, an E. coli 
transposon library of ~2x105 mutants was sequenced after growth in broth from 
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a frozen stock (Shan, Lazinski et al. 2015); libraries of this size would be 
expected to be better protected against loss of mutants. 
 
If the growth conditions used in this chapter are maintained in future libraries, 
the number of mutants would need to be increased to cover the whole genome. 
Pooling 36000 mutants lead to sequencing of insertions in 455/5717 protein-
coding genes. Using this information, use of a pool of at least 452000 mutants 
(5717 x 36000/455) is recommended, in order to have insertions in every gene 
across the whole library (although essential genes would still be expected to be 
absent from the library). This would allow for the loss of mutants during library 
growth conditions and DNA library preparation used here. 
 
Some mutants were probably lost from the library during the DNA preparation 
steps (van Opijnen and Camilli 2013). For future library sequencing projects, 
further optimisation of the various stages of DNA library preparation is 
recommended, to minimise bias towards particular mutant DNA 
sequences/fragments. For example, PCR is needed to increase the abundance 
of transposon containing fragments (as well as add FCBR and indexing 
barcodes to these fragments), but there is the risk that certain transposon-
containing fragments will be preferentially amplified over others (van Opijnen 
and Camilli 2013). Therefore, attempts to modify the PCR to reduce possible 
bias, perhaps by reducing the number of cycles, are encouraged. Alternatively, 
other library preparation methods are available, such as INSeq (Goodman, 
McNulty et al. 2009), which use more standardised fragment sizes as templates 
for PCR. This may help to reduce PCR bias (van Opijnen and Camilli 2013). An 
INSeq approach would require the use of a mariner-based transposon; in 
addition to miniTn5, mariner has been tested in B. thailandensis (Kang, Norris 
et al. 2009).  
 
In spite of the poor ~8% coverage of protein-coding genes in the genome, it 
was possible to compare the genes with transposon insertions present before 
and after ciprofloxacin treatment. This is the first report of TraDIS being used to 
study ciprofloxacin tolerance, and the first reported use of TraDIS to study 
persisters in B. thailandensis.  Given that wild type B. thailandensis can form 
persisters tolerant to ciprofloxacin (chapter 3, also (Hemsley, Luo et al. 2014)), 
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transposon mutants which do not survive treatment (are in the lost in treatment 
list) may be less able to form persisters tolerant to antibiotics. Therefore genes 
in the lost in treatment list (table 4.9) may be candidate “persister genes”, which 
positively regulate persister cells (Shan, Lazinski et al. 2015). It has been 
suggested that multiple pathways contribute to the formation of persister cells 
(Hansen, Lewis et al. 2008, Maisonneuve, Shakespeare et al. 2011, Amato, 
Fazen et al. 2014, Shan, Lazinski et al. 2015). Consistent with this, there were 
genes involved in a variety of processes in the lost in treatment list, such as 
translation (tRNA synthesis), membrane transport and amino acid synthesis. In 
particular, genes encoding aminoacyl-tRNA synthesis enzymes were highly 
represented, linking translation to antibiotic tolerance. A previous report 
indicated that disruption of translation in E. coli increases the number of 
ciprofloxacin persisters in a culture (Kwan, Valenta et al. 2013).  Therefore, the 
finding that mutations in these genes are less able to survive ciprofloxacin in the 
current study is unexpected. Differences between these studies may be due to 
different organisms and methods of translation inhibition. Shan et al. observed 
that mutations in amino acid synthesis decrease tolerance to antibiotics (Shan, 
Lazinski et al. 2015). Although that study used a different organism and 
antibiotic (E. coli treated with gentamicin), it does agree with the current study in 
suggesting a possible role for functional protein synthesis (amino acid synthesis 
and translation) in persisters. There was also a gene for a DNA helicase 
involved in DNA repair in the lost in treatment list. Defective DNA repair in 
helicase mutants has previously been linked to increased antibiotic 
susceptibility in mutant library studies. In P. aeruginosa, a mutant in the putative 
gene for the DinG DNA helicase was more susceptible to ofloxacin (De Groote, 
Verstraeten et al. 2009). 
 
Of the genes sequenced from mutants which survived antibiotic treatment (table 
4.10), two encoded helicases. These genes had many transposon insertions 
before and after treatment, suggesting that disruption of these individual 
helicases genes does not prevent persister cell formation and tolerance to 
ciprofloxacin, and may even increase tolerance. Disruption of helicases may 
result in slower growth and induction of stress responses (Wu and Brosh 2010), 
both of which could contribute to persister cell formation (Spoering and Lewis 
2001, Lewis 2008, Maisonneuve, Castro-Camargo et al. 2013, Goneau, Yeoh et 
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al. 2014). Insertions in the gene for a Fis-family transcriptional regulator was 
also associated with survival.  Fis was previously linked to persister cell 
formation in an E. coli genetic knockout library. However, in that report, a fis 
deletion strain was more susceptible to antibiotics, rather than the decreased 
susceptibility seen in this study (Hansen, Lewis et al. 2008). These contradicting 
observations may be due to different organisms used, and the fact that Fis is a 
global transcriptional regulator, whose disruption could have pleiotropic effects 
on bacterial cell survival and tolerance to antibiotics (Hansen, Lewis et al. 
2008).  
 
In the survived treatment list (table 4.10), there was also a complete operon 
(genes BTH_I2740-2742), and an adjacent gene (BTH_I2743), all of which have 
functions involved in restriction modification and phage defence. It is unclear 
how mutants in these genes would be less susceptible to ciprofloxacin. As 
stated above for PglY, phage limitation systems have been suggested to reduce 
the harmful effects of ciprofloxacin in other bacteria, as fluoroquinolones can 
activate lysogenic phage (Lopez, Domenech et al. 2014, Bearson and Brunelle 
2015).  Mutants that are less protected against phage are expected to be more 
susceptible to fluoroquinolone antibiotics. Therefore, the presence of several 
restriction modification mutants which are highly represented in the survived 
ciprofloxacin treatment list is unexpected. The possible link between phage 
defence and susceptibility to ciprofloxacin in B. thailandensis may warrant 
further study. However, it is unclear whether the transposon mutants are 
affected in their susceptibility to phage. It is possible that the increased 
ciprofloxacin tolerance may result from some other effect of transposon 
insertion.  
 
The two mutants that appeared after antibiotic treatment (BTH_II1788, which 
encodes glutaminase, and BTH_II2252, which encodes carbon starvation 
protein A) may form persisters at an increased rate. Carbon starvation protein A 
may help the bacteria use peptides for carbon sources in nutrient limited 
conditions (Schultz and Matin 1991) and glutaminase catalyses the conversion 
of glutamate to glutamine and the reverse reaction (Kanehisa and Goto 2000). If 
either mutation causes a loss of function of the gene, then the resulting lack of 
enzyme could potentially increase the nutritional stress on the mutant strain. 
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This may lead to induction of the stringent response, which could increase 
persister formation and antibiotic tolerance (Nguyen, Joshi-Datar et al. 2011, 
Gaca, Colomer-Winter et al. 2015). 
 
All of the suggestions above need to be experimentally tested, before any 
conclusions about the role of the listed genes in persister cells can be drawn. In 
order to study the role of these genes in ciprofloxacin tolerance, the next step 
would be to generate individual single mutants in the wild type strain (Moule, 
Hemsley et al. 2014). These can then be tested for an altered ciprofloxacin 
resistance/tolerance phenotype, such as by using MICs and persister frequency 
assays, as reported in chapter 3. In addition, although this study identified 
genes from before and after antibiotic treatment, the genome coverage was low, 
so future studies should focus on improving the mutant diversity from 
transposon mutagenesis, and optimising the sequencing library preparation so 
that more of the mutants in the library are sequenced. This should enable every 
gene in the genome to be simultaneously assayed for its importance in persister 
cell formation and antibiotic tolerance, leading to the development of new 
strategies to target persisters. 
  
203 
 
 
 
 
 
 
 
 
 
Chapter 5: Strategies to reduce the 
B. thailandensis persister frequency 
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5.1 Introduction  
In this chapter, two chemicals, itaconate and metronidazole, were studied, with 
the aim of reducing the number of B. thailandensis persisters following antibiotic 
treatment. Both compounds have been reported to have antibacterial activity 
(such as growth inhibition or reduction in number of viable counts). However, 
the hypothesis was that they may have some activity specifically against 
persisters when combined with antibiotics, which will result in a lower persister 
frequency. 
 
Itaconate is produced in macrophages by aconitate decarboxylase, the product 
of the irg-1 gene (Michelucci, Cordes et al. 2013). Irg-1 gene expression is 
increased in macrophages during infection with S. enterica and M. smegmatis, 
and activation with LPS (Basler, Jeckstadt et al. 2006, Michelucci, Cordes et al. 
2013). Increased itaconate levels have also been measured following activation 
of macrophages (Michelucci, Cordes et al. 2013). Irg-1 was recently shown to 
be highly expressed during chronic B. pseudomallei infection of mice, 
suggesting that itaconate is produced during melioidosis (Conejero, Potempa et 
al. 2015). Given the possible role for persisters in chronic melioidosis, this may 
suggest that B. pseudomallei persister cells are exposed to itaconate during 
infection. Therefore itaconate was tested for anti-persister effects in 
B. thailandensis. 
 
Itaconate is an inhibitor of the microbial enzyme ICL, which catalyses the first 
reaction of the glyoxylate pathway (McFadden and Purohit 1977, Hillier and 
Charnetzky 1981) (figure 5.1). This pathway replenishes intracellular TCA cycle 
intermediates when carbon sources are limited (Munoz-Elias and McKinney 
2006). ICL is a potential drug target for pathogens which cause chronic disease, 
as it is important for persistent chronic infection in the host (McKinney, Honer zu 
Bentrup et al. 2000, Munoz-Elias and McKinney 2005, Michelucci, Cordes et al. 
2013). In B. pseudomallei, ICL mutants were less able to establish a chronic 
infection, instead switching to an acute infection and rapid growth (van Schaik, 
Tom et al. 2009).  
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As an inhibitor of ICL, itaconate has been studied for its potential to eradicate 
Burkholderia persisters and chronic infections, in combination with other 
antibiotics (van Schaik, Tom et al. 2009, Van Acker, Sass et al. 2013). Itaconate 
was administered with ceftazidime in a B. pseudomallei murine chronic infection 
model, resulting in better survival rates than ceftazidime alone (van Schaik, 
Tom et al. 2009). Itaconate also improved the efficacy of tobramycin against 
persisters in B. cepacia complex biofilms by inhibiting the glyoxylate bypass, 
resulting in fewer persisters than for tobramycin alone (Van Acker, Sass et al. 
2013). 
 
These observations suggest that itaconate can increase the susceptibility of 
Burkholderia persister cells to antibiotics. It was hypothesised that 
B. thailandensis persister cells would be susceptible to itaconate, and that 
combining itaconate with ceftazidime would result in fewer persisters compared 
with ceftazidime alone. Itaconate was first studied for any growth-inhibitory 
effects, as growth inhibition caused by itaconate has been shown for other 
bacteria (McFadden and Purohit 1977, Hillier and Charnetzky 1981, Michelucci, 
Cordes et al. 2013). Itaconate was then used in combination with ceftazidime, in 
order to see whether it could affect the number of surviving culturable bacteria 
(CFU/ml, persisters) and culture density (OD600nm) following ceftazidime 
treatment.  
 
Previous studies of ICL and inhibition by itaconate have mainly used minimal 
media, with acetate as the sole carbon source. Under these conditions, ICL is 
active, while the enzyme and the glyoxylate pathway are inactive when the 
carbon source is glucose (McFadden and Purohit 1977, Hillier and Charnetzky 
1981). However, studies have also reported increased expression and activity 
of ICL in rich media such as LB, albeit at lower levels than on acetate (Hillier 
and Charnetzky 1981, van Schaik, Tom et al. 2009). It was therefore decided 
that itaconate would be tested against B. thailandensis in minimal media with 
acetate or, alternatively, LB.  
 
During chronic melioidosis, B. pseudomallei encounters different environments 
which vary in oxygen content. B. pseudomallei can infect a wide range of 
tissues, including the lungs, liver, spleen and skeletal muscle (Wong, 
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Puthucheary et al. 1995, White 2003), which naturally vary in oxygen tension 
(Park, Myers et al. 1992). Compared to other tissues, oxygen tension is 
particularly low in the liver and skeletal muscle, and generally all tissues will 
have less oxygen during infection and inflammation (Park, Myers et al. 1992, 
Sica, Melillo et al. 2011). Additionally, abscesses, a common feature of 
melioidosis, are believed to be hypoxic or even anaerobic (Hamad, Austin et al. 
2011). B. pseudomallei may also be present in biofilms in vivo (Vorachit, Lam et 
al. 1995, Ramli, Eng Guan et al. 2012, Limmathurotsakul, Paeyao et al. 2014), 
which contain hypoxic and anaerobic regions (Xu, Stewart et al. 1998, Stewart 
2002, Walters, Roe et al. 2003, Stewart and Franklin 2008). All of these 
observations suggest that some bacteria in persistent melioidosis are 
anaerobic, and provide a rationale for testing nitroimidazole antibiotics against 
B. pseudomallei.  
 
Nitroimidazoles (such as metronidazole) are only active under anaerobic 
conditions, where the inactive pro-drug is reduced by a nitroreductase enzyme, 
or from an electron from ferredoxin generated by pyruvate: ferredoxin 
oxidoreductase (Kaihovaara, Hook-Nikanne et al. 1998, Samuelson 1999). 
Reduction of nitroimidazoles results in the production of toxic nitro groups which 
damage DNA and proteins within the cell (Kaihovaara, Hook-Nikanne et al. 
1998, Samuelson 1999). Both B. pseudomallei and B. thailandensis are 
susceptible to metronidazole under anaerobic conditions (Hamad, Austin et al. 
2011, Hemsley, Luo et al. 2014). It has been shown that anaerobic 
B. pseudomallei persisters are tolerant to a range of conventional antibiotics but 
susceptible to metronidazole (Hamad, Austin et al. 2011). The studies reported 
here support the idea that anaerobic B. thailandensis cultures contain more 
persisters (chapter 3 and (Hemsley, Luo et al. 2014)). It was hypothesised that, 
under anaerobic conditions, B. thailandensis persister bacteria may be 
susceptible to metronidazole. The antibiotic used to select for persisters under 
anaerobic conditions was co-trimoxazole, a combination of sulphamethoxazole 
and trimethoprim. This drug combination inhibits two enzymes of the folate 
synthesis pathway (dihydropteroate synthetase (DHPS) and DHFR, 
respectively). Co-trimoxazole is usually the first choice for oral antibiotic 
treatment of melioidosis (Dance 2014), so it was of interest to see whether 
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metronidazole could help clear persisters in combination with co-trimoxazole, in 
an anaerobic in vitro assay. 
 
5.1.1 Aims and objectives 
Evaluate itaconate and metronidazole as antibacterial and anti-persister drugs 
- Test itaconate for antibacterial activity (growth inhibition) 
- Test effect of itaconate on ceftazidime persister frequency  
- Test effect of metronidazole on anaerobic persister frequency with and without 
co-trimoxazole 
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Figure 5.1 – Schematic of the glyoxylate bypass and the TCA cycle 
Growth on fatty acids generates acetyl-coA and propional-CoA.  
 
Acetyl-CoA is used to generate the TCA cycle intermediate citrate.  
The reactions of several enzymes are indicated: 
Aconitase (ACN) converts citrate to isocitrate (TCA cycle). 
Isocitrate lyase (ICL) converts isocitrate to glyoxylate and succinate (glyoxylate 
bypass). 
Glyoxylate is subsequently converted to malate by malate synthase, 
completing the glyoxylate bypass. 
Isocitrate dehydrogenase (ICD) converts isocitrate to α-ketoglutarate (TCA 
cycle). 
 
Also shown is part of the methylcitrate cycle. Propional-CoA is converted to 
methylcitrate and metabolised in the methylcitrate cycle (starting with 
methylcitrate lyase (MCL), indicated on the figure), not discussed in this thesis. 
This generates succinate and pyruvate.  
 
From (van Schaik, Tom et al. 2009). 
American society for microbiology: permission not required for use in thesis.  
Modification: fumarate hydratase enzyme label removed, numbering of 
enzymes removed. 
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5.2 Effect of itaconate on B. thailandensis culture 
density and CFU/ml 
5.2.1 Growth of B. thailandensis in the presence of itaconate 
5.2.1.1 Overnight cultures 
It was initially planned to test the effects of itaconate on growth in M9 minimal 
media, using acetate as a sole carbon source. Therefore, B. thailandensis was 
inoculated into M9 minimal media containing 30mM acetate without itaconate, in 
order to establish growth in the absence of itaconate. However, the bacteria did 
not grow (produce an increase in OD600nm) in overnight cultures (no change in 
OD600nm).  
 
Preliminary tests of cultures grown in LB indicated that 10mM itaconate 
significantly inhibited growth (measured by OD600nm) of bacteria, compared with 
controls (p<0.05, one-way ANOVA with Tukey’s multiple comparisons, figure 
5.2). Therefore, further studies of the effect of itaconate on B. thailandensis 
were conducted in LB.  
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  Figure 5.2 – Initial screening of itaconate for growth-inhibitory effects 
in LB 
Bacteria were inoculated into LB at a starting OD600nm of 0.05 (with 
itaconate at the concentrations indicated), which was then divided into 5ml 
aliquots in 30ml universals. This was incubated aerobically at 37°C, with 
200rpm shaking. After 18h incubation, the universals were removed from 
the incubator and the OD600nm was measured. Error bars show standard 
deviation of 3 assays. * indicates p<0.05 with one-way ANOVA with 
Tukey’s multiple comparisons. 
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5.2.1.2 Microtitre plate cultures 
In order to detect any effect of itaconate on growth kinetics of B. thailandensis, 
the optical density was measured over time (growth curve). Bacteria were 
incubated in the presence of LB containing itaconate, in microtitre assay plates. 
Growth curves are shown in figure 5.3A. 
 
In order to compare the final OD600nm reached by the cultures, one-way ANOVA 
(with Tukey’s multiple comparisons) was conducted on the data from t24. This 
time-point was chosen as it is during stationary phase of the plate cultures, and 
is the same time-point at which CFUs are measured in persister frequency 
assays. 16mM or 8mM itaconate both resulted in significantly lower ODs than 
control cultures at t24 (p<0.05, figure 5.3B), while 1mM, 2mM, 4mM and 5mM 
did not result in a significantly different OD600nm than controls (p>0.05, figure 
5.3B).  
 
There appeared to be an extended lag phase for 4mM, compared with the 
control cultures, leading to lower ODs between t10-t12 (figure 5.3A). To test 
whether any statistically significant differences in OD600nm existed between the 
itaconate treated cultures and untreated controls during exponential growth, 
one-way ANOVA tests were conducted on the data from t10, t12 and t14. All 
time-points had the same trend as t24, with the ODs for 8mM and 16mM being 
significantly lower than controls, while 1mM, 2mM, 4mM and 5mM were no 
different from controls (example figure shown for t14, figure 5.3C, other time-
points not shown).   
 
Therefore, 1mM, 2mM, 4mM and 5mM itaconate had no significant effect on 
OD600nm at any of the time-points, while 8mM and 16mM resulted in significantly 
lower ODs from t10 onwards, indicating growth inhibition. 
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Figure 5.3 – Growth of B. thailandensis in the presence of itaconate in 
microtitre trays 
Bacteria were inoculated into LB at a starting OD600nm of 0.0005 (with itaconate 
at the concentrations indicated in the legend), which was then divided into 200μl 
aliquots in a 96 well plate. These cultures were incubated at 37°C, without 
shaking. The OD600nm of the cultures were recorded automatically using a plate 
reader every 30 minutes. Results from 2 assays, with error bars indicating 
standard deviation between assays.  
A) OD600nm values between t0 and t24.  
B) OD600nm values at t24 from 5.3A. The difference between OD600nm in control 
medium without itaconate (0mM) and OD600nm in media containing 8mM or 
16mM itaconate at t24 was statistically significant (p<0.05 from one-way ANOVA 
with Tukey’s multiple comparisons).  
C) OD600nm values at t14 from 5.3A. The difference between OD600nm in control 
medium without itaconate (0mM) and OD600nm in media containing 8mM or 
16mM itaconate at t14 was statistically significant (p<0.05 from one-way ANOVA 
with Tukey’s multiple comparisons). 
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5.2.2 Persister frequency assays with itaconate and ceftazidime  
In order to study the effects of itaconate on the ceftazidime persister frequency, 
the number of culturable cells was measured following incubation with 0mM, 
1mM, 3mM or 5mM itaconate, with or without 400μg/ml ceftazidime (figure 5.4). 
The optical density was also measured after antibiotic treatment, in order to see 
how this was affected by ceftazidime and itaconate.  
 
The presence of 1mM, 3mM or 5mM itaconate resulted in an increase in 
CFU/ml and OD600nm, in a dose-dependent manner, in the absence of 
ceftazidime (figures 5.4A and C). Statistically significant increases in CFU/ml 
and OD600nm were seen for 3mM and 5mM itaconate, compared with control 
cultures (no itaconate) (p>0.05, one-way ANOVA with Dunnett’s multiple 
comparisons).  
 
The CFU/ml and OD600nm results for the cultures treated with ceftazidime in 
addition to itaconate are shown in figures 5.4B and D. 5mM itaconate combined 
with ceftazidime resulted in a significant increase in the CFU/ml counts, 
compared with ceftazidime controls (figure 5.4B, p<0.05, one-way ANOVA with 
Dunnett’s multiple comparisons).  None of the other concentrations of itaconate 
had any significant effect on CFU/ml when combined with ceftazidime (figure 
5.4B, p>0.05). Itaconate combined with ceftazidime had no effect on the 
OD600nm, compared with treatment with ceftazidime controls (figure 5.4D, 
p>0.05).  
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Figure 5.4 – Net effect of itaconate on ceftazidime treatment of 
B. thailandensis 
A stationary phase culture was adjusted to OD600nm 0.2 and mixed in equal 
volumes with itaconate  and/or ceftazidime at 2x the assay concentration, 
resulting in a final culture density of OD600nm 0.1 and itaconate at the 
concentrations indicated, with or without 400μg/ml ceftazidime. Samples were 
incubated in 1ml aliquots in a 24 well plate, under aerobic conditions (at 37°C, 
static incubation), for 24 hours. CFUs were enumerated before (t0) antibiotic 
treatment and after 24h incubation. OD600nm was measured after 24h incubation.  
A) CFU/ml change (ratio of t24/t0) before and after incubation with itaconate for 
24h, without ceftazidime. 
B) CFU/ml change (ratio of t24/t0) before and after incubation with itaconate 
and 400μg/ml ceftazidime. 
C) OD600nm measurements (at t24) after incubation with itaconate for 24h, 
without ceftazidime. 
D) OD600nm measurements (at t24) after incubation with itaconate and 400μg/ml 
ceftazidime. 
Error bars indicate standard deviation of at least 2 assays. 
* indicates p<0.05 with one-way ANOVA with Dunnett’s multiple comparisons vs 
control (0mM itaconate) cultures. 
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In order to account for the increase in CFU/ml caused by itaconate, for each 
itaconate concentration tested in figure 5.4, the CFU/ml result for the 
ceftazidime-treated sample (in figure 5.4B) was divided by the CFU/ml result for 
the control (no ceftazidime) sample (in figure 5.4A). This provided the change in 
CFU/ml caused by ceftazidime, while effects of itaconate on CFU/ml could be 
excluded. This showed that ceftazidime plus 3mM or 5mM itaconate results in 
significantly greater killing (drop in CFU/ml) caused by ceftazidime, than does 
ceftazidime without itaconate (p<0.05, one-way ANOVA with Tukey’s multiple 
comparisons) (figure 5.5A).  
 
The same process was done for OD600nm results, using the ODs from 
ceftazidime treated (figure 5.4D) and control (figure 5.4C) cultures. This 
provided the change in OD600nm caused by ceftazidime, excluding the effects of 
itaconate on OD600nm. There was no significant effect of itaconate on the change 
in OD600nm caused by ceftazidime (p>0.05) (figure 5.5B).  
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Figure 5.5 – Effect of itaconate and ceftazidime in combination on CFU/ml 
and OD600nm of B. thailandensis cultures, normalised against itaconate 
treated cultures 
Using data from figure 5.4. 
A) Frequencies of culturable survivors (CFU/ml t24/t0) after incubation with 
itaconate from figure 5.4B (ceftazidime and itaconate treated) were divided by 
their respective values in figure 5.4A (control, itaconate-only cultures). For 
example, for 1mM itaconate, the CFU/ml for 1mM itaconate +ceftazidime was 
divided by the CFU/ml for 1mM itaconate without ceftazidime. 
B) OD600nm values (t24) from figure 5.4D (ceftazidime and itaconate treated) 
were divided by their respective values in figure 5.4C. For example, for 1mM 
itaconate treated cultures, the OD600nm for 1mM itaconate +ceftazidime was 
divided by the OD600nm for 1mM itaconate without ceftazidime (control cultures).  
Error bars indicate standard deviation of at least 2 assays. 
* indicates p<0.05 with one-way ANOVA with Tukey’s multiple comparisons. 
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5.2.3 Effect of different culture inoculates on growth stimulation 
by itaconate 
Given the discrepancy between the growth curves (where 1-5mM caused no 
increase in OD600nm, figure 5.3) and the persister frequency assay control 
cultures (where 1-5mM caused significant increase in OD600nm, figure 5.4), it 
was possible that some aspect of the assay conditions could be affecting the 
way the bacteria behaved in the presence of itaconate.  
 
Both assays used static cultures maintained at 37°C in aerobic conditions for 24 
hours, so effects of oxygen and/or aeration and duration of treatment on 
itaconate activity were not tested. However, the assays differed in the starting 
inoculate of bacteria. The growth curves used a lower inoculate of bacteria 
(OD600nm = 0.0005, figure 5.3) compared with the persister frequency assays 
(OD600nm = 0.1 inoculate, figure 5.4). It was therefore hypothesised that 
itaconate might cause an increase in OD600nm, but only when higher culture 
densities are used (OD600nm 0.1 rather than 0.0005). It was also hypothesised 
that the changes in CFU/ml caused by itaconate might also depend on starting 
culture density. Therefore, B. thailandensis at a starting culture density of 
OD600nm 0.0005 or 0.1 was incubated in the presence or absence of 5mM 
itaconate. After 24h, CFUs and OD600nm were measured as before. 
 
Incubation with 5mM itaconate caused a statistically significant increase in the 
24h CFU/ml of the culture with a starting OD600nm of 0.0005 (p<0.05, one-way 
ANOVA with Tukey’s multiple comparisons, figure 5.6A). No statistically 
significant effect of itaconate on CFU/ml was seen when incubated with the 
culture at starting OD600nm of 0.1 (p>0.05). 
 
In contrast, incubation with 5mM itaconate resulted in a significant increase in 
OD600nm compared with non-itaconate treated cultures, when the starting 
OD600nm was 0.1 (p<0.05, one-way ANOVA with Tukey’s multiple comparisons, 
figure 5.6B). 5mM itaconate had no significant effect on the OD600nm of cultures 
with a starting OD600nm of 0.0005 (p>0.05, one-way ANOVA with Tukey’s 
multiple comparisons). 
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Figure 5.6 – Effect of itaconate on the CFU/ml and OD600nm of different 
culture densities of B. thailandensis 
A stationary phase culture was adjusted to 2x the assay OD600nm and mixed in 
equal volumes with or without 10mM itaconate, resulting in a final culture 
density of OD600nm 0.1. 0.05 or 0.0005, with or without 5mM itaconate. Samples 
were incubated in 1ml aliquots in a 24 well plate, under aerobic conditions (at 
37°C, static incubation), for 24 hours. CFUs were enumerated before (t0) 
antibiotic treatment and after 24h incubation. OD600nm was measured after 24h 
incubation.  
A) CFU/ml at t24 / CFU/ml at t0. 
B) OD600nm measurements at t24. 
Error bars indicate standard deviation of at least 2 assays. * indicates p<0.05 
with one-way ANOVA with Tukey’s multiple comparisons. 
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5.3 Metronidazole as an anti-persister drug under 
anaerobic conditions 
5.3.1 Co-trimoxazole is less effective under anaerobic 
conditions 
In chapter 3, several antibiotics were tested under different oxygen conditions, 
and it was found that ceftazidime, imipenem and trimethoprim were less 
effective (resulted in more persisters) under anaerobic conditions, compared 
with aerobic conditions. It was hypothesised that co-trimoxazole might similarly 
show an increased persister frequency under anaerobic conditions. The CFUs 
of bacteria treated with co-trimoxazole under three different oxygen conditions 
were measured. Significantly more culturable survivors (persisters) were 
detected after 24h under anaerobic conditions, compared with aerobic or 
microaerophilic conditions (figure 5.7). 
 
5.3.2 Effect of combination treatment of co-trimoxazole and 
metronidazole under anaerobic conditions 
It was hypothesised that the persisters tolerant to co-trimoxazole under 
anaerobic conditions (figure 5.7) might be susceptible to metronidazole. 
Bacteria were incubated with co-trimoxazole and metronidazole individually, or 
in combination, under anaerobic conditions.  
 
Culturable survivor frequencies are reported in figure 5.8.  Metronidazole 
reduced the frequency of survivors to 0.4% while treatment with co-trimoxazole 
alone under anaerobic conditions resulted in ~20% survivor frequency. The two 
antibiotics used in combination resulted in 0.7% survivors. This frequency is 
significantly lower than the frequency of co-trimoxazole survivors (p<0.05, one 
way ANOVA), but not statistically different from the metronidazole alone 
survivor frequency (p>0.05, one-way ANOVA), indicating that the combination 
of cotrimoxazole and metronidazole is more effective than co-trimoxazole alone, 
but not more effective than metronidazole alone.  
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Figure 5.7 – Persister frequencies for cultures treated with co-
trimoxazole under different oxygen conditions 
A stationary phase culture was adjusted to OD600nm 0.2 and mixed in equal 
volumes with co-trimoxazole at 2x the assay concentration, resulting in a final 
culture density of OD600nm 0.1 and 320μg/ml (5x MIC) co-trimoxazole. Samples 
were incubated in 1ml aliquots in a 24 well plate, under aerobic, 
microaerophilic or anaerobic conditions (all 37°C static incubation), for 24 
hours. CFUs were enumerated before (t0) antibiotic treatment and after 24h 
incubation. Error bars are standard deviations of at least 2 assays. * indicates 
p<0.05 with one-way ANOVA with Tukey’s multiple comparisons. 
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Figure 5.8 – Effect of metronidazole and co-trimoxazole combination 
treatment in anaerobic conditions 
A stationary phase culture was adjusted to OD600nm 0.2 and mixed in equal 
volumes with co-trimoxazole (CTZ) and/or metronidazole (MTZ) at 2x the 
assay concentration, resulting in a final culture density of OD600nm 0.1, and 
320μg/ml (5x MIC) co-trimoxazole and/or 100μg/ml metronidazole. Samples 
were incubated in 1ml aliquots in a 24 well plate, in an anaerobic cabinet 
(37°C, static incubation), for 24 hours. CFUs were enumerated before (t0) 
antibiotic treatment and after 24h incubation.  
Error bars are standard deviations of at least 2 assays. * indicates p<0.05 
with one-way ANOVA with Tukey’s multiple comparisons. 
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5.3.3 Efficacy of metronidazole and ceftazidime in treatment of 
B. pseudomallei infected mice 
The work in this section was carried out by Felipe Cia and Greg Bancroft at the 
LSHTM (shown with permission). 
 
BALB/c mice were infected with B. pseudomallei 576, and treated with 5 doses 
of ceftazidime and/or metronidazole every 24h for the first 5 days (figure 5.9).  3 
separate assays were conducted, shown separately in figure 5.9A-C. 
 
Saline treatment resulted in death of 100% of mice within 4-7 days (figure 5.9A-
C). 100% of mice treated with metronidazole died within 4 days, which was the 
same as the saline-treated mice in those assays (figure 5.9A-B). Ceftazidime 
treatment extended the survival of the mice, enabling 35-50% of the mice to 
survive until the end of the studies, at day 39 (figure 5.9B) and day 22 (figure 
5.9C). Treatment of metronidazole and ceftazidime in combination enabled 25-
38% of mice to survive until the end of the studies (figure 5.9B and 5.9C). 
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Figure 5.9 – Survival of B. pseudomallei 576 treated BALB/c mice treated 
with ceftazidime and metronidazole 
Mice (8 per treatment group) were infected intra-nasally with ~200CFU 
B. pseudomallei 576. Mice were treated once per day for 5 days with saline, 
1200mg/kg bodyweight ceftazidime (CEF), 200mg/kg bodyweight 
metronidazole (MTZ), or 1200mg/kg bodyweight ceftazidime and 200mg/kg 
bodyweight metronidazole (CEF+MTZ), by intra-peritoneal injection. 
(CEF+MTZ)+MTZ in figure C refers to CEF+MTZ treatment for 5 days, as 
above, followed by 16 daily MTZ injections. 
Performed by Felipe Cia and Greg Bancroft, reproduced with permission. 
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5.4 Discussion 
During infection of a host, pathogens must overcome various challenges, 
including nutrient limitation (including limited access to carbon sources) and 
varying oxygen tensions (including hypoxia and anoxia). The invading pathogen 
must be able to adapt its metabolism in order to be able to survive and 
proliferate in the face of these challenges. 
 
The ICL enzyme improves the adaptability of pathogens, as it enables acetate 
to be used as a carbon source, providing TCA cycle intermediates. The enzyme 
has been identified as a ‘persistence factor’ in M. tuberculosis. M. tuberculosis 
expression of ICL is increased in persistent infection (Honer Zu Bentrup, Miczak 
et al. 1999, McKinney, Honer zu Bentrup et al. 2000), and ICL is required for 
virulence in the persistent (rather than acute) stage of infection (McKinney, 
Honer zu Bentrup et al. 2000). Therefore ICL has been the focus of studies 
aimed at improving the efficacy of antibiotics against tuberculosis by inhibiting 
ICL (Lee, Wahab et al. 2015). It has been suggested that M. tuberculosis and 
B. pseudomallei may use some similar mechanisms to create persistent 
infections (Gan 2005, van Schaik, Tom et al. 2009). Indeed, as for 
M. tuberculosis, ICL has been shown to be important in chronic infection for 
B. pseudomallei in rats. Mutant B. pseudomallei lacking the ICL-encoding aceA 
gene were unable to establish a chronic infection in mice, instead switching to a 
hypervirulent acute infection, leading to increased cytotoxicity and death (van 
Schaik, Tom et al. 2009).  
 
There is potential for the development of ICL inhibitors as treatment for 
melioidosis (van Schaik, Tom et al. 2009). This study therefore tested the 
effects of itaconate, an ICL inhibitor, on B. thailandensis, as a model for 
B. pseudomallei. Itaconate was found to inhibit growth of B. thailandensis, as 
has been shown for many other bacteria, such as Yersinia pestis, S. enterica 
and Vogesella indigofera (McFadden and Purohit 1977, Hillier and Charnetzky 
1981, Michelucci, Cordes et al. 2013). These other studies focussed on minimal 
media with acetate as a sole carbon source, where ICL is most active. 
However, it has also been reported that ICL-encoding genes are expressed in 
rich media such as LB, albeit at a lower level than in acetate (McFadden and 
225 
 
Purohit 1977, Hillier and Charnetzky 1981, van Schaik, Tom et al. 2009). 
Expression of aceA (gene BPSL2188) was shown to be greater in LB than on 
minimal media containing glucose as a sole carbon source in B. pseudomallei 
(van Schaik, Tom et al. 2009), and expression of aceA (gene BTH_I1998) was 
detected in B. thailandensis grown in LB (Hemsley, Luo et al. 2014). 
Biochemical tests for ICL activity, such as measurement of glyoxylate or 
succinate levels, are warranted to test the enzyme activity in LB. However, the 
reports suggest that ICL may be a viable target for inhibition in LB-grown 
B. thailandensis. 
 
This study demonstrated that ICL inhibitors can be effective (caused inhibition 
of growth measured by OD600nm) against B. thailandensis in LB. Importantly, the 
B. pseudomallei ICL enzyme is inhibited by 8mM itaconate (1mg/ml) (van 
Schaik, Tom et al. 2009), a concentration which inhibited B. thailandensis 
growth in the assays reported in the current study. This may suggest that, at 
8mM and above, the growth inhibited B. thailandensis also have inhibited ICL 
activity. Another use for biochemical assays described above would be to study 
the extent of B. thailandensis ICL inhibition by itaconate in LB. Taking the 
studies above and the initial findings of this study together, further work 
continued the itaconate studies in LB, rather than trying to establish inhibition in 
acetate minimal media. However, given that ICL might be more active in 
acetate, it is a limitation of this work, and stronger effects of itaconate would be 
expected if the bacteria can be tested in acetate-containing minimal media.  
  
Although itaconate displayed antibacterial activity (growth inhibition) on its own, 
the main purpose of the work with itaconate was to determine whether it could 
function as an antibiotic adjuvant, and reduce the number of persisters with 
ceftazidime. Ceftazidime was chosen as the antibiotic used to measure 
persister frequencies, as it had previously been used to study persisters in 
chapter 3. Furthermore, work in B. pseudomallei suggests that itaconate can 
enhance the efficacy of ceftazidime (van Schaik, Tom et al. 2009). Also, 
B. thailandensis persisters tolerant to ceftazidime had higher levels of 
expression of the ICL-encoding gene (aceA), compared with untreated mid-log 
phase cultures (Hemsley, Luo et al. 2014), suggesting that ICL may be a viable 
drug target in B. thailandensis ceftazidime persisters. 
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Treatment of B. thailandensis with ceftazidime in combination with 1-5mM 
itaconate resulted in a drop in CFU/ml, which is not significantly different from 
the drop caused by ceftazidime alone (figure 5.4). This suggests that itaconate 
had no net effect on ceftazidime efficacy. However, itaconate caused increased 
growth of bacteria (increase in OD600nm and CFU/ml) (figure 5.4) and increased 
killing (decrease in CFU/ml) by ceftazidime (figure 5.5), compared with 
ceftazidime controls. It is likely the two effects are related, as rapid growth 
increases susceptibility to β–lactams (Cozens, Tuomanen et al. 1986, 
Tuomanen, Cozens et al. 1986, Wu and Livermore 1990, Chen, Jackson et al. 
1991). This may suggest that itaconate is causing reversion of some of the 
persisters to actively growing cells, which are then susceptible to ceftazidime. 
Reversion of persisters to growing cells has previously been reported as an 
anti-persister strategy, when used in combination with antibiotics (van Schaik, 
Tom et al. 2009, Kim, Heo et al. 2011).  
 
The effects of itaconate on bacterial growth were sensitive to culture density 
and method of measurement, as well as other possible factors. In low density 
cultures (OD600nm = 0.0005, such as in the growth curves), itaconate increased 
the OD600nm, but not the CFU/ml. In high density cultures (OD600nm = 0.1, used in 
the persister frequency assay), itaconate caused an increase in OD600nm, and 
an increase in CFU/ml which was detected in on assay but not another (figure 
5.4 and 5.6). This complexity in effects of itaconate on growth is unexpected, 
considering the degree of similarity between the two assays (except for culture 
density), and may be due to variation in ICL activity due to the use of LB. 
 
Some bacteria can grow in the presence of itaconate, by metabolising it to 
produce pyruvate (Fuchs and Berg 2014). KEGG and BGD searches indicate 
that B. thailandensis possesses the genes which encode succinyl-coA synthase 
(BTH_I0646 and BTH_I0647, from KEGG and BGD (Kanehisa and Goto 2000, 
Winsor, Khaira et al. 2008, Kanehisa, Sato et al. 2016)), which can convert 
itaconate to itaconyl-coA, but it lacks itaconyl-coA hydratase, which degrades 
itaconyl-coA, and other enzymes which complete the conversion of itaconate to 
pyruvate (pathway bte00660 on KEGG (Kanehisa and Goto 2000, Kanehisa, 
Sato et al. 2016). However, it should be noted that a negative result of these 
searches does not exclude the possibility of an undiscovered functional 
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homologue of itaconate-metabolising enzymes, with a different amino acid 
sequence. Nevertheless, these search results suggests that B. thailandensis 
cannot use itaconate to provide pyruvate or TCA cycle intermediates. 
Therefore, it is unclear how itaconate was able to increase growth in the 
assays.  
 
Oxygen availability is a potential challenge for pathogenic bacteria inside an 
infected host, as tissues vary in oxygen concentrations, with some sites, such 
as the liver, being hypoxic (Park, Myers et al. 1992). Furthermore, oxygen 
tension in tissues drops during tissue damage, infection and inflammation (Park, 
Myers et al. 1992, Sica, Melillo et al. 2011). In addition to these conditions, 
B. pseudomallei may also encounter low oxygen levels in biofilms and 
abscesses in melioidosis (Costerton, Stewart et al. 1999, Hamad, Austin et al. 
2011). B. pseudomallei is able to adapt to anaerobic conditions, which involves 
switching to anaerobic respiration, using nitrate as an alternate carbon source 
(Yabuuchi, Kosako et al. 1992, Hamad, Austin et al. 2011). During anaerobic 
adaptation, B. pseudomallei loses susceptibility to many antibiotics due to an 
increased fraction of persisters (Hamad, Austin et al. 2011). Hemsley et al. 
showed that B. thailandensis also loses susceptibility to ceftazidime under 
anaerobic conditions (Hemsley, Luo et al. 2014). The current study added to 
this observation by showing that B. thailandensis tolerance to co-trimoxazole, 
imipenem or trimethoprim is also affected by anaerobic conditions (chapter 3, 
section 3.4 and this chapter, section 5.3.1). These add to the list of antibiotics 
which could be less effective against persisters in anaerobic sites in melioidosis. 
However, further tests with B. pseudomallei in infection models would be 
needed to support this.  
 
These anaerobic persisters present a problem for treatment of melioidosis, and 
warrant investigation into antibiotics that can eliminate anaerobic, drug-tolerant 
Burkholderia (Hamad, Austin et al. 2011). Anaerobic cells are expected to be 
inherently susceptible to metronidazole, as activation of the drug is dependent 
on the absence of oxygen (Samuelson 1999). This chapter showed that 
persisters tolerant to co-trimoxazole were mostly susceptible to metronidazole 
under anaerobic conditions. This is in agreement with the observations of 
Hamad et al. for B. pseudomallei. It was shown that, under anaerobic 
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conditions, B. pseudomallei became  tolerant to several melioidosis drugs, but 
susceptible to the anaerobically-active nitroimidazoles such as metronidazole 
(Hamad, Austin et al. 2011). This highlights the potential of metronidazole as a 
drug capable of targeting drug-tolerant anaerobic B. thailandensis, as a model 
for B. pseudomallei, and its ability to work in combination with other antibiotics, 
to develop a system which targets both aerobic and anaerobic bacteria. 
 
It has been suggested that metronidazole would be highly effective against 
persisters in anaerobic conditions during infection, such as in abscesses in 
chronic infections (Hamad, Austin et al. 2011). Collaborators tested the ability of 
metronidazole to improve antibiotic treatment of B. pseudomallei infected mice. 
The infection studies (figure 5.10) showed that mice were killed within 4-7 days 
by B. pseudomallei in the presence or absence of metronidazole. The rapid 
death rate of saline controls suggests an acute infection, which has previously 
been shown for the same mouse strain (BALB/c), which is highly susceptible to 
B. pseudomallei (Leakey, Ulett et al. 1998, Hoppe, Brenneke et al. 1999, 
Conejero, Patel et al. 2011). In the collaborator study, a more prolonged 
infection was seen when mice were treated with ceftazidime (figure 5.10). 
However, ceftazidime and metronidazole in combination were not more 
effective than ceftazidime alone. Collectively, the results suggest that 
metronidazole was ineffective in these acute conditions, perhaps due to a lack 
of anaerobic bacteria in acute melioidosis. These findings are in agreement with 
data for M. tuberculosis, which suggests that metronidazole does not affect 
progression of active tuberculosis (Brooks, Furney et al. 1999, Lin, Dartois et al. 
2012). Therefore, metronidazole may have limited potential against acute 
melioidosis. 
  
Data for M. tuberculosis suggests that metronidazole is effective against chronic 
tuberculosis (Brooks, Furney et al. 1999, Lin, Dartois et al. 2012). More studies 
are warranted to explore the possibility of metronidazole efficacy against 
B. pseudomallei persisters. These studies could use a more chronic (rather than 
acute) infection (such the system reported by (Conejero, Patel et al. 2011)), 
where more persisters would be expected (introduction section 1.3.2 and 
(Fauvart, De Groote et al. 2011, Fattorini, Piccaro et al. 2013)). This may result 
in more hypoxic/anaerobic regions (such as abscesses), where the bacteria 
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would be deprived of oxygen and may be more susceptible to metronidazole 
(Park, Myers et al. 1992, Wong, Puthucheary et al. 1995, Via, Lin et al. 2008, 
Lofmark, Edlund et al. 2010). It would also be interesting to test other drugs in 
combination with metronidazole. For example, the data in chapter 3 showed 
that, while imipenem was highly effective in aerobic conditions in vitro (with a 
persister frequency of ~10-6), the number of imipenem-tolerant survivors was 
~104 fold greater under anaerobic conditions. Therefore, it is expected that 
metronidazole would be highly effective in combination with imipenem against 
B. thailandensis in vitro, which may lead to better treatment of disease in 
infection models. The findings from chapter 3 also suggest that imipenem and 
ceftazidime is a combination that warrants testing in an in vivo infection model, 
such as those described above. 
 
In summary, both itaconate and metronidazole showed antibacterial activity 
against B. thailandensis. Itaconate caused growth inhibition, but also had some 
possible growth stimulating properties which require further investigation. There 
was no significant net effect on ceftazidime efficacy in vitro. Metronidazole 
reduced the frequency of persisters tolerant to co-trimoxazole in vitro, when the 
two drugs were used in combination. However, metronidazole was not able to 
improve the efficacy of ceftazidime in an acute mouse B. pseudomallei infection 
model. Despite these results, further work may demonstrate a use for either 
chemical as an antibiotic adjuvant in persistent B. pseudomallei infections. 
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Chapter 6: Final discussion and 
conclusions  
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Phenotypic heterogeneity within a clonal bacterial population generates 
persister cells, which are able to survive in the presence of high doses of 
antibiotic. Persisters can re-grow once the antibiotic has been removed, and 
generate a new population. These properties have led to the suggestion that 
persisters may contribute to chronic, latent, recurrent or otherwise persistent 
infection. Supporting these predictions, persister formation and tolerance to 
antibiotics are selected for in vivo. Persister frequencies are increased in E. coli 
from recurrent UTI (Goneau, Yeoh et al. 2014), and P. aeruginosa from the 
chronically infected lungs of CF patients (Mulcahy, Burns et al. 2010). 
Persisters have also been detected in vivo, such as the non-replicating 
S. enterica persisters inside macrophages (Helaine, Cheverton et al. 2014, 
Fisher, Cheverton et al. 2016), and the MDT S. aureus persisters in biofilms in a 
deep-seated mouse thigh infection (Conlon, Nakayasu et al. 2013). Therefore, 
persisters may contribute to persistent infection. 
 
Various aspects of melioidosis pathogenesis suggest that B. pseudomallei can 
persist in the host for long periods of time, in spite of immune activity and 
antibiotic treatment. These include the prolonged period of symptoms in chronic 
melioidosis, the risk of relapse of an apparently cured disease, and long periods 
of latency without symptoms. Like other persistent pathogens, such as 
M. tuberculosis, B. pseudomallei is thought to use a variety of strategies to 
persist in the host (Vorachit, Lam et al. 1995, Wong, Puthucheary et al. 1995, 
Chantratita, Wuthiekanun et al. 2007, van Schaik, Tom et al. 2009, Allwood, 
Devenish et al. 2011, Goodyear, Bielefeldt-Ohmann et al. 2012, Hayden, Lim et 
al. 2012). Like many of these other bacteria, it is now known that 
B. pseudomallei forms persister cells (Hamad, Austin et al. 2011, Butt, Higman 
et al. 2014). Therefore, the idea underlying this study was that persister cells 
may be one strategy of B. pseudomallei which contributes to persistence in 
melioidosis.  
 
As a model to investigate persisters in melioidosis, this study focussed on 
persister cells in the closely-related B. thailandensis, in in vitro antibiotic 
treatment assays, as has been used previously (Hemsley, Luo et al. 2014). This 
was done in order to enable various aspects of persisters to be tested without 
handling a BSL3 organism. The in vitro antibiotic treatment assays also enabled 
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the effect of various antibiotics and conditions to be tested on persisters in 
isolation, in a controlled manner. The main limitations are that B. thailandensis 
does not cause melioidosis, and assay conditions in vitro are different from the 
environment in the infected host. Therefore, results from this work cannot be 
directly applied to B. pseudomallei and melioidosis without further testing. For 
example, the persister frequencies may vary in comparative assays between 
the two species. Indeed, this has been reported for several assay conditions 
(Hemsley, Luo et al. 2014, Nierman, Yu et al. 2015). However, the current work 
was undertaken in order to identify general trends, which may warrant further 
testing, to see if they apply to B. pseudomallei and melioidosis. An increased 
understanding of persisters in B. thailandensis also increases the future utility of 
this organism as a model to study persister cells in melioidosis. 
 
The work focussed on persisters in planktonic cultures. Planktonic cells are 
commonly the focus of persister assays (Keren, Kaldalu et al. 2004, Lechner, 
Lewis et al. 2012, Butt, Higman et al. 2014, Hemsley, Luo et al. 2014). A 
limitation of focussing on planktonic cells is that there may be other cells 
present which adhere to the assay plates, so are not easily extracted for CFU 
enumeration, and their number may vary over the course of an assay. 
Therefore, cells which adhere to the assay plates in a biofilm present a possible 
complication in interpreting results. However, this is an inherent risk in working 
with an adherent organism, and testing under static conditions. The assays 
used here can still be used to test planktonic cells, as long as the above caveat 
is considered. Additionally, it is important to test biofilm cultures for persisters. 
The methods used by others to study persisters in biofilms for other 
Burkholderia species (Van Acker, Sass et al. 2013, Anutrakunchai, Sermswan 
et al. 2015) should be used to test the level of persisters in B. thailandensis 
biofilms. 
 
In order to gain insight into how persisters may contribute to persistent 
melioidosis, this study measured changes in persister frequencies caused by 
choice of antibiotics, growth phase and oxygen tension. These factors are all 
involved in persistent melioidosis. For example, the choice of antibiotics is a key 
determinant in the success of treating persistent melioidosis (Limmathurotsakul, 
Chaowagul et al. 2006, Dance 2014). Variable oxygen levels and stationary 
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phase-like conditions (such as nutrient starvation and pH stress) are also highly 
relevant conditions which the bacterium must adapt to during persistent 
infection of the host (Park, Myers et al. 1992, Hamad, Austin et al. 2011, Ooi, 
Ong et al. 2013, Anutrakunchai, Sermswan et al. 2015, Nierman, Yu et al. 
2015). All of these conditions affected the amount of persisters in a 
B. thailandensis culture. Stationary phase and anaerobic conditions, rather than 
mid-exponential phase and aerobic conditions, were associated with increased 
persister frequencies. These add to existing findings (Hamad, Austin et al. 
2011, Butt, Higman et al. 2014, Hemsley, Luo et al. 2014, Nierman, Yu et al. 
2015), and support the idea that oxygen and/or nutrient depleted environments 
such as biofilms, abscesses, and inflamed tissues may contain persisters. 
 
These findings also add to the growing evidence that persisters are 
heterogeneous in B. thailandensis and B. pseudomallei. Rather than being a 
single homogenous sub-population, persisters arise from a range of conditions. 
Some of the conditions linked to persister formation are stationary phase, 
anaerobic conditions and sub-inhibitory antibiotic treatment (this study and 
(Hamad, Austin et al. 2011, Butt, Higman et al. 2014, Hemsley, Luo et al. 2014, 
Nierman, Yu et al. 2015)). In B. pseudomallei, the HipBA TA system (Butt, 
Higman et al. 2014), anaerobic metabolism and gene expression (Hamad, 
Austin et al. 2011), and the stringent response (Claudia Hemsley, unpublished 
data) have been suggested to contribute to persister formation. Further work is 
needed to understand what other processes occur in a cell to cause the switch 
to a persister state, and what effectors are involved. 
 
As persisters form under a range of conditions, it was hypothesised that they 
might vary in their tolerance to antibiotics. This has been reported previously for 
several antibiotics in B. pseudomallei (Hamad, Austin et al. 2011, Nierman, Yu 
et al. 2015) and ceftazidime and ciprofloxacin in B. thailandensis (Hemsley, Luo 
et al. 2014). This was tested directly, by treating persister cultures with a 
second antibiotic. The finding of ciprofloxacin efficacy against ceftazidime 
persisters was reproduced (Hemsley, Luo et al. 2014), and it was also shown 
that imipenem, but not trimethoprim, is effective against ceftazidime persisters. 
This demonstrates multiple persister types in an assay, some of which are 
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MDT. The metabolic state may vary within these persister types, with less 
metabolically active persisters being MDT. 
 
The heterogeneity of antibiotic tolerances in B. thailandensis, and potentially 
B. pseudomallei, persisters would theoretically make complete eradication more 
difficult. Future work should try to identify common patterns or active processes 
in persisters that can be exploited. For example, disruption of the cellular 
protease Clp by ADEPs was effective against all persisters in E. coli and 
S. aureus cultures, providing a basis for eradication of heterogeneous 
populations (Conlon, Nakayasu et al. 2013). In the absence of a method of 
eradicating all B. pseudomallei persisters, the finding that imipenem is effective 
against ceftazidime persisters may be of interest, as ceftazidime and imipenem 
are both used separately in melioidosis chemotherapy (Dance 2014). Imipenem 
should be tested against B. pseudomallei ceftazidime persisters, to see if it is 
effective in reducing the number of survivors. This information may be used to 
design combination antibiotic therapies which could potentially give fewer 
persisters in melioidosis patients. 
 
An aim of this project was to try to identify genes involved in persister cell 
formation. This approach used transposon mutagenesis, which has been 
previously used in several studies in B. thailandensis (Baugh, Gallagher et al. 
2013, Gallagher, Ramage et al. 2013, Andreae, Titball et al. 2014). The current 
study demonstrated that it can be used to study persister cells in 
B. thailandensis, by using transposon-directed HTS methods, such as TraDIS, 
on an antibiotic-treated culture. TraDIS enabled study of the contribution of 
every gene in the library to persister formation and ciprofloxacin tolerance in 
parallel. The results suggested that genes involved in DNA repair, translation 
and phage defence are linked to ciprofloxacin tolerance; these processes may 
warrant further study as potential targets for persister cell inhibition. 
 
The main limitation of the TraDIS work was that most of the genes in the 
genome were not represented in the TraDIS library. However, TraDIS 
successfully enabled comparison of the library before and after antibiotic 
treatment, providing lists of genes which may influence persister formation and 
antibiotic tolerance. This suggests that, with a larger library, TraDIS has the 
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potential to evaluate every gene for its role in persisters. This work suggested 
factors which might contribute to improved library coverage and sequencing in 
future work. Furthermore, using the persister assays tested throughout the 
project, a range of persister types could be tested in future studies.  
Comparison of gene lists from TraDIS studies of different persister types could 
be useful in identifying universal or drug-specific persister genes, while the gene 
lists obtained in this study could be used for comparison with future studies.  
 
As well as TraDIS, other approaches are encouraged to investigate molecular 
processes in persisters, in order to overcome the inherent limitations of 
individual approaches. Transposon-directed approaches such as TraDIS would 
be expected to miss genes which are redundant for persister formation. 
Therefore, expression libraries could be used to test the effect of over-
production of such genes on persister formation. Also, more studies of other 
types of molecular events in persisters, such as the gene expression studies 
reported for B. thailandensis ceftazidime persisters (Hemsley, Luo et al. 2014) 
and B. pseudomallei anaerobic persisters (which show general antibiotic 
tolerance) (Hamad, Austin et al. 2011), and other approaches such as 
proteomics, are encouraged. The recent report of a pure persister culture of 
B. pseudomallei (Nierman, Yu et al. 2015) is of great interest to study molecular 
events that occur in persisters. Proteomic, metabolomic or transcriptomic 
studies would all shed light on the molecular makeup of persisters. It is unclear 
whether culture of B. thailandensis in the same conditions reported by Nierman 
et al. for B. pseudomallei would result in 100% persisters; this also warrants 
testing as another potential resource for persister studies. Together, these 
approaches may be used to understand processes underlying persister 
formation and antibiotic tolerance in B. thailandensis and B. pseudomallei, and 
suggest potential targets for inhibition. 
 
Although no clear anti-persister targets were suggested from the TraDIS, as 
was originally hoped, the current study tested two anti-persister strategies 
based on other reports. The glyoxylate bypass enzyme ICL appears to be an 
important factor in persistence of B. pseudomallei in the host. B. pseudomallei 
requires the enzyme for chronic infection (van Schaik, Tom et al. 2009), and 
macrophages in chronically infected mice strongly express the gene which 
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generates itaconate, an ICL inhibitor (Conejero, Potempa et al. 2015). Van 
Schaik et al. suggested that itaconate might be causing growth of persistent 
bacteria in infection, resulting in susceptibility to ceftazidime (van Schaik, Tom 
et al. 2009). Given the possible role for persisters in melioidosis, the current 
study aimed to test the direct effect of itaconate on persister populations in vitro. 
Data for ceftazidime-treated persisters suggested that itaconate was stimulating 
growth, which caused susceptibility to the β-lactam, possibly due to a direct 
effect on the persister cells. This conclusion would support the observations of 
Van Schaik et al. in B. pseudomallei. If this effect can be confirmed, it would 
appear to be a separate mechanism of persister targeting by itaconate from that 
reported by Van Acker et al., who found that itaconate targets B. cenocepacia 
persisters by inducing ROS following antibiotic treatment (Van Acker, Sass et 
al. 2013). However, the findings of the current study warrant further testing on 
persister cultures, in more controlled media (such as minimal media with 
acetate as a sole carbon source), before conclusions about any anti-persister 
effects of itaconate can be drawn.  
 
Another anti-persister strategy tested was based on the previous observations 
of increased persister frequencies of B. pseudomallei or B. thailandensis under 
anaerobic conditions (Hamad, Austin et al. 2011, Hemsley, Luo et al. 2014). 
Those studies showed that metronidazole is effective against both bacteria 
under anaerobic conditions. The current study showed that anaerobic persisters 
which are tolerant to co-trimoxazole are susceptible to metronidazole. 
Collaborators tested metronidazole in combination with ceftazidime in a murine 
infection model, where metronidazole did not improve the survival rates of 
ceftazidime alone (Felipe Cia and Greg Bancroft, LSHTM). Nonetheless, further 
tests of combinations of aerobic (i.e. the conventional melioidosis regimen) + 
anaerobic (i.e. nitroimidazoles such as metronidazole) drugs should be carried 
out in melioidosis infection models. These may try to establish the effectiveness 
of metronidazole in treating persistent infection. 
  
237 
 
 
 
 
 
 
 
 
 
 
Bibliography   
 
 
 
 
 
 
 
 
 
238 
 
Abel Zur Wiesch, P., S. Abel, S. Gkotzis, P. Ocampo, J. Engelstadter, T. Hinkley, C. 
Magnus, M. K. Waldor, K. Udekwu and T. Cohen (2015). "Classic reaction kinetics can 
explain complex patterns of antibiotic action." Sci Transl Med 7(287): 287ra273. 
Ahmad, N., R. Hashim and A. Mohd Noor (2013). "The in vitro antibiotic susceptibility of 
Malaysian isolates of Burkholderia pseudomallei." Int J Microbiol 2013: 121845. 
Allison, K. R., M. P. Brynildsen and J. J. Collins (2011). "Heterogeneous bacterial 
persisters and engineering approaches to eliminate them." Curr Opin Microbiol 14(5): 
593-598. 
Allison, K. R., M. P. Brynildsen and J. J. Collins (2011). "Metabolite-enabled eradication 
of bacterial persisters by aminoglycosides." Nature 473(7346): 5. 
Allwood, E. M., R. J. Devenish, M. Prescott, B. Adler and J. D. Boyce (2011). 
"Strategies for intracellular survival of Burkholderia pseudomallei." Front Microbiol 2: 
170. 
Altschul, S. F., W. Gish, W. Miller, E. W. Myers and D. J. Lipman (1990). "Basic local 
alignment search tool." J Mol Biol 215(3): 403-410. 
Amato, S. M., C. H. Fazen, T. C. Henry, W. W. Mok, M. A. Orman, E. L. Sandvik, K. G. 
Volzing and M. P. Brynildsen (2014). "The role of metabolism in bacterial persistence." 
Front Microbiol 5: 70. 
Amato, S. M., M. A. Orman and M. P. Brynildsen (2013). "Metabolic control of persister 
formation in Escherichia coli." Mol Cell 50(4). 
Amornchai, P., W. Chierakul, V. Wuthiekanun, Y. Mahakhunkijcharoen, R. 
Phetsouvanh, B. J. Currie, P. N. Newton, N. van Vinh Chau, S. Wongratanacheewin, 
N. P. Day and S. J. Peacock (2007). "Accuracy of Burkholderia pseudomallei 
identification using the API 20NE system and a latex agglutination test." J Clin 
Microbiol 45(11): 3774-3776. 
Andreae, C. A., R. W. Titball and C. S. Butler (2014). "Influence of the molybdenum 
cofactor biosynthesis on anaerobic respiration, biofilm formation and motility in 
Burkholderia thailandensis." Res Microbiol 165(1): 41-49. 
Anutrakunchai, C., R. W. Sermswan, S. Wongratanacheewin, A. Puknun and S. 
Taweechaisupapong (2015). "Drug susceptibility and biofilm formation of Burkholderia 
pseudomallei in nutrient-limited condition." Trop Biomed 32(2): 300-309. 
Austin, C. R., A. W. Goodyear, I. L. Bartek, A. Stewart, M. D. Sutherland, E. B. Silva, A. 
Zweifel, N. P. Vitko, A. Tuanyok, G. Highnam, D. Mittelman, P. Keim, H. P. Schweizer, 
A. Vazquez-Torres, S. W. Dow and M. I. Voskuil (2015). "A Burkholderia pseudomallei 
colony variant necessary for gastric colonization." mBio 6(1). 
Baharoglu, Z. and D. Mazel (2014). "SOS, the formidable strategy of bacteria against 
aggressions." FEMS Microbiol Rev 38(6): 1126-1145. 
Balaban, N. Q., J. Merrin, R. Chait, L. Kowalik and S. Leibler (2004). "Bacterial 
persistence as a phenotypic switch." Science 305(5690): 1622-1625. 
Barraud, N., A. Buson, W. Jarolimek and S. A. Rice (2013). "Mannitol enhances 
antibiotic sensitivity of persister bacteria in Pseudomonas aeruginosa biofilms." PLoS 
One 8(12): e84220. 
239 
 
Basler, T., S. Jeckstadt, P. Valentin-Weigand and R. Goethe (2006). "Mycobacterium 
paratuberculosis, Mycobacterium smegmatis, and lipopolysaccharide induce different 
transcriptional and post-transcriptional regulation of the IRG1 gene in murine 
macrophages." J Leukoc Biol 79(3): 628-638. 
Baugh, L., L. A. Gallagher, R. Patrapuvich, M. C. Clifton, A. S. Gardberg, T. E. 
Edwards, B. Armour, D. W. Begley, S. H. Dieterich, D. M. Dranow, J. Abendroth, J. W. 
Fairman, D. Fox, 3rd, B. L. Staker, I. Phan, A. Gillespie, R. Choi, S. Nakazawa-Hewitt, 
M. T. Nguyen, A. Napuli, L. Barrett, G. W. Buchko, R. Stacy, P. J. Myler, L. J. Stewart, 
C. Manoil and W. C. Van Voorhis (2013). "Combining functional and structural 
genomics to sample the essential Burkholderia structome." PLoS One 8(1): e53851. 
Bearson, B. L. and B. W. Brunelle (2015). "Fluoroquinolone induction of phage-
mediated gene transfer in multidrug-resistant Salmonella." Int J Antimicrob Agents 
46(2): 201-204. 
Bernier, S. P., D. Lebeaux, A. S. DeFrancesco, A. Valomon, G. Soubigou, J. Y. 
Coppee, J. M. Ghigo and C. Beloin (2013). "Starvation, together with the SOS 
response, mediates high biofilm-specific tolerance to the fluoroquinolone ofloxacin." 
PLoS Genet 9(1): e1003144. 
Bigger, J. W. (1944). "Treatment of Staphylococcal infections with penicillin." Lancet: 
497-500. 
Bishop, A. H. and P. A. Rachwal (2014). "Identification of genes required for soil 
survival in Burkholderia thailandensis by transposon-directed insertion site 
sequencing." Curr Microbiol 68(6): 693-701. 
Black, D. S., A. J. Kelly, M. J. Mardis and H. S. Moyed (1991). "Structure and 
organization of hip, an operon that affects lethality due to inhibition of peptidoglycan or 
DNA synthesis." J Bacteriol 173(18): 5732-5739. 
Blake, K. L. and A. J. O'Neill (2013). "Transposon library screening for identification of 
genetic loci participating in intrinsic susceptibility and acquired resistance to 
antistaphylococcal agents." J Antimicrob Chemother 68(1): 12-16. 
Brauner, A., O. Fridman, O. Gefen and N. Q. Balaban (2016). "Distinguishing between 
resistance, tolerance and persistence to antibiotic treatment." Nat Rev Microbiol 14(5): 
320-330. 
Briers, Y., M. Walmagh, B. Grymonprez, M. Biebl, J. P. Pirnay, V. Defraine, J. Michiels, 
W. Cenens, A. Aertsen, S. Miller and R. Lavigne (2014). "Art-175 is a highly efficient 
antibacterial against multidrug-resistant strains and persisters of Pseudomonas 
aeruginosa." Antimicrob Agents Chemother 58(7): 3774-3784. 
Brooks, J. V., S. K. Furney and I. M. Orme (1999). "Metronidazole therapy in mice 
infected with tuberculosis." Antimicrob Agents Chemother 43(5): 1285-1288. 
Brooun, A., S. Liu and K. Lewis (2000). "A dose-response study of antibiotic resistance 
in Pseudomonas aeruginosa biofilms." Antimicrob Agents Chemother 44(3): 640-646. 
Brotz-Oesterhelt, H., D. Beyer, H. P. Kroll, R. Endermann, C. Ladel, W. Schroeder, B. 
Hinzen, S. Raddatz, H. Paulsen, K. Henninger, J. E. Bandow, H. G. Sahl and H. 
Labischinski (2005). "Dysregulation of bacterial proteolytic machinery by a new class of 
antibiotics." Nat Med 11(10): 1082-1087. 
240 
 
Burchall, J. J. (1973). "Mechanism of action of trimethoprim-sulfamethoxazole. II." J 
Infect Dis 128: Suppl: 437-441. 
Burtnick, M. N., P. J. Brett, S. V. Harding, S. A. Ngugi, W. J. Ribot, N. Chantratita, A. 
Scorpio, T. S. Milne, R. E. Dean, D. L. Fritz, S. J. Peacock, J. L. Prior, T. P. Atkins and 
D. Deshazer (2011). "The cluster 1 type VI secretion system is a major virulence 
determinant in Burkholderia pseudomallei." Infect Immun 79(4): 1512-1525. 
Butt, A., N. Halliday, P. Williams, H. S. Atkins, G. J. Bancroft and R. W. Titball (2016). 
"Burkholderia pseudomallei kynB plays a role in AQ production, biofilm formation, 
bacterial swarming and persistence." Res Microbiol 167(3): 159-167. 
Butt, A., V. A. Higman, C. Williams, M. P. Crump, C. M. Hemsley, N. Harmer and R. W. 
Titball (2014). "The HicA toxin from Burkholderia pseudomallei has a role in persister 
cell formation." Biochem J 459(2): 333-344. 
Butt, A., C. Muller, N. Harmer and R. W. Titball (2013). "Identification of type II toxin-
antitoxin modules in Burkholderia pseudomallei." FEMS Microbiol Lett 338(1): 86-94. 
Capasso, C. and C. T. Supuran (2014). "Sulfa and trimethoprim-like drugs - 
antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and 
dihydrofolate reductase inhibitors." J Enzyme Inhib Med Chem 29(3): 379-387. 
CDC (2012). "Possession, use, and transfer of select agents and toxins; biennial 
review. Final rule." Fed Regist 77(194): 61083-61115. 
Chantratita, N., D. A. Rholl, B. Sim, V. Wuthiekanun, D. Limmathurotsakul, P. 
Amornchai, A. Thanwisai, H. H. Chua, W. F. Ooi, M. T. Holden, N. P. Day, P. Tan, H. 
P. Schweizer and S. J. Peacock (2011). "Antimicrobial resistance to ceftazidime 
involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei." Proc Natl 
Acad Sci U S A 108(41): 17165-17170. 
Chantratita, N., V. Wuthiekanun, K. Boonbumrung, R. Tiyawisutsri, M. Vesaratchavest, 
D. Limmathurotsakul, W. Chierakul, S. Wongratanacheewin, S. Pukritiyakamee, N. J. 
White, N. P. Day and S. J. Peacock (2007). "Biological relevance of colony morphology 
and phenotypic switching by Burkholderia pseudomallei." J Bacteriol 189(3): 807-817. 
Chaudhuri, R. R., E. Morgan, S. E. Peters, S. J. Pleasance, D. L. Hudson, H. M. 
Davies, J. Wang, P. M. van Diemen, A. M. Buckley, A. J. Bowen, G. D. Pullinger, D. J. 
Turner, G. C. Langridge, A. K. Turner, J. Parkhill, I. G. Charles, D. J. Maskell and M. P. 
Stevens (2013). "Comprehensive assignment of roles for Salmonella typhimurium 
genes in intestinal colonization of food-producing animals." PLoS Genet 9(4): 
e1003456. 
Chen, H. Y., G. G. Jackson and D. M. Livermore (1991). "Dependence of the 
interaction of ceftazidime and gentamicin against Pseudomonas aeruginosa on the 
bacterial growth-rate." J Antimicrob Chemother 28(4): 610-612. 
Cheng, A. C. and B. J. Currie (2005). "Melioidosis: epidemiology, pathophysiology, and 
management." Clin Microbiol Rev 18(2): 383-416. 
Chetchotisakd, P., W. Chaowagul, P. Mootsikapun, D. Budhsarawong and B. 
Thinkamrop (2001). "Maintenance therapy of melioidosis with ciprofloxacin plus 
azithromycin compared with cotrimoxazole plus doxycycline." Am J Trop Med Hyg 
64(1-2): 24-27. 
241 
 
Cohen, N. R., M. A. Lobritz and J. J. Collins (2013). "Microbial persistence and the road 
to drug resistance." Cell Host Microbe 13(6): 632-642. 
Conejero, L., N. Patel, M. de Reynal, S. Oberdorf, J. Prior, P. L. Felgner, R. W. Titball, 
F. J. Salguero and G. J. Bancroft (2011). "Low-dose exposure of C57BL/6 mice to 
Burkholderia pseudomallei mimics chronic human melioidosis." Am J Pathol 179(1): 
270-280. 
Conejero, L., K. Potempa, C. M. Graham, N. Spink, S. Blankley, F. J. Salguero, R. 
Pankla-Sranujit, P. Khaenam, J. F. Banchereau, V. Pascual, D. Chaussabel, G. 
Lertmemongkolchai, A. O'Garra and G. J. Bancroft (2015). "The blood transcriptome of 
experimental melioidosis reflects disease severity and shows considerable similarity 
with the human disease." J Immunol 195(7): 3248-3261. 
Conlon, B. P. (2014). "Staphylococcus aureus chronic and relapsing infections: 
Evidence of a role for persister cells: An investigation of persister cells, their formation 
and their role in S. aureus disease." Bioessays 36(10): 991-996. 
Conlon, B. P., E. S. Nakayasu, L. E. Fleck, M. D. LaFleur, V. M. Isabella, K. Coleman, 
S. N. Leonard, R. D. Smith, J. N. Adkins and K. Lewis (2013). "Activated ClpP kills 
persisters and eradicates a chronic biofilm infection." Nature 503(7476): 365-370. 
Costerton, J. W., P. S. Stewart and E. P. Greenberg (1999). "Bacterial biofilms: a 
common cause of persistent infections." Science 284(5418): 1318-1322. 
Cozens, R. M., Z. Markiewicz and E. Tuomanen (1989). "Role of autolysins in the 
activities of imipenem and CGP 31608, a novel penem, against slowly growing 
bacteria." Antimicrob Agents Chemother 33(10): 1819-1821. 
Cozens, R. M., E. Tuomanen, W. Tosch, O. Zak, J. Suter and A. Tomasz (1986). 
"Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing 
bacteria cultured in the chemostat." Antimicrob Agents Chemother 29(5): 797-802. 
Crowe, A., N. McMahon, B. J. Currie and R. W. Baird (2014). "Current antimicrobial 
susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the 
Northern Territory, Australia." Int J Antimicrob Agents 44(2): 160-162. 
Cuccui, J., A. Easton, K. K. Chu, G. J. Bancroft, P. C. Oyston, R. W. Titball and B. W. 
Wren (2007). "Development of signature-tagged mutagenesis in Burkholderia 
pseudomallei to identify genes important in survival and pathogenesis." Infect Immun 
75(3): 1186-1195. 
Currie, B. J. (2015). "Melioidosis: evolving concepts in epidemiology, pathogenesis, 
and treatment." Semin Resp Crit Care 36(1): 111-125. 
Currie, B. J., D. A. Fisher, N. M. Anstey and S. P. Jacups (2000). "Melioidosis: acute 
and chronic disease, relapse and re-activation." T Roy Soc Trop Med H 94(3): 301-304. 
Currie, B. J., L. Ward and A. C. Cheng (2010). "The epidemiology and clinical spectrum 
of melioidosis: 540 cases from the 20 year Darwin prospective study." PLoS Negl Trop 
Dis 4(11): e900. 
Dance, D. (2014). "Treatment and prophylaxis of melioidosis." Int J Antimicrob Agents 
43(4): 310-318. 
242 
 
Dance, D. A. (2000). "Ecology of Burkholderia pseudomallei and the interactions 
between environmental Burkholderia spp. and human-animal hosts." Acta Trop 74(2-3): 
159-168. 
Dance, D. A., V. Davong, S. Soeng, R. Phetsouvanh, P. N. Newton and P. Turner 
(2014). "Trimethoprim/sulfamethoxazole resistance in Burkholderia pseudomallei." Int J 
Antimicrob Agents 44(4): 368-369. 
Dance, D. A., V. Wuthiekanun, P. Naigowit and N. J. White (1989). "Identification of 
Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 
20NE." J Clin Pathol 42(6): 645-648. 
De Groote, V. N., N. Verstraeten, M. Fauvart, C. I. Kint, A. M. Verbeeck, S. Beullens, P. 
Cornelis and J. Michiels (2009). "Novel persistence genes in Pseudomonas aeruginosa 
identified by high-throughput screening." FEMS Microbiol Lett 297(1): 73-79. 
de la Fuente-Nunez, C., F. Reffuveille, E. F. Haney, S. K. Straus and R. E. Hancock 
(2014). "Broad-spectrum anti-biofilm peptide that targets a cellular stress response." 
PLoS Pathog 10(5): e1004152. 
de Lorenzo, V., M. Herrero, U. Jakubzik and K. N. Timmis (1990). "Mini-Tn5 
transposon derivatives for insertion mutagenesis, promoter probing, and chromosomal 
insertion of cloned DNA in gram-negative eubacteria." J Bacteriol 172(11): 6568-6572. 
Dembek, M., L. Barquist, C. J. Boinett, A. K. Cain, M. Mayho, T. D. Lawley, N. F. 
Fairweather and R. P. Fagan (2015). "High-throughput analysis of gene essentiality 
and sporulation in Clostridium difficile." mBio 6(2): e02383. 
DeShazer, D., P. J. Brett and D. E. Woods (1998). "The type II O-antigenic 
polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for 
serum resistance and virulence." Mol Microbiol 30(5): 1081-1100. 
Desmarchelier, P. M., D. A. Dance, W. Chaowagul, Y. Suputtamongkol, N. J. White 
and T. L. Pitt (1993). "Relationships among Pseudomonas pseudomallei isolates from 
patients with recurrent melioidosis." J Clin Microbiol 31(6): 1592-1596. 
Dorr, T., B. M. Davis and M. K. Waldor (2015). "Endopeptidase-mediated beta lactam 
tolerance." PLoS Pathog 11(4): e1004850. 
Dorr, T., M. Vulic and K. Lewis (2010). "Ciprofloxacin causes persister formation by 
inducing the TisB toxin in Escherichia coli." PLoS Biol 8(2): e1000317. 
Drlica, K., M. Malik, R. J. Kerns and X. Zhao (2008). "Quinolone-mediated bacterial 
death." Antimicrob Agents Chemother 52(2): 385-392. 
Dwyer, D. J., P. A. Belenky, J. H. Yang, I. C. MacDonald, J. D. Martell, N. Takahashi, 
C. T. Chan, M. A. Lobritz, D. Braff, E. G. Schwarz, J. D. Ye, M. Pati, M. Vercruysse, P. 
S. Ralifo, K. R. Allison, A. S. Khalil, A. Y. Ting, G. C. Walker and J. J. Collins (2014). 
"Antibiotics induce redox-related physiological alterations as part of their lethality." Proc 
Natl Acad Sci U S A 111(20): E2100-2109. 
Dwyer, D. J., J. J. Collins and G. C. Walker (2015). "Unraveling the physiological 
complexities of antibiotic lethality." Annu Rev Pharmacol Toxicol 55: 313-332. 
Eng, R. H., F. T. Padberg, S. M. Smith, E. N. Tan and C. E. Cherubin (1991). 
"Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria." 
Antimicrob Agents Chemother 35(9): 1824-1828. 
243 
 
Essex-Lopresti, A. E., J. A. Boddey, R. Thomas, M. P. Smith, M. G. Hartley, T. Atkins, 
N. F. Brown, C. H. Tsang, I. R. Peak, J. Hill, I. R. Beacham and R. W. Titball (2005). "A 
type IV pilin, PilA, contributes to adherence of Burkholderia pseudomallei and virulence 
in vivo." Infect Immun 73(2): 1260-1264. 
Fasani, R. A. and M. A. Savageau (2013). "Molecular mechanisms of multiple toxin-
antitoxin systems are coordinated to govern the persister phenotype." Proc Natl Acad 
Sci U S A. 
Fattorini, L., G. Piccaro, A. Mustazzolu and F. Giannoni (2013). "Targeting dormant 
bacilli to fight tuberculosis." Mediterr J Hematol Infect Dis 5(1): e2013072. 
Fauvart, M., V. N. De Groote and J. Michiels (2011). "Role of persister cells in chronic 
infections: clinical relevance and perspectives on anti-persister therapies." J Med 
Microbiol 60(Pt 6): 699-709. 
Fisher, R. A., A. M. Cheverton and S. Helaine (2016). "Analysis of macrophage-
induced Salmonella persisters." Method Mol Biol 1333: 177-187. 
Fuchs, G. and I. A. Berg (2014). "Unfamiliar metabolic links in the central carbon 
metabolism." J Biotechnol 192 Pt B: 314-322. 
Gaca, A. O., C. Colomer-Winter and J. A. Lemos (2015). "Many means to a common 
end: the intricacies of (p)ppGpp metabolism and its control of bacterial homeostasis." J 
Bacteriol 197(7): 1146-1156. 
Gallagher, L. A., E. Ramage, R. Patrapuvich, E. Weiss, M. Brittnacher and C. Manoil 
(2013). "Sequence-defined transposon mutant library of Burkholderia thailandensis." 
mBio 4(6): e00604-00613. 
Galyov, E. E., P. J. Brett and D. DeShazer (2010). "Molecular insights into Burkholderia 
pseudomallei and Burkholderia mallei pathogenesis." Annu Rev Microbiol 64: 495-517. 
Gamage, A. M., G. Shui, M. R. Wenk and K. L. Chua (2011). "N-Octanoylhomoserine 
lactone signalling mediated by the BpsI-BpsR quorum sensing system plays a major 
role in biofilm formation of Burkholderia pseudomallei." Microbiology 157(Pt 4): 1176-
1186. 
Gan, Y. H. (2005). "Interaction between Burkholderia pseudomallei and the host 
immune response: sleeping with the enemy?" J Infect Dis 192(10): 1845-1850. 
Gawronski, J. D., S. M. Wong, G. Giannoukos, D. V. Ward and B. J. Akerley (2009). 
"Tracking insertion mutants within libraries by deep sequencing and a genome-wide 
screen for Haemophilus genes required in the lung." Proc Natl Acad Sci U S A 106(38): 
16422-16427. 
Gerdes, K. and E. Maisonneuve (2012). "Bacterial persistence and toxin-antitoxin 
Loci." Annu Rev Microbiol 66: 103-123. 
Germain, E., D. Castro-Roa, N. Zenkin and K. Gerdes (2013). "Molecular mechanism 
of bacterial persistence by HipA." Mol Cell 52(2): 248-254. 
Germain, E., M. Roghanian, K. Gerdes and E. Maisonneuve (2015). "Stochastic 
induction of persister cells by HipA through (p)ppGpp-mediated activation of mRNA 
endonucleases." Proc Natl Acad Sci U S A 112(16): 5171-5176. 
244 
 
Goneau, L. W., N. S. Yeoh, K. W. Macdonald, P. A. Cadieux, J. P. Burton, H. Razvi 
and G. Reid (2014). "Selective target inactivation rather than global metabolic 
dormancy causes antibiotic tolerance in uropathogens." Antimicrob Agents Chemother 
58(4): 2089-2097. 
Goodman, A. L., N. P. McNulty, Y. Zhao, D. Leip, R. D. Mitra, C. A. Lozupone, R. 
Knight and J. I. Gordon (2009). "Identifying genetic determinants needed to establish a 
human gut symbiont in its habitat." Cell Host Microbe 6(3): 279-289. 
Goodyear, A., H. Bielefeldt-Ohmann, H. Schweizer and S. Dow (2012). "Persistent 
gastric colonization with Burkholderia pseudomallei and dissemination from the 
gastrointestinal tract following mucosal inoculation of mice." PLoS One 7(5): e37324. 
Goryshin, I. Y. and W. S. Reznikoff (1998). "Tn5 in vitro transposition." Journal of 
Biological Chemistry 273(13): 7367-7374. 
Griffiths, A., J. Miller and D. Suzuki (2000). Mechanism of transposition in prokaryotes. 
An Introduction to Genetic Analysis, 7th Edition. 
Gutierrez, D., P. Ruas-Madiedo, B. Martinez, A. Rodriguez and P. Garcia (2014). 
"Effective removal of staphylococcal biofilms by the endolysin LysH5." PLoS One 9(9): 
e107307. 
Hamad, M. A., C. R. Austin, A. L. Stewart, M. Higgins, A. Vazquez-Torres and M. I. 
Voskuil (2011). "Adaptation and antibiotic tolerance of anaerobic Burkholderia 
pseudomallei." Antimicrob Agents Chemother 55(7): 11. 
Hansen, S., K. Lewis and M. Vulic (2008). "Role of global regulators and nucleotide 
metabolism in antibiotic tolerance in Escherichia coli." Antimicrob Agents Chemother 
52(8): 2718-2726. 
Hashizume, T., F. Ishino, J. Nakagawa, S. Tamaki and M. Matsuhashi (1984). "Studies 
on the mechanism of action of imipenem (N-formimidoylthienamycin) in vitro: binding to 
the penicillin-binding proteins (PBPs) in Escherichia coli and Pseudomonas 
aeruginosa, and inhibition of enzyme activities due to the PBPs in E. coli." J Antibiot 
(Tokyo) 37(4): 394-400. 
Hayden, H. S., R. Lim, M. J. Brittnacher, E. H. Sims, E. R. Ramage, C. Fong, Z. Wu, E. 
Crist, J. Chang, Y. Zhou, M. Radey, L. Rohmer, E. Haugen, W. Gillett, V. Wuthiekanun, 
S. J. Peacock, R. Kaul, S. I. Miller, C. Manoil and M. A. Jacobs (2012). "Evolution of 
Burkholderia pseudomallei in recurrent melioidosis." PLoS One 7(5): e36507. 
Hayes, M. V. and D. C. Orr (1983). "Mode of action of ceftazidime: affinity for the 
penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and 
Staphylococcus aureus." J Antimicrob Chemother 12(2): 119-126. 
Helaine, S., A. M. Cheverton, K. G. Watson, L. M. Faure, S. A. Matthews and D. W. 
Holden (2014). "Internalization of Salmonella by macrophages induces formation of 
nonreplicating persisters." Science 343(6167): 204-208. 
Helaine, S. and E. Kugelberg (2014). "Bacterial persisters: formation, eradication, and 
experimental systems." Trends Microbiol 22(7): 417-424. 
Hemsley, C. M., J. X. Luo, C. A. Andreae, C. S. Butler, O. S. Soyer and R. W. Titball 
(2014). "Bacterial drug tolerance under clinical conditions is governed by anaerobic 
adaptation, but not anaerobic respiration." Antimicrob Agents Chemother. 
245 
 
Herrero, M., V. de Lorenzo and K. N. Timmis (1990). "Transposon vectors containing 
non-antibiotic resistance selection markers for cloning and stable chromosomal 
insertion of foreign genes in gram-negative bacteria." J Bacteriol 172(11): 6557-6567. 
Hillier, S. and W. T. Charnetzky (1981). "Glyoxylate bypass enzymes in Yersinia 
species and multiple forms of isocitrate lyase in Yersinia pestis." J Bacteriol 145(1): 
452-458. 
Hofsteenge, N., E. van Nimwegen and O. K. Silander (2013). "Quantitative analysis of 
persister fractions suggests different mechanisms of formation among environmental 
isolates of Escherichia coli." BMC Microbiology 13(1): 25. 
Hoiby, N., O. Ciofu, H. K. Johansen, Z. J. Song, C. Moser, P. O. Jensen, S. Molin, M. 
Givskov, T. Tolker-Nielsen and T. Bjarnsholt (2011). "The clinical impact of bacterial 
biofilms." Int J Oral Sci 3(2): 55-65. 
Holden, M. T., R. W. Titball, S. J. Peacock, A. M. Cerdeno-Tarraga, T. Atkins, L. C. 
Crossman, T. Pitt, C. Churcher, K. Mungall, S. D. Bentley, M. Sebaihia, N. R. 
Thomson, N. Bason, I. R. Beacham, K. Brooks, K. A. Brown, N. F. Brown, G. L. Challis, 
I. Cherevach, T. Chillingworth, A. Cronin, B. Crossett, P. Davis, D. DeShazer, T. 
Feltwell, A. Fraser, Z. Hance, H. Hauser, S. Holroyd, K. Jagels, K. E. Keith, M. 
Maddison, S. Moule, C. Price, M. A. Quail, E. Rabbinowitsch, K. Rutherford, M. 
Sanders, M. Simmonds, S. Songsivilai, K. Stevens, S. Tumapa, M. Vesaratchavest, S. 
Whitehead, C. Yeats, B. G. Barrell, P. C. Oyston and J. Parkhill (2004). "Genomic 
plasticity of the causative agent of melioidosis, Burkholderia pseudomallei." Proc Natl 
Acad Sci U S A 101(39): 14240-14245. 
Honer Zu Bentrup, K., A. Miczak, D. L. Swenson and D. G. Russell (1999). 
"Characterization of activity and expression of isocitrate lyase in Mycobacterium avium 
and Mycobacterium tuberculosis." J Bacteriol 181(23): 7161-7167. 
Hoppe, I., B. Brenneke, M. Rohde, A. Kreft, S. Haussler, A. Reganzerowski and I. 
Steinmetz (1999). "Characterization of a murine model of melioidosis: comparison of 
different strains of mice." Infect Immun 67(6): 2891-2900. 
Hoskisson, P. A., P. Sumby and M. C. Smith (2015). "The phage growth limitation 
system in Streptomyces coelicolor A(3)2 is a toxin/antitoxin system, comprising 
enzymes with DNA methyltransferase, protein kinase and ATPase activity." Virology 
477: 100-109. 
Houghton, R. L., D. E. Reed, M. A. Hubbard, M. J. Dillon, H. Chen, B. J. Currie, M. 
Mayo, D. S. Sarovich, V. Theobald, D. Limmathurotsakul, G. Wongsuvan, N. 
Chantratita, S. J. Peacock, A. R. Hoffmaster, B. Duval, P. J. Brett, M. N. Burtnick and 
D. P. Aucoin (2014). "Development of a prototype lateral flow immunoassay (LFI) for 
the rapid diagnosis of melioidosis." PLoS Negl Trop Dis 8(3): e2727. 
Hu, Y. and A. R. Coates (2005). "Transposon mutagenesis identifies genes which 
control antimicrobial drug tolerance in stationary-phase Escherichia coli." FEMS 
Microbiol Lett 243(1): 117-124. 
Hu, Y., A. R. Coates and D. A. Mitchison (2003). "Sterilizing activities of 
fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis." 
Antimicrob Agents Chemother 47(2): 653-657. 
Imlay, J. A. (2015). "Diagnosing oxidative stress in bacteria: not as easy as you might 
think." Curr Opin Microbiol 24: 124-131. 
246 
 
Ismail, G., N. Razak, R. Mohamed, N. Embi and O. Omar (1988). "Resistance of 
Pseudomonas pseudomallei to normal human serum bactericidal action." Microbiol 
Immunol 32(7): 645-652. 
Jenney, A. W., G. Lum, D. A. Fisher and B. J. Currie (2001). "Antibiotic susceptibility of 
Burkholderia pseudomallei from tropical northern Australia and implications for therapy 
of melioidosis." Int J Antimicrob Agents 17(2): 109-113. 
Jensen, E. T., A. Kharazmi, K. Lam, J. W. Costerton and N. Hoiby (1990). "Human 
polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in 
biofilms." Infect Immun 58(7): 2383-2385. 
Jitprasutwit, S., W. Thaewpia, V. Muangsombut, A. Lulitanond, C. Leelayuwat, G. 
Lertmemongkolchai and S. Korbsrisate (2010). "Effect of acidic pH on the invasion 
efficiency and the type III secretion system of Burkholderia thailandensis." J Microbiol 
(Seoul, Korea) 48(4): 526-532. 
Jones, A. L., T. J. Beveridge and D. E. Woods (1996). "Intracellular survival of 
Burkholderia pseudomallei." Infect Immun 64(3): 782-790. 
Kaestli, M., L. J. Richardson, R. E. Colman, A. Tuanyok, E. P. Price, J. R. Bowers, M. 
Mayo, E. Kelley, M. L. Seymour, D. S. Sarovich, T. Pearson, D. M. Engelthaler, D. M. 
Wagner, P. S. Keim, J. M. Schupp and B. J. Currie (2012). "Comparison of TaqMan 
PCR assays for detection of the melioidosis agent Burkholderia pseudomallei in clinical 
specimens." J Clin Microbiol 50(6): 2059-2062. 
Kaihovaara, P., J. Hook-Nikanne, M. Uusi-Oukari, T. U. Kosunen and M. Salaspuro 
(1998). "Flavodoxin-dependent pyruvate oxidation, acetate production and 
metronidazole reduction by Helicobacter pylori." J Antimicrob Chemother 41(2): 171-
177. 
Kanehisa, M. and S. Goto (2000). "KEGG: kyoto encyclopedia of genes and genomes." 
Nucleic Acids Res 28(1): 27-30. 
Kanehisa, M., Y. Sato, M. Kawashima, M. Furumichi and M. Tanabe (2016). "KEGG as 
a reference resource for gene and protein annotation." Nucleic Acids Res 44(D1): 
D457-462. 
Kang, Y., M. H. Norris, A. R. Barrett, B. A. Wilcox and T. T. Hoang (2009). "Engineering 
of tellurite-resistant genetic tools for single-copy chromosomal analysis of Burkholderia 
spp. and characterization of the Burkholderia thailandensis betBA operon." Appl 
Environ Microbiol 75(12): 4015-4027. 
Kaspy, I., E. Rotem, N. Weiss, I. Ronin, N. Q. Balaban and G. Glaser (2013). "HipA-
mediated antibiotic persistence via phosphorylation of the glutamyl-tRNA-synthetase." 
Nat Commun 4: 3001. 
Keren, I., N. Kaldalu, A. Spoering, Y. Wang and K. Lewis (2004). "Persister cells and 
tolerance to antimicrobials." FEMS Microbiol Lett 230(1): 13-18. 
Keren, I., S. Minami, E. Rubin and K. Lewis (2011). "Characterization and 
transcriptome analysis of Mycobacterium tuberculosis persisters." mBio 2(3): e00100-
00111. 
Keren, I., D. Shah, A. Spoering, N. Kaldalu and K. Lewis (2004). "Specialized persister 
cells and the mechanism of multidrug tolerance in Escherichia coli." J Bacteriol 
186(24): 8172-8180. 
247 
 
Keren, I., Y. Wu, J. Inocencio, L. R. Mulcahy and K. Lewis (2013). "Killing by 
bactericidal antibiotics does not depend on reactive oxygen species." Science 
339(6124): 1213-1216. 
Khakimova, M., H. G. Ahlgren, J. J. Harrison, A. M. English and D. Nguyen (2013). 
"The stringent response controls catalases in Pseudomonas aeruginosa and is 
required for hydrogen peroxide and antibiotic tolerance." J Bacteriol 195(9): 2011-2020. 
Khoury, A. E., K. Lam, B. Ellis and J. W. Costerton (1992). "Prevention and control of 
bacterial infections associated with medical devices." Asaio j 38(3): M174-178. 
Kim, H. S., M. A. Schell, Y. Yu, R. L. Ulrich, S. H. Sarria, W. C. Nierman and D. 
DeShazer (2005). "Bacterial genome adaptation to niches: divergence of the potential 
virulence genes in three Burkholderia species of different survival strategies." BMC 
Genomics 6: 174. 
Kim, J. S., P. Heo, T. J. Yang, K. S. Lee, D. H. Cho, B. T. Kim, J. H. Suh, H. J. Lim, D. 
Shin, S. K. Kim and D. H. Kweon (2011). "Selective killing of bacterial persisters by a 
single chemical compound without affecting normal antibiotic-sensitive cells." 
Antimicrob Agents Chemother 55(11): 5380-5383. 
Kim, Y., X. Wang, X. S. Zhang, S. Grigoriu, R. Page, W. Peti and T. K. Wood (2010). 
"Escherichia coli toxin/antitoxin pair MqsR/MqsA regulate toxin CspD." Environ 
Microbiol 12(5): 1105-1121. 
Kint, C. I., N. Verstraeten, M. Fauvart and J. Michiels (2012). "New-found fundamentals 
of bacterial persistence." Trends Microbiol. 
Kohanski, M. A., D. J. Dwyer and J. J. Collins (2010). "How antibiotics kill bacteria: 
from targets to networks." Nat Rev Microbiol 8(6): 423-435. 
Kohanski, M. A., D. J. Dwyer, B. Hayete, C. A. Lawrence and J. J. Collins (2007). "A 
common mechanism of cellular death induced by bactericidal antibiotics." Cell 130(5): 
797-810. 
Korch, S. B., T. A. Henderson and T. M. Hill (2003). "Characterization of the hipA7 
allele of Escherichia coli and evidence that high persistence is governed by (p)ppGpp 
synthesis." Mol Microbiol 50(4): 1199-1213. 
Korch, S. B. and T. M. Hill (2006). "Ectopic overexpression of wild-type and mutant 
hipA genes in Escherichia coli: effects on macromolecular synthesis and persister 
formation." J Bacteriol 188(11): 3826-3836. 
Kwan, B. W., J. A. Valenta, M. J. Benedik and T. K. Wood (2013). "Arrested protein 
synthesis increases persister-like cell formation." Antimicrob Agents Chemother 57(3): 
1468-1473. 
Langridge, G. C., M. D. Phan, D. J. Turner, T. T. Perkins, L. Parts, J. Haase, I. Charles, 
D. J. Maskell, S. E. Peters, G. Dougan, J. Wain, J. Parkhill and A. K. Turner (2009). 
"Simultaneous assay of every Salmonella Typhi gene using one million transposon 
mutants." Genome Res 19(12): 2308-2316. 
Larsen, E., J. J. Smith, R. Norton and M. Corkeron (2013). "Survival, sublethal injury, 
and recovery of environmental Burkholderia pseudomallei in soil subjected to 
desiccation." Appl Environ Microbiol 79(7): 2424-2427. 
248 
 
Leakey, A. K., G. C. Ulett and R. G. Hirst (1998). "BALB/c and C57Bl/6 mice infected 
with virulent Burkholderia pseudomallei provide contrasting animal models for the acute 
and chronic forms of human melioidosis." Microb Pathog 24(5): 269-275. 
Lebeaux, D., A. Chauhan, S. Letoffe, F. Fischer, H. de Reuse, C. Beloin and J. M. 
Ghigo (2014). "pH-mediated potentiation of aminoglycosides kills bacterial persisters 
and eradicates in vivo biofilms." J Infect Dis 210(9): 1357-1366. 
LeBel, M. (1988). "Ciprofloxacin: chemistry, mechanism of action, resistance, 
antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions." 
Pharmacother 8(1): 3-33. 
Lechner, S., K. Lewis and R. Bertram (2012). "Staphylococcus aureus persisters 
tolerant to bactericidal antibiotics." J Mol Microb Biotechn 22(4): 235-244. 
Lechner, S., P. Patra, S. Klumpp and R. Bertram (2013). "Interplay between population 
dynamics and drug tolerance of Staphylococcus aureus persister cells." J Mol Microb 
Biotechn 22(6): 381-391. 
Lee, Y. V., H. A. Wahab and Y. S. Choong (2015). "Potential inhibitors for isocitrate 
lyase of Mycobacterium tuberculosis and non-M. tuberculosis: a summary." Biomed 
Res Int 2015: 895453. 
Leung, V. and C. M. Levesque (2012). "A stress-inducible quorum-sensing peptide 
mediates the formation of persister cells with noninherited multidrug tolerance." J 
Bacteriol 194(9): 2265-2274. 
Levin, B. R. and D. E. Rozen (2006). "Non-inherited antibiotic resistance." Nat Rev 
Microbiol 4(7): 556-562. 
Lewis, K. (2007). "Persister cells, dormancy and infectious disease." Nat Rev Microbiol 
5(1): 48-56. 
Lewis, K. (2008). "Multidrug tolerance of biofilms and persister cells." Curr Top 
Microbiol 322: 107-131. 
Lewis, K. (2010). "Persister cells." Annu Rev Microbiol 64: 357-372. 
Lewis, K. (2012). "Persister cells: molecular mechanisms related to antibiotic 
tolerance." Handb Exp Path(211): 121-133. 
Li, Y. and Y. Zhang (2007). "PhoU is a persistence switch involved in persister 
formation and tolerance to multiple antibiotics and stresses in Escherichia coli." 
Antimicrob Agents Chemother 51(6): 2092-2099. 
Limmathurotsakul, D., W. Chaowagul, W. Chierakul, K. Stepniewska, B. Maharjan, V. 
Wuthiekanun, N. J. White, N. P. Day and S. J. Peacock (2006). "Risk factors for 
recurrent melioidosis in northeast Thailand." Clin Infect Dis 43(8): 979-986. 
Limmathurotsakul, D., W. Chaowagul, N. P. Day and S. J. Peacock (2009). "Patterns of 
organ involvement in recurrent melioidosis." Am J Trop Med Hyg 81(2): 335-337. 
Limmathurotsakul, D., N. Golding, D. A. Dance, J. P. Messina, D. M. Pigott, C. L. 
Moyes, D. B. Rolim, E. Bertherat, N. P. Day, S. J. Peacock and S. I. Hay (2016). 
"Predicted global distribution of and burden of melioidosis." Nat Microbiol 1(1). 
249 
 
Limmathurotsakul, D., A. Paeyao, S. Wongratanacheewin, N. Saiprom, N. Takpho, J. 
Thaipadungpanit, N. Chantratita, V. Wuthiekanun, N. P. Day and S. J. Peacock (2014). 
"Role of Burkholderia pseudomallei biofilm formation and lipopolysaccharide in relapse 
of melioidosis." Clin Microbiol Infect 20(11): O854-856. 
Limmathurotsakul, D. and S. J. Peacock (2011). "Melioidosis: a clinical overview." Br 
Med Bull 99: 125-139. 
Limmathurotsakul, D., S. Wongratanacheewin, N. Teerawattanasook, G. Wongsuvan, 
S. Chaisuksant, P. Chetchotisakd, W. Chaowagul, N. P. Day and S. J. Peacock (2010). 
"Increasing incidence of human melioidosis in Northeast Thailand." Am J Trop Med 
Hyg 82(6): 1113-1117. 
Lin, P. L., V. Dartois, P. J. Johnston, C. Janssen, L. Via, M. B. Goodwin, E. Klein, C. E. 
Barry, 3rd and J. L. Flynn (2012). "Metronidazole prevents reactivation of latent 
Mycobacterium tuberculosis infection in macaques." Proc Natl Acad Sci U S A 109(35): 
14188-14193. 
Liu, Y. and J. A. Imlay (2013). "Cell death from antibiotics without the involvement of 
reactive oxygen species." Science 339(6124): 1210-1213. 
Lo, T. J., L. W. Ang, L. James and K. T. Goh (2009). "Melioidosis in a tropical city state, 
Singapore." Emerg Infect Dis 15(10): 1645-1647. 
Lofmark, S., C. Edlund and C. E. Nord (2010). "Metronidazole is still the drug of choice 
for treatment of anaerobic infections." Clin Infect Dis 50 Suppl 1: S16-23. 
Lopez, E., A. Domenech, M. J. Ferrandiz, M. J. Frias, C. Ardanuy, M. Ramirez, E. 
Garcia, J. Linares and A. G. de la Campa (2014). "Induction of prophages by 
fluoroquinolones in Streptococcus pneumoniae: implications for emergence of 
resistance in genetically-related clones." PLoS One 9(4): e94358. 
Lowe, P., C. Engler and R. Norton (2002). "Comparison of automated and 
nonautomated systems for identification of Burkholderia pseudomallei." J Clin Microbiol 
40(12): 4625-4627. 
Lu, Q., Y. Xu, Q. Yao, M. Niu and F. Shao (2015). "A polar-localized iron-binding 
protein determines the polar targeting of Burkholderia BimA autotransporter and actin 
tail formation." Cell Microbiol 17(3): 408-424. 
Lu, T. K. and J. J. Collins (2009). "Engineered bacteriophage targeting gene networks 
as adjuvants for antibiotic therapy." Proc Natl Acad Sci U S A 106(12): 4629-4634. 
Magrane, M. and The Uniprot Consortium (2011). "UniProt Knowledgebase: a hub of 
integrated protein data." Database (Oxford) 2011: bar009. 
Maisonneuve, E., M. Castro-Camargo and K. Gerdes (2013). "(p)ppGpp controls 
bacterial persistence by stochastic induction of toxin-antitoxin activity." Cell 154(5): 
1140-1150. 
Maisonneuve, E. and K. Gerdes (2014). "Molecular mechanisms underlying bacterial 
persisters." Cell 157(3): 539-548. 
Maisonneuve, E., L. J. Shakespeare, M. G. Jorgensen and K. Gerdes (2011). 
"Bacterial persistence by RNA endonucleases." Proc Natl Acad Sci U S A 108(32): 
13206-13211. 
250 
 
Malczewski, A. B., K. M. Oman, R. E. Norton and N. Ketheesan (2005). "Clinical 
presentation of melioidosis in Queensland, Australia." T Roy Soc Trop Med H 99(11): 
856-860. 
Manuel, J., G. G. Zhanel and T. de Kievit (2010). "Cadaverine suppresses persistence 
to carboxypenicillins in Pseudomonas aeruginosa PAO1." Antimicrob Agents 
Chemother 54(12): 5173-5179. 
Marrie, T. J., J. Nelligan and J. W. Costerton (1982). "A scanning and transmission 
electron microscopic study of an infected endocardial pacemaker lead." Circulation 
66(6): 1339-1341. 
McClintock, B. (1950). "The origin and behavior of mutable loci in maize." Proc Natl 
Acad Sci U S A 36(6): 344-355. 
McFadden, B. A. and S. Purohit (1977). "Itaconate, an isocitrate lyase-directed inhibitor 
in Pseudomonas indigofera." J Bacteriol 131(1): 136-144. 
McKinney, J. D., K. Honer zu Bentrup, E. J. Munoz-Elias, A. Miczak, B. Chen, W. T. 
Chan, D. Swenson, J. C. Sacchettini, W. R. Jacobs, Jr. and D. G. Russell (2000). 
"Persistence of Mycobacterium tuberculosis in macrophages and mice requires the 
glyoxylate shunt enzyme isocitrate lyase." Nature 406(6797): 735-738. 
Michelucci, A., T. Cordes, J. Ghelfi, A. Pailot, N. Reiling, O. Goldmann, T. Binz, A. 
Wegner, A. Tallam, A. Rausell, M. Buttini, C. L. Linster, E. Medina, R. Balling and K. 
Hiller (2013). "Immune-responsive gene 1 protein links metabolism to immunity by 
catalyzing itaconic acid production." Proc Natl Acad Sci U S A 110(19): 7820-7825. 
Mok, W. W., M. A. Orman and M. P. Brynildsen (2015). "Impacts of global 
transcriptional regulators on persister metabolism." Antimicrob Agents Chemother 
59(5): 2713-2719. 
Moker, N., C. R. Dean and J. Tao (2010). "Pseudomonas aeruginosa increases 
formation of multidrug-tolerant persister cells in response to quorum-sensing signaling 
molecules." J Bacteriol 192(7): 1946-1955. 
Moule, M. G., C. M. Hemsley, Q. Seet, J. A. Guerra-Assuncao, J. Lim, M. Sarkar-
Tyson, T. G. Clark, P. B. Tan, R. W. Titball, J. Cuccui and B. W. Wren (2014). 
"Genome-wide saturation mutagenesis of Burkholderia pseudomallei K96243 predicts 
essential genes and novel targets for antimicrobial development." mBio 5(1): e00926-
00913. 
Moule, M. G., N. Spink, S. Willcocks, J. Lim, J. A. Guerra-Assuncao, F. Cia, O. 
Champion, N. Senior, H. S. Atkins, T. Clark, G. J. Bancroft, J. Cuccui and B. W. Wren 
(2015). "Characterization of new virulence factors involved in the intracellular growth 
and survival of Burkholderia pseudomallei." Infect Immun. 
Moyed, H. S. and K. P. Bertrand (1983). "hipA, a newly recognized gene of Escherichia 
coli K-12 that affects frequency of persistence after inhibition of murein synthesis." J 
Bacteriol 155(2): 768-775. 
Moyed, H. S. and S. H. Broderick (1986). "Molecular cloning and expression of hipA, a 
gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of 
murein synthesis." J Bacteriol 166(2): 399-403. 
251 
 
Mulcahy, L. R., J. L. Burns, S. Lory and K. Lewis (2010). "Emergence of Pseudomonas 
aeruginosa strains producing high levels of persister cells in patients with cystic 
fibrosis." J Bacteriol 192(23): 6191-6199. 
Muller, C. M., L. Conejero, N. Spink, M. E. Wand, G. J. Bancroft and R. W. Titball 
(2012). "Role of RelA and SpoT in Burkholderia pseudomallei virulence and immunity." 
Infect Immun 80(9): 3247-3255. 
Munoz-Elias, E. J. and J. D. McKinney (2005). "Mycobacterium tuberculosis isocitrate 
lyases 1 and 2 are jointly required for in vivo growth and virulence." Nat Med 11(6): 
638-644. 
Munoz-Elias, E. J. and J. D. McKinney (2006). "Carbon metabolism of intracellular 
bacteria." Cell Microbiol 8(1): 10-22. 
Munoz-Lopez, M. and J. L. Garcia-Perez (2010). "DNA transposons: nature and 
applications in genomics." Curr Genomics 11(2): 115-128. 
Murakami, K., T. Ono, D. Viducic, S. Kayama, M. Mori, K. Hirota, K. Nemoto and Y. 
Miyake (2005). "Role for rpoS gene of Pseudomonas aeruginosa in antibiotic 
tolerance." FEMS Microbiol Lett 242(1): 161-167. 
Ngauy, V., Y. Lemeshev, L. Sadkowski and G. Crawford (2005). "Cutaneous 
melioidosis in a man who was taken as a prisoner of war by the Japanese during World 
War II." J Clin Microbiol 43(2): 970-972. 
Nguyen, D., A. Joshi-Datar, F. Lepine, E. Bauerle, O. Olakanmi, K. Beer, G. McKay, R. 
Siehnel, J. Schafhauser, Y. Wang, B. E. Britigan and P. K. Singh (2011). "Active 
starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited 
bacteria." Science 334(6058): 982-986. 
Nierman, W. C., Y. Yu and L. Losada (2015). "The in vitro antibiotic tolerant persister 
population in Burkholderia pseudomallei is altered by environmental factors." Front 
Microbiol 6: 1338. 
Ooi, W. F., C. Ong, T. Nandi, J. F. Kreisberg, H. H. Chua, G. Sun, Y. Chen, C. Mueller, 
L. Conejero, M. Eshaghi, R. M. Ang, J. Liu, B. W. Sobral, S. Korbsrisate, Y. H. Gan, R. 
W. Titball, G. J. Bancroft, E. Valade and P. Tan (2013). "The condition-dependent 
transcriptional landscape of Burkholderia pseudomallei." PLoS Genet 9(9): e1003795. 
Orman, M. A. and M. P. Brynildsen (2013). "Dormancy is not necessary or sufficient for 
bacterial persistence." Antimicrob Agents Chemother 57(7). 
Orman, M. A. and M. P. Brynildsen (2013). "Establishment of a method to rapidly assay 
bacterial persister metabolism." Antimicrob Agents Chemother. 
Orman, M. A., W. W. Mok and M. P. Brynildsen (2015). "Aminoglycoside-enabled 
elucidation of bacterial persister metabolism." Curr Protoc Microbiol 36: 17.19.11-14. 
Papp-Wallace, K. M., A. Endimiani, M. A. Taracila and R. A. Bonomo (2011). 
"Carbapenems: past, present, and future." Antimicrob Agents Chemother 55(11): 4943-
4960. 
Park, M. K., R. A. Myers and L. Marzella (1992). "Oxygen tensions and infections: 
modulation of microbial growth, activity of antimicrobial agents, and immunologic 
responses." Clin Infect Dis 14(3): 720-740. 
252 
 
Peacock, S. J., G. Chieng, A. C. Cheng, D. A. Dance, P. Amornchai, G. Wongsuvan, 
N. Teerawattanasook, W. Chierakul, N. P. Day and V. Wuthiekanun (2005). 
"Comparison of Ashdown's medium, Burkholderia cepacia medium, and Burkholderia 
pseudomallei selective agar for clinical isolation of Burkholderia pseudomallei." J Clin 
Microbiol 43(10): 5359-5361. 
Podnecky, N. L., K. A. Rhodes and H. P. Schweizer (2015). "Efflux pump-mediated 
drug resistance in Burkholderia." Front Microbiol 6: 305. 
Popham, D. L. and K. D. Young (2003). "Role of penicillin-binding proteins in bacterial 
cell morphogenesis." Curr Opin Microbiol 6(6): 594-599. 
Prax, M. and R. Bertram (2014). "Metabolic aspects of bacterial persisters." Front Cell 
Infect Microbiol 4: 148. 
Pumpuang, A., N. Chantratita, C. Wikraiphat, N. Saiprom, N. P. Day, S. J. Peacock and 
V. Wuthiekanun (2011). "Survival of Burkholderia pseudomallei in distilled water for 16 
years." T Roy Soc Trop Med H 105(10): 598-600. 
Ramli, N. S., C. Eng Guan, S. Nathan and J. Vadivelu (2012). "The effect of 
environmental conditions on biofilm formation of Burkholderia pseudomallei clinical 
isolates." PLoS One 7(9): e44104. 
Reckseidler-Zenteno, S. L., R. DeVinney and D. E. Woods (2005). "The capsular 
polysaccharide of Burkholderia pseudomallei contributes to survival in serum by 
reducing complement factor C3b deposition." Infect Immun 73(2): 1106-1115. 
Reffuveille, F., C. de la Fuente-Nunez, S. Mansour and R. E. Hancock (2014). "A 
broad-spectrum antibiofilm peptide enhances antibiotic action against bacterial 
biofilms." Antimicrob Agents Chemother 58(9): 5363-5371. 
Reznikoff, W. S. (2008). "Transposon Tn5." Annu Rev Genet 42: 269-286. 
Rodloff, A. C., E. J. Goldstein and A. Torres (2006). "Two decades of imipenem 
therapy." J Antimicrob Chemother 58(5): 916-929. 
Rotem, E., A. Loinger, I. Ronin, I. Levin-Reisman, C. Gabay, N. Shoresh, O. Biham and 
N. Q. Balaban (2010). "Regulation of phenotypic variability by a threshold based 
mechanism underlies bacterial persistence " Proc Natl Acad Sci U S A 13(107): 12541-
12546. 
Russell, P., S. M. Eley, J. Ellis, M. Green, D. L. Bell, D. J. Kenny and R. W. Titball 
(2000). "Comparison of efficacy of ciprofloxacin and doxycycline against experimental 
melioidosis and glanders." J Antimicrob Chemother 45(6): 813-818. 
Saidani, N., K. Griffiths, M. Million, P. Gautret, G. Dubourg, P. Parola, P. Brouqui and J. 
C. Lagier (2015). "Melioidosis as a travel-associated infection: Case report and review 
of the literature." Travel Med Infect Dis 13(5): 367-381. 
Samuelson, J. (1999). "Why metronidazole is active against both bacteria and 
parasites." Antimicrob Agents Chemother 43(7): 1533-1541. 
Sarovich, D. S., E. P. Price, A. T. Von Schulze, J. M. Cook, M. Mayo, L. M. Watson, L. 
Richardson, M. L. Seymour, A. Tuanyok, D. M. Engelthaler, T. Pearson, S. J. Peacock, 
B. J. Currie, P. Keim and D. M. Wagner (2012). "Characterization of ceftazidime 
resistance mechanisms in clinical isolates of Burkholderia pseudomallei from 
Australia." PLoS One 7(2): e30789. 
253 
 
Sarovich, D. S., E. P. Price, J. R. Webb, L. M. Ward, M. Y. Voutsinos, A. Tuanyok, M. 
Mayo, M. Kaestli and B. J. Currie (2014). "Variable virulence factors in Burkholderia 
pseudomallei (melioidosis) associated with human disease." PLoS One 9(3): e91682. 
Sawasdidoln, C., S. Taweechaisupapong, R. W. Sermswan, U. Tattawasart, S. 
Tungpradabkul and S. Wongratanacheewin (2010). "Growing Burkholderia 
pseudomallei in biofilm stimulating conditions significantly induces antimicrobial 
resistance." PLoS One 5(2): e9196. 
Schaible, B., K. Schaffer and C. T. Taylor (2010). "Hypoxia, innate immunity and 
infection in the lung." Respir Physiol Neurobi 174(3): 235-243. 
Schultz, J. E. and A. Matin (1991). "Molecular and functional characterization of a 
carbon starvation gene of Escherichia coli." J Mol Biol 218(1): 129-140. 
Schweizer, H. P. (2012). "Mechanisms of antibiotic resistance in Burkholderia 
pseudomallei: implications for treatment of melioidosis." Future Microbiol 7(12): 1389-
1399. 
Shah, D., Z. Zhang, A. Khodursky, N. Kaldalu, K. Kurg and K. Lewis (2006). 
"Persisters: a distinct physiological state of Escherichia coli." BMC Microbiology 6: 53. 
Shan, Y., D. Lazinski, S. Rowe, A. Camilli and K. Lewis (2015). "Genetic basis of 
persister tolerance to aminoglycosides in Escherichia coli." mBio 6(2). 
Sharma, B., A. V. Brown, N. E. Matluck, L. T. Hu and K. Lewis (2015). "Borrelia 
burgdorferi, the causative agent of lyme disease, forms drug-tolerant persister cells." 
Antimicrob Agents Chemother 59(8): 4616-4624. 
Shih, H. I., Y. C. Chuang, B. M. Cheung, J. J. Yan, C. M. Chang, K. Chang, N. Y. Lee, 
H. C. Lee, C. J. Wu, P. L. Chen, C. C. Lee, L. R. Wang, N. Y. Ko and W. C. Ko (2009). 
"Sporadic and outbreak cases of melioidosis in southern Taiwan: clinical features and 
antimicrobial susceptibility." Infection 37(1): 9-15. 
Sica, A., G. Melillo and L. Varesio (2011). "Hypoxia: a double-edged sword of 
immunity." J Mol Med (Berl) 89(7): 657-665. 
Simmen, H. P. and J. Blaser (1993). "Analysis of pH and pO2 in abscesses, peritoneal 
fluid, and drainage fluid in the presence or absence of bacterial infection during and 
after abdominal surgery." Am J Surg 166(1): 24-27. 
Singh, R., C. E. Barry, 3rd and H. I. Boshoff (2010). "The three RelE homologs of 
Mycobacterium tuberculosis have individual, drug-specific effects on bacterial antibiotic 
tolerance." J Bacteriol 192(5): 1279-1291. 
Slattery, A., A. H. Victorsen, A. Brown, K. Hillman and G. J. Phillips (2013). "Isolation of 
highly persistent mutants of Salmonella enterica serovar typhimurium reveals a new 
toxin-antitoxin module." J Bacteriol 195(4): 647-657. 
Smith, M. D., V. Wuthiekanun, A. L. Walsh and N. J. White (1996). "In-vitro activity of 
carbapenem antibiotics against beta-lactam susceptible and resistant strains of 
Burkholderia pseudomallei." J Antimicrob Chemother 37(3): 611-615. 
Spoering, A. L. and K. Lewis (2001). "Biofilms and planktonic cells of Pseudomonas 
aeruginosa have similar resistance to killing by antimicrobials." J Bacteriol 183(23): 
6746-6751. 
254 
 
Spoering, A. L., M. Vulic and K. Lewis (2006). "GlpD and PlsB participate in persister 
cell formation in Escherichia coli." J Bacteriol 188(14): 5136-5144. 
Stevens, M. P., A. Friebel, L. A. Taylor, M. W. Wood, P. J. Brown, W. D. Hardt and E. 
E. Galyov (2003). "A Burkholderia pseudomallei type III secreted protein, BopE, 
facilitates bacterial invasion of epithelial cells and exhibits guanine nucleotide 
exchange factor activity." J Bacteriol 185(16): 4992-4996. 
Stevens, M. P., A. Haque, T. Atkins, J. Hill, M. W. Wood, A. Easton, M. Nelson, C. 
Underwood-Fowler, R. W. Titball, G. J. Bancroft and E. E. Galyov (2004). "Attenuated 
virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion 
mutant in murine models of melioidosis." Microbiology 150(Pt 8): 2669-2676. 
Stevens, M. P., J. M. Stevens, R. L. Jeng, L. A. Taylor, M. W. Wood, P. Hawes, P. 
Monaghan, M. D. Welch and E. E. Galyov (2005). "Identification of a bacterial factor 
required for actin-based motility of Burkholderia pseudomallei." Mol Microbiol 56(1): 40-
53. 
Stevens, M. P., M. W. Wood, L. A. Taylor, P. Monaghan, P. Hawes, P. W. Jones, T. S. 
Wallis and E. E. Galyov (2002). "An Inv/Mxi-Spa-like type III protein secretion system in 
Burkholderia pseudomallei modulates intracellular behaviour of the pathogen." Mol 
Microbiol 46(3): 649-659. 
Stewart, P. S. (2002). "Mechanisms of antibiotic resistance in bacterial biofilms." Int J 
Med Microbiol 292(2): 107-113. 
Stewart, P. S. (2015). "Antimicrobial tolerance in biofilms." Microbiol Spectr 3(3). 
Stewart, P. S. and M. J. Franklin (2008). "Physiological heterogeneity in biofilms." Nat 
Rev Microbiol 6(3): 199-210. 
Stone, J. K., D. DeShazer, P. J. Brett and M. N. Burtnick (2014). "Melioidosis: 
molecular aspects of pathogenesis." Expert Rev Anti Infect Ther 12(12): 1487-1499. 
Sumby, P. and M. C. Smith (2002). "Genetics of the phage growth limitation (Pgl) 
system of Streptomyces coelicolor A3(2)." Mol Microbiol 44(2): 489-500. 
Taber, H. W., J. P. Mueller, P. F. Miller and A. S. Arrow (1987). "Bacterial uptake of 
aminoglycoside antibiotics." Microbiol Rev 51(4): 439-457. 
Tan, A. L. and M. L. Tan (2008). "Melioidosis: antibiogram of cases in Singapore 1987-
2007." T Roy Soc Trop Med H 102 Suppl 1: S101-102. 
Tandhavanant, S., A. Thanwisai, D. Limmathurotsakul, S. Korbsrisate, N. P. Day, S. J. 
Peacock and N. Chantratita (2010). "Effect of colony morphology variation of 
Burkholderia pseudomallei on intracellular survival and resistance to antimicrobial 
environments in human macrophages in vitro." BMC Microbiol 10: 303. 
Tuomanen, E., R. Cozens, W. Tosch, O. Zak and A. Tomasz (1986). "The rate of killing 
of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of 
bacterial growth." J Gen Microbiol 132(5): 1297-1304. 
Utaisincharoen, P., N. Tangthawornchaikul, W. Kespichayawattana, N. Anuntagool, P. 
Chaisuriya and S. Sirisinha (2000). "Kinetic studies of the production of nitric oxide 
(NO) and tumour necrosis factor-alpha (TNF-alpha) in macrophages stimulated with 
Burkholderia pseudomallei endotoxin." Clin Exp Immunol 122(3): 324-329. 
255 
 
Van Acker, H., A. Sass, S. Bazzini, K. De Roy, C. Udine, T. Messiaen, G. Riccardi, N. 
Boon, H. J. Nelis, E. Mahenthiralingam and T. Coenye (2013). "Biofilm-grown 
Burkholderia cepacia Complex cells survive antibiotic treatment by avoiding production 
of reactive oxygen species." PLoS One 8(3): e58943. 
van Opijnen, T., K. L. Bodi and A. Camilli (2009). "Tn-seq: high-throughput parallel 
sequencing for fitness and genetic interaction studies in microorganisms." Nat Methods 
6(10): 767-772. 
van Opijnen, T. and A. Camilli (2013). "Transposon insertion sequencing: a new tool for 
systems-level analysis of microorganisms." Nat Rev Microbiol 11(7): 435-442. 
van Schaik, E. J., M. Tom and D. E. Woods (2009). "Burkholderia pseudomallei 
isocitrate lyase is a persistence factor in pulmonary melioidosis: implications for the 
development of isocitrate lyase inhibitors as novel antimicrobials." Infect Immun 77(10): 
4275-4283. 
Vass, R. H. and P. Chien (2016). "Two ways to skin a cat: ADEP antibiotics can kill 
bacteria through activation or inhibition of ClpP activity." Mol Microbiol. 
Via, L. E., P. L. Lin, S. M. Ray, J. Carrillo, S. S. Allen, S. Y. Eum, K. Taylor, E. Klein, U. 
Manjunatha, J. Gonzales, E. G. Lee, S. K. Park, J. A. Raleigh, S. N. Cho, D. N. 
McMurray, J. L. Flynn and C. E. Barry, 3rd (2008). "Tuberculous granulomas are 
hypoxic in guinea pigs, rabbits, and nonhuman primates." Infect Immun 76(6): 2333-
2340. 
Volzing, K. G. and M. P. Brynildsen (2015). "Stationary-phase persisters to ofloxacin 
sustain DNA damage and require repair systems only during recovery." mBio 6(5): 
e00731-00715. 
Vorachit, M., K. Lam, P. Jayanetra and J. W. Costerton (1993). "Resistance of 
Pseudomonas pseudomallei growing as a biofilm on silastic discs to ceftazidime and 
co-trimoxazole." Antimicrob Agents Chemother 37(9): 2000-2002. 
Vorachit, M., K. Lam, P. Jayanetra and J. W. Costerton (1995). "Electron microscopy 
study of the mode of growth of Pseudomonas pseudomallei in vitro and in vivo." J Trop 
Med Hyg 98(6): 379-391. 
Wagner, E. G. and C. Unoson (2012). "The toxin-antitoxin system tisB-istR1: 
Expression, regulation, and biological role in persister phenotypes." RNA Biology 9(12). 
Wakamoto, Y., N. Dhar, R. Chait, K. Schneider, F. Signorino-Gelo, S. Leibler and J. D. 
McKinney (2013). "Dynamic persistence of antibiotic-stressed mycobacteria." Science 
339(6115): 91-95. 
Walters, M. C., 3rd, F. Roe, A. Bugnicourt, M. J. Franklin and P. S. Stewart (2003). 
"Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to 
tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin." 
Antimicrob Agents Chemother 47(1): 317-323. 
Wang, W., J. Chen, G. Chen, X. Du, P. Cui, J. Wu, J. Zhao, N. Wu, W. Zhang, M. Li 
and Y. Zhang (2015). "Transposon mutagenesis identifies novel genes associated with 
Staphylococcus aureus persister formation." Front Microbiol 6: 1437. 
Wang, X. and X. Zhao (2009). "Contribution of oxidative damage to antimicrobial 
lethality." Antimicrob Agents Chemother 53(4): 1395-1402. 
256 
 
Wen, Y., E. Behiels and B. Devreese (2014). "Toxin-Antitoxin systems: their role in 
persistence, biofilm formation, and pathogenicity." Pathog Dis 70(3): 240-249. 
Wexselblatt, E., Y. Oppenheimer-Shaanan, I. Kaspy, N. London, O. Schueler-Furman, 
E. Yavin, G. Glaser, J. Katzhendler and S. Ben-Yehuda (2012). "Relacin, a novel 
antibacterial agent targeting the Stringent Response." PLoS Pathog 8(9): e1002925. 
White, N. J. (2003). "Melioidosis." Lancet 361(9370): 1715-1722. 
Wiersinga, W. J., B. J. Currie and S. J. Peacock (2012). "Melioidosis." N Engl J Med 
367(11): 1035-1044. 
Wiersinga, W. J., T. van der Poll, N. J. White, N. P. Day and S. J. Peacock (2006). 
"Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei." Nat Rev 
Microbiol 4(4): 272-282. 
Willcocks, S. J., C. C. Denman, H. S. Atkins and B. W. Wren (2016). "Intracellular 
replication of the well-armed pathogen Burkholderia pseudomallei." Curr Opin Microbiol 
29: 94-103. 
Winsor, G. L., B. Khaira, T. Van Rossum, R. Lo, M. D. Whiteside and F. S. Brinkman 
(2008). "The Burkholderia Genome Database: facilitating flexible queries and 
comparative analyses." Bioinformatics 24(23): 2803-2804. 
Wong, K. T., S. D. Puthucheary and J. Vadivelu (1995). "The histopathology of human 
melioidosis." Histopathology 26(1): 51-55. 
Wood, T. K., S. J. Knabel and B. W. Kwan (2013). "Bacterial persister cell formation 
and dormancy." Appl Environ Microbiol 79(23): 7116-7121. 
Wu, P. J. and D. M. Livermore (1990). "Response of chemostat cultures of 
Pseudomonas aeruginosa to carbapenems and other beta-lactams." J Antimicrob 
Chemother 25(6): 891-902. 
Wu, Y. and R. M. Brosh, Jr. (2010). "Helicase-inactivating mutations as a basis for 
dominant negative phenotypes." Cell Cycle 9(20): 4080-4090. 
Wu, Y., M. Vulic, I. Keren and K. Lewis (2012). "Role of oxidative stress in persister 
tolerance." Antimicrob Agents Chemother 56(9): 4922-4926. 
Wuthiekanun, V., P. Amornchai, N. Saiprom, N. Chantratita, W. Chierakul, G. C. Koh, 
W. Chaowagul, N. P. Day, D. Limmathurotsakul and S. J. Peacock (2011). "Survey of 
antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades 
in Northeast Thailand." Antimicrob Agents Chemother 55(11): 5388-5391. 
Wuthiekanun, V., D. A. Dance, Y. Wattanagoon, Y. Supputtamongkol, W. Chaowagul 
and N. J. White (1990). "The use of selective media for the isolation of Pseudomonas 
pseudomallei in clinical practice." J Med Microbiol 33(2): 121-126. 
Wuthiekanun, V., Y. Suputtamongkol, A. J. Simpson, P. Kanaphun and N. J. White 
(2001). "Value of throat swab in diagnosis of melioidosis." J Clin Microbiol 39(10): 
3801-3802. 
Xu, K. D., P. S. Stewart, F. Xia, C. T. Huang and G. A. McFeters (1998). "Spatial 
physiological heterogeneity in Pseudomonas aeruginosa biofilm is determined by 
oxygen availability." Appl Environ Microbiol 64(10): 4035-4039. 
257 
 
Yabuuchi, E., Y. Kosako, I. Yano, H. Hotta, Y. Hashimoto, T. Ezaki and M. Arakawa 
(1992). "Proposal of Burkholderia gen. nov. and transfer of seven species of the genus 
Pseudomonas homology group II to the new genus, with the type species Burkholderia 
cepacia (Palleroni and Holmes 1981) comb. nov." Microbiol Immunol 36(12): 1251-
1275. 
Yamaguchi, Y., J. H. Park and M. Inouye (2011). "Toxin-antitoxin systems in bacteria 
and archaea." Annu Rev Genet 45: 61-79. 
Yoon, S. S., R. F. Hennigan, G. M. Hilliard, U. A. Ochsner, K. Parvatiyar, M. C. 
Kamani, H. L. Allen, T. R. DeKievit, P. R. Gardner, U. Schwab, J. J. Rowe, B. H. 
Iglewski, T. R. McDermott, R. P. Mason, D. J. Wozniak, R. E. Hancock, M. R. Parsek, 
T. L. Noah, R. C. Boucher and D. J. Hassett (2002). "Pseudomonas aeruginosa 
anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis." Dev Cell 
3(4): 593-603. 
Yu, Y., H. S. Kim, H. H. Chua, C. H. Lin, S. H. Sim, D. Lin, A. Derr, R. Engels, D. 
DeShazer, B. Birren, W. C. Nierman and P. Tan (2006). "Genomic patterns of 
pathogen evolution revealed by comparison of Burkholderia pseudomallei, the 
causative agent of melioidosis, to avirulent Burkholderia thailandensis." BMC Microbiol 
6: 46. 
Zhao, X., Y. Hong and K. Drlica (2015). "Moving forward with reactive oxygen species 
involvement in antimicrobial lethality." J Antimicrob Chemother 70(3): 639-642. 
 
  
258 
 
 
 
 
 
 
 
 
 
Appendix 
 
 
 
 
 
 
  
259 
 
Appendix 1 – Full “lost in treatment” TraDIS gene list 
Gene Tn insertions in 
input list 
BTH_I2723 13.5 
BTH_I2738 11 
BTH_I2702 10 
BTH_II0083 9.5 
BTH_I1442 8.5 
BTH_I2595 8.5 
BTH_I2633 7.5 
BTH_I0113 7.5 
BTH_I3301 7 
BTH_I0112 6.5 
BTH_I0096 6 
BTH_I0002 6 
BTH_I2661 5.5 
BTH_I2719 5.5 
BTH_I3135 5.5 
BTH_I0081 5.5 
BTH_I2722 5.5 
BTH_II0611 5.5 
BTH_I2613 5 
BTH_I2977 5 
BTH_II0702 5 
BTH_I1444 5 
BTH_I2718 5 
BTH_I2582 4.5 
BTH_I2699 4.5 
BTH_I2721 4.5 
BTH_I2717 4.5 
BTH_I1755 4.5 
BTH_I3242 4.5 
BTH_II0707 4.5 
260 
 
BTH_II2002 4.5 
BTH_I3271 4.5 
BTH_I0115 4 
BTH_I0001 4 
BTH_I0118 4 
BTH_I3253 4 
BTH_I1107 4 
BTH_I2750 4 
BTH_I2952 4 
BTH_I3276 4 
BTH_II2013 4 
BTH_I2597 3.5 
BTH_II0084 3.5 
BTH_I0498 3.5 
BTH_I2772 3.5 
BTH_I2773 3.5 
BTH_I3014 3.5 
BTH_I3029 3.5 
BTH_II1415 3.5 
BTH_II1783 3.5 
BTH_I0928 3.5 
BTH_I2696 3.5 
BTH_I2703 3.5 
BTH_I0007 3 
BTH_I0220 3 
BTH_I0761 3 
BTH_I1050 3 
BTH_I2276 3 
BTH_I2278 3 
BTH_I2592 3 
BTH_II0375 3 
BTH_I0075 3 
BTH_I0095 3 
BTH_I2010 3 
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BTH_I2269 3 
BTH_I2720 3 
BTH_II0480 3 
BTH_II2040 3 
BTH_I0638 3 
BTH_I1858 3 
BTH_I2643 3 
BTH_I3024 3 
BTH_I3225 3 
BTH_I0712 2.5 
BTH_I0763 2.5 
BTH_I1322 2.5 
BTH_I2692 2.5 
BTH_I2733 2.5 
BTH_I2865 2.5 
BTH_I3270 2.5 
BTH_II0631 2.5 
BTH_II1454 2.5 
BTH_II2021 2.5 
BTH_I1225 2.5 
BTH_I1295 2.5 
BTH_I1913 2.5 
BTH_I2608 2.5 
BTH_I2621 2.5 
BTH_I2963 2.5 
BTH_II0708 2.5 
BTH_I0042 2 
BTH_I0055 2 
BTH_I0116 2 
BTH_I0223 2 
BTH_I0607 2 
BTH_I0660 2 
BTH_I0887 2 
BTH_I1915 2 
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BTH_I2079 2 
BTH_I2197 2 
BTH_I2288 2 
BTH_I2512 2 
BTH_I2589 2 
BTH_I2609 2 
BTH_I2634 2 
BTH_I2686 2 
BTH_I2700 2 
BTH_I2965 2 
BTH_I3174 2 
BTH_I3193 2 
BTH_I3305 2 
BTH_II0034 2 
BTH_II0988 2 
BTH_II1041 2 
BTH_II1594 2 
BTH_II1998 2 
BTH_II2105 2 
BTH_II2145 2 
BTH_II2189 2 
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Appendix 2 – Full “survived treatment” TraDIS gene list 
 
Gene  Tn insertions in input 
list 
Tn insertions in output 
list 
BTH_I2739 53 15 
BTH_I0114 37 12 
BTH_I2743 21.5 10 
BTH_I3143 21.5 7.3 
BTH_I2742 21.5 7.3 
BTH_I2691 20.5 6.3 
BTH_I2740 26.5 6 
BTH_I1443 24.5 6 
BTH_I2698 20.5 5.3 
BTH_I0093 14.5 5 
BTH_I3136 19 5 
BTH_I2701 23 5 
BTH_I0097 6.5 5 
BTH_II0082 17.5 5 
BTH_I2741 14.5 4.3 
BTH_I0094 9.5 4 
BTH_I1594 2.5 4 
BTH_I3137 7 3.7 
BTH_I0117 5.5 3 
BTH_I0896 2.5 2.7 
BTH_I2099 8 2.3 
BTH_I2590 3 2.3 
BTH_I1932 7.5 2.3 
BTH_I1666 2 2.3 
BTH_I3234 4 2 
BTH_I3021 2 2 
BTH_I2900 5 2 
BTH_II2027 2 2 
BTH_I0102 2.5 2 
